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Infectious Bronchitis Virus (IBV) is a gammacoronavirus that is prevalent in poultry flocks 
worldwide. Infection results in Infectious Bronchitis (IB), an economically important disease 
characterised by snicking, rales, lethargy, loss of tracheal ciliary activity, reduced weight gain 
and reduced egg production. Vaccination is commonly practiced using both live attenuated 
and inactivated vaccines. Live attenuated vaccines are generated by serial passage of a 
pathogenic field strain in embryonated chicken eggs; the molecular mechanism is unknown. 
A fine balance needs to be achieved between the loss of pathogenic in vivo phenotype and 
the retention of immunogenicity. Due to the unpredictability of the process and the time 
required there is a drive to rationally design and rationally attenuate recombinant IBV (rIBV) 
that can be subsequently utilised as live attenuated vaccines.     
 
Vaccine induced protection is predominantly associated with the spike (S) glycoprotein, 
which consists of two subunits, the immunodominant S1 and the highly conserved S2. Whilst 
the latter is considered to be less immunogenic, it has been reported to play a role in 
protective immunity. In this thesis rIBVs, based on the apathogenic rIBV, Beau-R, that 
express heterologous S1 or S2 subunits BeauR-QX(S1), BeauR-M41(S1), BeauR-M41(S2), 
or S glycoproteins, BeauR-M41(S) and BeauR-4/19(S) are investigated as vaccines against 
either homologous or heterologous challenge. The rIBV expressing a heterologous S 
glycoprotein, BeauR-M41(S) offered increased protection against homologous challenge as 
defined by the retention of ciliary activity in comparison to those expressing heterologous S1 
or S2 subunits, BeauR-M41(S1) and BeauR-M41(S2) respectively. The protection induced 
however fell short of the standards set by the European Pharomopiea and further 
investigation demonstrated that rIBV expressing heterologous S glycoproteins, BeauR-
M41(S) and BeauR-4/91(S) could not protect against a heterologous QX challenge. One 
possible explanation is the limited replication of the vaccine viruses in vivo.  Investigation of 
the Beau-R vaccine backbone determined that replication is temperature sensitive and highly 
restricted at 41°C, the core body temperature of a chicken.  As a consequence a rIBV based 
on the laboratory strain M41-CK was subsequently investigated for its potential to act as a 




Lay summary of thesis. 
 
Infectious Bronchitis Virus (IBV) is a virus that is prevalent in poultry flocks worldwide. 
Infection results in Infectious Bronchitis (IB), an economically important disease 
characterised by snicking (sneezing), rales (rattle in the lungs), lethargy, reduced weight gain 
as well as reduced egg production, in terms of both quantity and quality. The virus also 
renders infected birds susceptible to secondary bacterial infections which can lead to 
mortality. Vaccination is commonly practiced using both live attenuated and inactivated 
vaccines. Live attenuated vaccines are traditionally generated by serial passage of a 
pathogenic field strain in embryonated chicken eggs; the molecular mechanism is unknown. 
A fine balance needs to be achieved between loss of a pathogenic in vivo phenotype and the 
retention of immunogenicity. Due to the unpredictability of the process and the time required 
there is a drive to rationally design and rationally attenuate recombinant IBV (rIBV) that can 
be subsequently utilised as live attenuated vaccines.     
 
Research detailed in this thesis investigates the potential for rationally designed rIBVs to act 
as vaccine viruses. The research involves characterisation through vaccine-challenge 
experiments in specific pathogen free (SPF) chickens as well as characterisation through in 
vitro experiments in cell culture. Research assessing temperature sensitive replication is also 
included in these in vitro experiments. The information provided in this thesis will help in the 
design of the next generation of rationally designed, rationally attenuated rIBVs for use as 
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EDTA - Ethylenediaminetetraacetic acid 
ELISA - Enzyme linked immunosorbent assay 
EMEM - Eagle’s minimum essential medium  
ER - Endoplasmic reticulum  
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ERGIC - Endoplasmic reticulum Golgi intermediate compartment  
ExoN - Exoribonuclease  
FCoV - Feline coronavirus  
FCS - Foetal Bovine Serum  
FIPV - Feline infectious peritonitis virus  
FP - Fusion Peptide 
FPV - Fowlpox virus 
g - Gram 
Gln - Glutamine 
Glu - Glutamic Acid  
Gly - Glycine 
GMEM - Glasgow’s minimum essential medium  
GPT - Escherichia coli guanine phosphoribosyltransferase  
GTase - Guanylyltransferase 
h - Hour 
HCoV - Human coronavirus  
HE - Haemagglutinin Esterase 
HG - Harderian Gland  
His - Histidine 
hpi - Hours post infection 
HPIV3 - Human parainfluenza virus type 3  
hpv - Hours post vaccination  
HR - Heptad repeat  
HVR - Hypervariable region 
HδR - Hepatitis delta antigenome ribozyme 
i.m. - Intramuscular  
IB - Infectious bronchitis  
IBV - Infectious bronchitis virus  
ICTV - International Committee for the Taxonomy of Viruses  
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IFN - Interferon  
IIe - Isoleucine 
Il18 - Interleukin I18  
IR - Intergenic Region  
kb - Kilobases  
LB - Luria-Bertani broth 
Leu - Leucine 
Lys - Lysine  
M - Membrane  
MDA – Maternally derived anitbody 
MDA5 - Melanoma differentiation associated protein 5  
MERS-CoV - Middle East respiratory syndrome coronavirus  
Met - Methioninie 
Mg - Magnesium  
mg - Milligram 
MgCl2 - Magnesium Chloride  
MHV - Mouse hepatitis virus  
min - Minute 
ml - Milliliter 
MOI - Multiplicity of infection 
MPA - Mycophenolic acid  
Mtase - N7 Methyltransferase  
N - Nucleocapsid  
NaOH - Sodium hydroxide 
NARF - National Avian Resource Facility 
NBBS - Newborn Calf Serum 
NDV - Newcastle disease virus 
NendoU - Manganese-dependant endoribonuclease  
NK – Natural Killer cell 
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ns - Not significant 
nsp - Non-structural protein  
nt - Nucleotide 
NTD - Amino terminal domain  
ORF - Open reading frame  
PBS - Phosphate buffered saline  
PBSa - Phosphate buffered saline a 
PCR - Polymerase chain reaction 
PDCoV - Porcine delta coronavirus  
PEDV - Porcine epidemic diarrhoea virus  
PFU - Plaque forming unit  
Phe - Phenylalanine 
PLPro/PLP - Papain-like protease  
pp - Polypeptide  
PPU - Poultry production unit  
PRCV - Porcine respiratory coronavirus  
Pro - Proline  
qRT-PCR - Quantitative real time polymerase chain reaction  
RBD - Receptor binding domain  
RdRp - RNA-dependent RNA polymerase  
rFPV - Recombinant fowlpox virus  
RFS – Ribsomal Frame Shift 
rIBV - Recombinant infectious bronchitis virus 
RIR - Rhode Island Red 
rN - Recombinant N  
rNDV - Recombinant Newcastle Disease Virus  
RNP - Ribonucleoprotein  
rph - Revolutions per hour  
rpm - Revolutions per minute  
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rS - Recombinant S  
rS1 - Recombinant S1  
RSV - Respiratory syncytial virus 
RTC - Replication-transcription complex  
RT-PCR - Reverse transcription polymerase chain reaction  
s - Second  
S - Spike  
s/pratio - Sample/positive ratio  
SAM - S-adenosyl methionine 
SARS-CoV - Severe acute respiratory syndrome coronavirus  
SD - Standard deviation  
SDS - Sodium Dodecyl Sulfate 
SEM - Standard error of mean 
Ser - Serine 
sg - Sub-genomic  
sgmRNA - Sub-genomic messenger RNA  
SIII - Superscript III 
SPF - Specific pathogen free  
ss - Single stranded  
SSIV - Superscript IV 
TAE - Tris-acetate EDTA 
TBE - Tris Borate EDTA  
TCoV - Turkey coronavirus  
TDS - Transient dominant selection  
TE buffer - Tris-EDTA buffer  
TGEV - Transmissible gastroenteritis virus  
Thr - Threonine 
TK - Thymidine Kinase 
TM - Transmembrane  
22 
 
TOC - Tracheal organ culture  
TPB - Tryptose phosphate broth  
Tris-HCl - Tris(hydroxymethyl)aminomethane hydrochloride  
Trp - Tryptophan 
TRS - Transcription regulatory sequence  
Tyr - Tyrosine 
U - Unit 
Ubl - Ubiquitin-like domain  
UTR - Untranslated region  
Val - Valine - Val 
VN - Virus neutralising  
VV - Vaccinia virus  
WT - Wild type   
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Chapter 1: Introduction 
 
1.1 Classification: the Coronavirinae. 
 
The Orthocoronavirinae is a subfamily of the family Coronaviridae that is part of the 
Nidovirales order (Figure 1.1). The subfamily Orthocoronavirinae is divided into four genera 
including Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus 
(International Committee for the Taxonomy of Viruses, ICTV, October, 2018). Members 
across each of the genera pose significant threats to human health, animal health and 
welfare, as well as food security. Notable members of each genera are listed in Table 1.1. 
Despite the identification of coronaviruses across all four genera that infect over 30 species, 
the most widely researched and characterised viruses are that of the betacoronavirus genus 
and include the zoonotic human pathogen Severe Acute Respiratory Syndrome Coronavirus 
(SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) as well as 









Table 1.1 Members of the four genera of the Orthocoronavirinae subfamily as 
determined by the ICTV, 2018. 
 
Genus Species Host species 
Alphacoronavirus 
Porcine epidemic diarrhoea virus (PEDV) Pigs 
Human coronavirus 229E  (HCoV-229E) Human 
Human coronavirus NL63 (HCoV-NL63) Human 
Feline Coronavirus (FCoV) Cats 
Canine Coronavirus (CCoV) Dogs 
Transmissible gastroenteritis virus (TEGV) Pigs 
Betacoronavirus  
Murine Coronavirus (MHV) Mouse 
Human coronavirus HKU1 (HCoV-HKU1) Human 
Severe Acute Respiratory syndrome related  
coronavirus (SARS-CoV) 
Human 
Middle East Respiratory syndrome related 
coronavirus (MERS-CoV) 
Human 
Bovine Coronavirus (BCoV) 
Cows 
Gammacoronavirus 
Beluga whale coronavirus SW1 Beluga Whale* 
Avian coronavirus (IBV) 
Poultry (domestic 
fowl) 
Turkey Coronavirus (TCoV) Turkey 
Deltacoronavirus 




Thrush coronavirus Bird (Turdidae)* 
 
Notes: * Viruses were identified from genome screening, and no known infectious virus has 
been isolated (Mihindukulasuriya et al., 2008; Woo et al., 2009).  
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1.2 Infectious Bronchitis Virus. 
 
Infectious bronchitis virus (IBV) is the prototype gammacoronavirus that was first identified in 
1937 (Beaudette and Hudson, 1937). IBV infects domestic fowl (Gallus gallus), is spread by 
droplet transmission and is the aetiological agent of Infectious Bronchitis (reviewed by 
Cavanagh, 2007). There is a wide variety of both circulating and non-circulating strains, 
which is unusual in comparison to other known coronaviruses (Valastro et al., 2016). Notably 
strains include Beaudette, an apathogenic commonly utilised laboratory strain and M41, a 
pathogenic field strain with global distribution, that is also commonly used in the laboratory.  
Both M41 and Beaudette are of the Massachusetts serotype. Other notable field strains 
include 4/91 which appeared in the UK in the 1990’s (Gough et al., 1992) and has spread 
globally although not to the USA, Australia or New Zealand (reviewed by de Wit et al., 2011). 
Similarly, the QX strain first identified in China in the later 1990’s (Lui and Kong, 2004; Liu et 
al., 2006) and subsequently spread through Russia into Europe is also not circulating in the 
USA, Australia nor New Zealand.   
 
Although new IBV strains appear continuously, not all these strains are able to spread and 
become global problems. The Connecticut and Arkansas strains that appeared in the USA in 
the 1950’s and 1970’s respectively, remain still largely confined to the USA (reviewed by de 
Wit et al., 2011). The strain B1648, that first appeared in Belgium in the 1990’s remained 
confined to neighbouring countries and did not become endemic throughout Europe. 
Common IBV strains circulating in Egypt and Israel have also not established infection 
outside of their current geographical location. A further example is D1466, first reported in 
the 1970’s, which remains a concern in Europe but not for the rest of the world (reviewed by 
de Wit et al., 2011). This variety of IBV strains and the associated geographical dispersal 
means that each country/area has strains of interest and/or concern. Research and vaccine 
development projects, therefore, are tailored to reflect these interests.   
  
 
1.3 The coronavirus genome. 
 
The coronavirus (CoV) genome consists of a linear non-segmented positive sense single 
stranded RNA molecule that possesses a methylated cap structure (cap-1) at the 5′ end and 
is polyadenylated at the 3′ end. Each CoV genome therefore resembles eukaryotic mRNA 
(reviewed by Britton and Cavanagh, 2008). In addition each genome contains an 
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untranslated region (UTR) at both the 5′ and 3′ end which have roles in both genome and 
subgenomic mRNA (sgmRNA) synthesis (Hsue and Masters, 1997; Williams et al., 1999; Liu 
et al., 2001).  The genomes of coronaviruses are the largest recorded of all the known RNA 
viruses ranging from approximately 26 kb to 32 kb (reviewed by Gorbalenya et al., 2006); the 
genome of IBV is 27.6 kb (Boursnell et al., 1987).  
 
General genome organisation is shared between coronaviruses; 5′ UTR – replicase gene – 
structural and accessory genes – 3′ UTR (Figure 1.2A). The replicase gene comprises 
approximately the 5′ most proximal two thirds of the genome, and is divided into two open 
reading frames (ORF), ORF1a and ORF1b. Translation of the replicase gene results in the 
generation of two polypeptides, pp1a, approximately 3950 amino acids (aa) in length and 
pp1ab, 6630 aa, of which the latter is a result of -1 programmed ribosomal frame shift 
(Brierley et al., 1987; Brierley et al., 1989). Both polypeptide pp1a and pp1ab are 
proteolytically cleaved by virus encoded proteinases into 16 or in the case of IBV, 15 non-
structural proteins (nsps; Ziebuhur et al., 2000; Sawicki et al., 2007). Of note, the genome of 
IBV is missing nsp 1. The resulting nsps assemble into replication-transcription complexes 








Figure 1.2 Coronavirus genome organisation. (A) Schematic of IBV genome. The 5′ two 
thirds of the genome consists of two ORFs that are translated as two polyproteins, via a -1 
ribosome frameshift site (RFS). The 3′  third of the genome contains the structural genes 
spike (S), envelope (E), membrane (M) and nucleocapsid (N) genes  as well as the 
accessory genes 3a, 3b, 4b, 5a and 5b. At each end of the genome is an untranslated region 
(UTR) denoted in grey. (B) Schematic detailing the organisation of the structural and 
accessory genes of HCoV-229E, MHV, SARS-CoV and MERS-CoV. Image adapted from 




The 3′  proximal end of the genome encodes the structural genes, Spike (S), Envelope (E), 
Membrane (M) and Nucleocapsid (N) as well as several small non-structural genes referred 
to as either the accessory or group specific genes (Figure 1.2A). The location and quantity of 
the accessory genes varies from one coronavirus to another (Figure 1.2B). It must be noted 
that the naming of the accessory genes/proteins is related to genome location and not 
biological function. The IBV genome is widely accepted to encode four accessory proteins, 
designated 3a, 3b, 5a and 5b, encoded by gene 3 and gene 5 respectively (Figure 1.1A).  A 
fifth accessory protein, 4b, has been proposed from a previously unidentified ORF often 
referred to as the intergenic region (IR) that is located between gene M and gene 5 (Bentley 
et al., 2013B).  
 
1.4 Virion structure. 
 
The coronavirus virion has been studied by both cryo-electron tomography and cryo-electron 
microscopsy (Neuman et al., 2006; Barcena et al., 2009). The characteristic feature is the 
distinct solar corona-like morphology, which is the result of the S glycoprotein protomers 
protruding outward from the virion surface (Figure 1.3). The membrane of the virion which 
houses a helically symmetrical nucleocapsid contains at least the S, M and E proteins. The 
virion membrane of the betacoronavirus, MHV, also contains haemagglutinin esterase (HE). 




Figure 1.3: Coronavirus virion morphology. (A) Schematic detailing the structural 
organisation of a coronavirus virion. (B) Electron micrograph of IBV. Image taken from the 




1.5 Replication cycle. 
 
All coronaviruses including IBV replicate solely in the cell cytoplasm (Figure 1.4). Attachment 
and entry of the virus particle to the host cell is mediated by the S glycoprotein. The exact 
mechanism of IBV entry is not completely understood; the coronavirus entry process is 
complex, exhibits differences between coronavirus species and strains and additionally is 
dependent on the host cell (reviewed by Belouzard et al., 2012). It is thought that IBV enters 
via endocytosis where pH dependant viral to membrane fusion occurs releasing the 
nucleocaspid into the cells cytosol (Chu et al., 2006). It must be noted, and will be discussed 
further in Chapter 1 and Chapter 3, that after receptor binding, the S glycoprotein undergoes 
extensive conformational changes which exposes a fusion peptide (FP) allowing the fusion 
of viral and host cell membranes (Walls et al., 2017; Shang et al., 2018).  These 
conformational changes are not only driven by receptor binding but are thought to require 
additional triggers such as pH acidification and/or proteolytic cleavage (reviewed by 





Figure 1.4: Schematic representation detailing the main events in the replication cycle 
of IBV. (1) The virus particle attaches to the host cell via a receptor; this event is mediated 
by the S glycoprotein. (2) The virus particle is thought to enter the cell via endocytosis, 
where membrane fusion results in the release of the nucleocapsid containing the viral 
genome into the cell cytoplasm initiating the translation of ORF1a and ORF1b.  (3) The 
resulting nsps form the replication transcription complexes (RTCs) which mediate both 
genome replication and sg mRNA synthesis. (4) Newly synthesised RNA genomes are 
encapisated by the N protein. (5) The structural proteins are transported to the endoplasmic 
reticulum (ER) via the secretory pathway. (6) Progeny virions are assembled at the ER-Golgi 





Once the nucleocaspid has been released into the cytoplasm the genomic RNA acts directly 
as mRNA for the translation of the replicase polyproteins, pp1a and pp1ab. Expression of the 
latter is the result of a slippery sequence and an RNA pseudoknot that causes a -1ribosomal 
frameshift from ORF1a to ORF1b (Brierley et al., 1989; Baranov et al., 2005). The 
polyproteins are proteolytically cleaved by virus encoded proteinases, notably papain-like 
proteases encoded by nsp 3 and nsp 5, generating 16 or for IBV, 15 nsps (Ziebuhr et al., 
2000).  The frameshift event is thought to be a method of regulating production of the nsps, 
as those encoded by ORF 1b are produced less than those encoded by ORF 1a.  Once 
produced, some of the resulting nsps assemble to form replication-transcription complexes 
(RTCs). Despite extensive research the exact composition of the coronavirus RTC remains 
undetermined however it is thought the core structure will include nsp 7, 8, 9, 10, 12, 13 and 




Table 1.2: Known functions of the coronavirus non-structural proteins. 
Protein Function 
1 • Promotes cellular mRNA degradation and blocks host cell translation. 
• Blocks innate immune response. 
• The IBV genome does not contain nsp 1.  
2 • No known function, binds to prohibitin proteins 
3 Large, multi-domain transmembrane protein with several functions:  
• Ubiquitin-like domain 1 (Ubl1); interacts with N protein. 
• ADP-ribose-1”-phosphate phosphatase or otherwise known X domain; 
promotes cytokine expression and has been demonstrated to be a 
pathogenicity factor although the ADRP domain alone from the pathogenic 
IBV strain M41-CK cannot confer a pathogenic phenotype to Beau-R.*  
• Papain-like protease (PLPro or PLP) domain; cleaves viral polyprotein at 
nsp 1/2, 2/3 and 3/4 junctions. PLP2 may interact with the ADRP domain.* 
• Deubiquitinase activity; blocks host innate immune response.  
•  Ubl2, NAB, G2M, SUD, Y domains, unknown functions. 
4 • Potential transmembrane scaffold protein, important for proper structure of 
double membrane vesicles (DMV) that are possibly the site of viral 
replication. 
• Nsp 4 from IBV can induce membrane pairing.* 
5 • Protease activity, cleaves viral polyprotein. 
6 • Potential transmembrane scaffold protein. 
7 • Forms hexadecameric complex with nsp8, may act as processivity clamp 
for RNA polymerase. 
8 • Forms hexadecameric complex with nsp7, may act as processivity clamp 
for RNA polymerase; may act as a primase. 
9 • RNA binding protein. 
10 • Cofactor for nsp16 and nsp14. 
11 • Unknown. 
12 • RNA dependant RNA polymerase (RdRp). 
13 • RNA helicase and 5′ triphosphatase activity. 
14 • Consists of two domains:  
• N7 Methyltransferease (MTase) activity; involved in 5′ capping of viral RNA 
• 3′-5′ exoribonuclease (ExoN) activity, important for RNA proofreading 
15 • Manganese-dependent endoribonuclease (NendoU); preferentially cleave 
3′ of uridylates on both single and double-stranded RNA. 
16 • 2’O-methyltransferase; involved in capping of viral RNA which shields viral 
RNA from Melanoma differentiation associated protein 5 (MDA5) 
recognition. 
 
Notes: Adapted from Fehr and Perlman (2015), with further specific information (*) added 




The RTC performs both RNA-dependant RNA synthesis for genome replication as well as 
subgenomic mRNA (sgmRNA) synthesis for the production of the structural and accessory 
proteins. Genome replication is a process of continuous synthesis from full length negative 
copies of the genomic RNA. Synthesis of the negative strand copies is initiated from the very 
3′ end of the genome, a process which will involve the RTC as well as RNA sequences and 
RNA structures including stem loops and pseudoknots present in the 3′ UTR (Hsue and 
Masters, 1997; Williams et al., 1999). A positive sense copy is then generated from the 
negative strand template generating new genomic RNA that is encapsidated into newly 
formed progeny virions.  
 
Unlike genomic RNA synthesis the production of the sgmRNAs occurs via a process of 
discontinuous RNA synthesis (Figure 1.5). The process, referred to as discontinuous 
transcription during negative strand synthesis was proposed in the mid 1990’s by Sawicki 
and Sawicki (1995). The model relies on the presence of two complementary transcription 
regulatory sequences (TRS), one, TRS-L, located at the 5′  end of the genome within what is 
referred to as the leader sequence and the second, TRS-B, in the body of the genome, 
upstream of each structural and accessory gene. Each TRS-B essentially acts a pause 
signal for the RTC during negative strand synthesis, and when a TRS-B is encountered one 
of two events occurs; either the RTC will continue to the next TRS-B or, the now 
complementary TRS-B of the newly synthesised negative-strand RNA will translocate and 
hybridize to the TRS-L present at the 5′ end of the genome. This hybridisation event 
facilitates a template switch resulting in RNA synthesis continuing to the very 5′ end of the 
genomic template thereby adding the anti-leader sequence to each negative sense sub 
genomic (sg) RNA. The negative sense sg RNA is subsequently copied by the RTC into a 
positive sense sgmRNA. A defining characteristic of this transcription process is the 







Figure 1.5: Schematic detailing the process of discontinuous transcription during 
negative strand synthesis. RNA synthesis is initiated at the 3′ -end of the genome, 
generating a negative sense copy of the positive sense viral genome. RNA synthesis 
continues until a transcriptional regulatory sequence (TRS) is reached within the body of the 
genome (TRS-B). Once a TRS-B is encountered RNA synthesis either continues until the 
next TRS-B or undergoes a translocation event after hybridisation to the TRS located within 
the Leader sequence (TRS-L) at the 5′ end of the viral genome. RNA synthesis continues so 
that the newly synthesised RNA contains an anti-leader sequence. The negative sense 
copies act as templates for the transcription of positive sense sgmRNAs which are 




The synthesis of the sgmRNAs is a complicated process which is not fully understood, 
however it has been demonstrated that the presence of a TRS is essential. For IBV the 
accepted consensus sequence of the TRS is CUUAACAA (Bentley et al., 2013; reviewed by 
Armesto et al., 2013). Whilst the model proposed by Sawicki and Sawicki (1995) suggests 
the need for complementary TRS-L and TRS-B, this is not necessarily the case as in IBV 
there are naturally occurring variations in the TRS-B for the S gene and gene 5. Bentley et 
al., (2013) demonstrated further flexibility by identifying the presence of a sgmRNA, relating 
to gene 4b, which is transcribed from a shortened, non-canonical TRS-B of only 3 
nucleotides, CAA. It is likely therefore that the production of the sgmRNAs also involves 
regulatory RNA-RNA interactions as well as protein-RNA interactions (reviewed by Sola et 
al., 2015).  
 
Once synthesised, the sgmRNAs are translated by cellular machinery producing the 
structural and accessory proteins. The structural proteins are subsequently transported the 
endoplasmic reticulum (ER), and then to the ER-Golgi intermediate compartment (ERGIC), 
via the secretory pathway (reviewed by Fehr and Perlmann, 2015). The structural proteins 
embed into the membranes of the ERGIC and encapsulated viral progeny genomes bud 
from these membranes forming mature virions which are released from the cell by 
exocytosis (Tooze et al., 1987; Klumperman et al., 1994; Krijnse-Locker 1994). Several viral 
proteins have been implicated in the assembly and release process including E and M 
(Vennema et al., 1996). Unsurprisingly the process of coronavirus replication is 
accompanied by extensive membrane re-arrangements including double membrane 
vesicles, zippered ER and spherules (Knoops et al., 2008; Ulasli et al., 2010; Maier et al., 
2013; Maier et al., 2016). There are several hypothesised reasons for the observed 
membrane re-arrangements; they may provide a scaffold for the RTC and genome 
replication and/or shield potential replication derived immunogenic molecules such as 
double-stranded RNA thereby providing a method of evading of host immune responses 
and/or aid in virion assembly by concentrating the necessary viral proteins. 
 
1.6 Non-structural proteins. 
  
Numerous functions have been attributed to the coronavirus nsps which are summarised in 
Table 1.2. Although much is known about certain nsps, the function of others remains 
elusive. In addition, the interactions between certain nsps are still poorly understood. Despite 
the many unknowns however, there is increasing evidence surrounding the fundamental role 
of the nsps in viral replication and pathogencity (reviewed by Weiss and Navas-Martin, 2005; 
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Sevajol et al., 2014; Enjuanes et al., 2016) however, it must be noted that much of this 
research focuses on MHV and SARS-CoV and not IBV. Research by Armesto et al., (2009) 
has however identified the replicase gene as a pathogenic determinant in IBV. Continuing 
research in the coronavirus field has identified several of the nsps as promising antiviral and 
vaccine targets and it is those nsps which will be discussed further in this Chapter.  
 
1.6.1 Nsp 3. 
 
Nsp 3 is the largest of the nsps, and is a multi-functional protein containing a number of 
domains which are found to be conserved amongst members of the orthocoronavirinae 
(reviewed by Lei et al., 2018). One such domain, which has been investigated in the context 
of vaccine development is the macrodomain/X domain, or otherwise termed ADRP domain 
due to its ADP-ribose-1”-phosphate phosphatase activity (Putics et al., 2005; Saikaterdu et 
al., 2005; Egloff et al., 2006). Mutations of key residues in SARS-CoV, MHV and HCoV-229E 
has demonstrated that ADRP activity is not required for RNA synthesis and viral replication 
in vitro (Putics et al., 2005; Eriksson et al., 2008; Kuri et al., 2011). In support of this, the 
non-pathogenic IBV strain Beaudette, presumed to have an inactive ADRP due to a Glycine 
(Gly) to Serine (Ser) mutation at residue 48 (Xu et al., 2009; Piotrowski et al., 2009) is also 
able to replicate efficiently in cell culture (Casais et al., 2003). The role of the ADRP domain 
has been investigated in terms of pathogenicity. Although modification of residue 48 to a Gly 
in the infectious Beaudette based clone, recombinant IBV (rIBV) Beau-R, did not confer a 
pathogenic phenotype (Casais et al., 2001; Keep et al., 2018), Eriksson et al., (2008) 
modified the ADRP domain in MHV at the conserved residue 1348 (Aspartic acid, Asp, to 
Alanine, Ala) with the resulting recombinant virus not causing acute viral hepatitis in vivo. 
Incorporating the equivalent mutation in mouse adapted SARS-CoV, Fehr et al., (2016) 
demonstrated an inactive ADRP domain resulted in reduced viral load and reduced 
pathology in vivo. Further research has identified a possible role for the ADRP domain in the 
regulation of innate immune responses (Kuri et al., 2011; Fehr et al., 2015) which alongside 
the in vivo data generated by Eriksson et al., (2008) and Fehr et al., (2016) identifies the 
ADRP domain as a promising target for vaccine development.  
 
1.6.2 Nsp 10. 
 
Nsp 10 is a small 15 k Da protein which belongs to the zinc protein family (Joseph et al., 
2006). The protein consists of two zinc fingers, which in SARS-CoV, one is co-ordinated by 
the following residues Cysteine (Cys) 74, Cys 77, Histidine (His) 83, Cys 90 and the other by 
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Cys 117, Cys 120, Cy 128 and Cys 130 (Joseph et al., 2006). Interestingly despite the 
crystal structure being solved (Joseph et al., 2006; Su et al., 2006), the protein has no known 
enzymatic function, however due to the presence of zinc finger Joseph et al., (2006) 
hypothesised an RNA binding function. The protein has since been identified to act as a 
stimulatory co-factor to both nsp 16 (Chen et al., 2011; Wang et al., 2015, Decroly et al., 
2011, Bouvet et al., 2010) and the EXoN activity of nsp 14 (Bouvet et al., 2012; Bouvet et al., 
2014). No stimulatory effect on the N7-MTase activity of nsp 14 in vitro has been 
demonstrated (Bouvet et al., 2010).  Mutagenesis studies have identified that nsp 10 is 
essential for viral replication (Donaldson et al., 2007; Bouvet et al., 2014) whether that is 
through direct action or indirectly through stimulation of another nsp, remains undetermined.   
 
Several key residues have been identified including a Tyrosine (Tyr) at position 96 and either 
a Lysine (Lys) or Arginine (Arg) at position 93, which were found to be critical for the 
interaction with nsp 16 (Lugari et al., 2010) as well as Phenylalanine (Phe) at position 19 that 
is critical to the interaction with nsp 14 (Bouvet et al., 2014). Alanine scanning mutagenesis 
in MHV of residues that were deemed to be conserved within the coronavirus family 
identified a central core in which modification resulted in a lethal phenotype; this included 
residues Ser 72, Gly 69, Phenylalanine (Phe) 68, Aspartic acid (Asp) 123, His 113, Lysine 
(Lys) 104, Glutamic acid (Glu) 82 and Arginine (Arg) 78 (Donaldson et al., 2007).  Similar 
alanine mutagenesis studies in SARS-CoV identified modification of Phe 19, His 80 and Tyr 
96 also resulted in a lethal phenotype (Bouvet et al., 2014). Interestingly these lethal 
phenotypes were not attributed to a reduction in nsp 14 EXoN activities raising the distinct 
possibility that additional functions of nsp 10 have yet to be identified.  Nsp 10 is therefore an 
appealing target for vaccine and antiviral therapy.  
 
1.6.3 Nsp 14. 
 
Nsp 14 is a 59 kDa protein that is bifunctional, consisting of two distinct domains. Encoded 
by amino terminal residues is a 3′-5′ exoribonuclease (ExoN), and by the residues at the C 
terminal a S-adenosyl methionine (SAM)-dependent (guanine-N7) methyl transferase (N7-
MTase; Minskaia et al., 2006; Chen et al., 2009; Chen et al., 2013). Interactions with nsp 10 
have been demonstrated to enhance ExoN activity by ~35 fold (Bouvet et al., 2012) but 
seemingly has a minimal effect on N7-MTase activity (Bouvet et al., 2010; Bouvet et al., 
2104). Whilst it is simpler to consider the functions of the two domains as separate, both the 
ExoN and N7-MTase domains are interlinked, interacting through hydrophobic interactions 
(Ma et al., 2015). Structural analysis of nsp 14 from SARS-CoV identified a number of 
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residues important for these interactions including Isoleucine (lle) 80, Valine (Val) 83, 
Leucine (Leu) 177, Val 282, Phe 286, Val 294, Tyr 296, Pro 297, Ile 299, Leu 411, Pro 412, 
and Leu 419. Notably all these residues are highly conserved between members of the 
orthcoronavirinae.  
 
Mutations in nsp 14, notably in the ExoN domain have been investigated for vaccine 
development (Graham et al., 2012; Menachery et al., 2018). The ExoN active core 
encompasses three motifs, I (DE), II (E) and III (D), with in vitro studies of nsp 14 derived 
from SARS-CoV demonstrating that Ala substitutions in these motifs either reduced or 
abolished ExoN activity (Minskaia et al., 2006).  Ala mutations in motif I engineered into 
infectious clones of both SARS-CoV and MHV, as well as in motif III in MHV resulted in 
modest replication defects in cell culture as well as increases in mutation frequency within 
the viral genome (Eckerle et al., 2007; Eckerle et al., 2010). Of note, infectious progeny 
SARS-CoV could be recovered with Ala substitutions in motif III however the mutations were 
deemed not stable enough to warrant further investigation by Eckerle et al., (2010). 
Interestingly, engineered ExoN mutations within the TGEV genome, despite limited effects 
on viral RNA synthesis were lethal to the production of infectious progeny virus therefore 
indicating that ExoN activity is essential for productive viral replication (Becares et al., 2016). 
Mouse adapted SARS-CoV containing the ExoN I motif mutations were assessed for 
pathogenicity in vivo; no mortality was reported  and young mice showed no signs of clinical 
disease, although aged mice did exhibit weight loss, (Graham et al., 2012). This therefore 
indicates that ExoN activity may be a pathogenicity factor. Vaccine-challenge experiments in 
aged mice demonstrated that vaccination with the engineered ExoN I motif mutant could 
induce protection against virulent challenge (Graham et al., 2012).  
 
The other role of nsp 14 is in the capping process of viral RNAs (Figure 1.6). The cap-1 
structure located on the 5′ end of all viral RNAs both assists in translation and in the evasion 
of host defences, primarily the innate immune response (reviewed by Savajol et al., 2014). 
Four sequential reactions are required; nsp 13 hydrolyzes nascent RNA to yield pp-RNA, 
which then is modified by a yet unidentified guanylyltransferase to generate Gppp-RNA. The 
N7-MTase activity of nsp 14 then methylates the 5′ guanine molecule at the N7 position 
resulting in a final substrate that is further methylated by nsp 16 (Ma et al., 2015). The 
conserved residue Asp 331 in SARS-CoV has been identified as essential for N7-MTase 
activity (Chen et al., 2009). Due to the importance of the capping process in viral replication 
several inhibitors of N7-MTase have been investigated as antiviral drugs (Bouvet et al., 








Figure 1.6: Capping of viral RNA in a process mediated by several viral proteins.  Viral 
RNA is synthesized by the RNA dependant RNA polymerase (RdRp) encoded by nsp 12; the 
polymerization site is denoted by a red circle. The Exon domain (green) of nsp 14 provides a 
proof-reading function to the RNA synthesis step, which is enhanced through the nsp10/nsp 
14 interaction. A cap-1 structure is added to the 5′ end of all newly synthesised RNA 
molecules which involves several sequential activities including an RTPase activity provided 
by nsp 13, GTase activity from a currently unknown source, N7-MTase activity provided by 
nsp 14 (blue), and 2′-O–MTase activity (purple) provided by  nsp 16. Nsp 10 has been 




1.6.4 Nsp 15. 
 
Nsp 15 is a highly conserved manganese-dependent endoribonuclease (NendoU) that has 
been shown to preferentially cleave 3′ of uridylates on both single and double-stranded RNA 
(Ivanov et al., 2004; Bhardwaj et al., 2004; Cao et al., 2008; Snijder et al., 2003). RNA 
substrates that are 2′-O-ribose- methylated are resistant to cleavage by NendoU, therefore 
implying a functional link in the coronavirus replication cycle with the 2′-O-ribose 
methyltransferase encoded in nsp 16 (Ivanov et al., 2004; reviewed in Deng and Baker, 
2018). In IBV the NendoU core domain  is reported to be between aa position 221 and 338, 
with catalytic residues predicted at position 223 and 238 (Deng and Baker, 2018). In 
addition, a threonine (Thr) at position 232 and a Tyr at position 234 may be involved in 
substrate specificity (Deng and Baker 2018). 
 
It was thought originally that NendoU activity was essential for viral RNA synthesis (Snijder 
et al., 2003; Ivanov et al., 2004). Neither HCoV-229E nor MHV could be successfully 
rescued with an engineered Asp to Ala mutation in the non-catalytic residue 298 (HCoV-
229E) or the equivalent residue, 324 (MHV) (Kang et al., 2007; Ivanov et al., 2004). 
Expression of the mutated protein in Escherichia coli (E.coli) demonstrated that the 
Asp324Ala mutation resulted in the MHV nsp 15 protein being insoluble (Kang et al., 2007). 
Interestingly Ala substitutions at three key residues in the catalytic pocket, His 262, His 277 
and Gly 275 resulted in three recombinant MHV viruses which exhibited a subtle defect in 
RNA synthesis and only a slight reduction in progeny viral titres (Kang et al., 2007). A double 
mutant MHV was also constructed, His262Pro and His277Ala, which also exhibited 
reductions in both RNA synthesis and viral titres (Kang et al., 2007). The ablity of these 
mutatant viruses to replicate in vitro indicated to Kang et al., (2007) that NendoU activity may 
not be essential for viral replication.  
 
Overexpression studies have identified that nsp 15 stimulates an interferon (IFN) response 
(Frieman et al., 2009) and can inhibit cellular responses (Lei et al., 2009; Wang et al., 2015). 
These studies however do not take in to account that nsp 15 exist as part of the RTCs in wild 
type (WT) infection. Differences in the cellular localisation of over expressed nsp 15, and nsp 
15 expressed from natural infection have been reported (Heusipp et al., 1997; Shi et al., 
1999; Deng et al., 2017; Athmer et al., 2017; Cao and Zhang 2012). Recent research has 
identified that replication of MHV with deficiency in NendoU activity as a result of either a 
Threonine (Thr) to Methionine (Met) mutation at residue 98 or His to Ala at 262, was highly 
restricted in bone marrow macrophages yet not in fibroblasts (Deng et al., 2017). It was 
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determined that the inoculation of the macrophages stimulated higher levels of type I 
interferon in early infection compared to WT, which restricted viral replication. A similar study 
utilised an MHV virus containing the mutation His277Ala (Kindler et al., 2017); the replication 
of the mutant virus was also restricted in murine bone marrow derived macrophages, and 
viral replication was hampered in IFN treated murine L929 cells. HCoV-229E with the 
corresponding mutation His250Ala also exhibited reduced replication in human blood derived 
macrophages as well as in IFN treated human MRC5 lung fibroblasts. Deng and Baker 
(2018) theorised that the difference in viral replication of the NendoU mutant viruses in the 
different cell types may be a consequence of differences in basal gene expression. 
 
As well as a potential role in mediating antiviral responses, both Kindler et al., (2017) and 
Deng et al., (2017) demonstrated that nsp 15 plays a role in pathogenicity as in both studies 
the mutant viruses were attenuated in vivo. Kindler et al., (2017), could not detect the mutant 
MHV in the livers or spleens of experimental infected mice and concluded that NendU is 
required for efficient viral replication and dissemination in vivo. Interestingly Deng et al., 
(2017) demonstrated that mice infected with the mutant viruses were protected against 
challenge, highlighting a potential role for nsp 15 mutants in coronavirus vaccine 
development.   
 
1.6.5 Nsp 16. 
 
Nsp 16 functions as part of the 5′ capping process on coronavirus RNAs. Computational 
studies first predicted that nsp 16 was a 2′O-methyltransferase (Snijder et al., 2003), with 
functional activity confirmed in FCoV (Decroly et al., 2008). Nsp 16 works in conjunction with 
several other enzymes as part of the capping process, which is summarised in Figure 1.6. 
Notably, nsp 16 mediated methylation is sequence dependent, with methylation occurring on 
the exposed 2’OH on the N7 position of the guanyl cap (Chen et al., 2011). This indicates 
that a functional nsp 14 must be present in WT infection in order for viral RNAs to be capped 
properly (Bouvet et al., 2010). In addition several studies have identified nsp 10 as a 
necessary stimulatory co-factor (Chen et al., 2011; Wang et al., 2015B, Decroly et al., 2011, 
Bouvet et al., 2010). 
 
Mutagenesis studies have identified a role for nsp 16 in both viral replication in vitro and in 
vivo, as well as pathogenicity (Zust et al., 2011; Menachery et al., 2014; Wang et al., 2015B). 
The conserved Lys-Asp-Lys-Glu (KDKE) motif has been identified as essential for 2′O-
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methyltransferase activity (Chen et al., 2011). HCoV-299E with the mutation Asp129Ala in 
the conserved KDKE motif, was found to have altered growth kinetics in fibroblasts, and 
induced greater levels of IFN in macrophages (Zust et al., 2011). The corresponding 
mutation in MHV, Asp130Ala also resulted in reduced viral replication in macrophages and 
increased levels of IFN. The Asp130Ala MHV was also found to be attenuated in 
experimentally infected mice demonstrating that nsp 16 has a role in coronavirus 
pathogenicity (Zust et al., 2011). Similarly Menachery et al., 2014 constructed three SARS-
CoV mutant viruses with individual alanine substitution at KDKE motif residues Lys 46, Lys 
170, and Asp 130. Interestingly replication in IFN lacking Vero cells was unaltered however 
replication in IFN competent Calu3 respiratory cells was reduced. Furthermore vaccination of 
mice with a mouse adapted SARS-CoV containing the Asp130Ala mutation protected 
against lethal challenge.   
 
One other way to reduce nsp 16 activity is to interfere with the nsp10/16 interaction (Chen et 
al., 2011; Wang et al., 2015). Biochemical activity assays demonstrated that nsp 16 activity 
increased in a dose dependant manner with nsp 10 (Wang et al., 2015B). A number of 
residues have been identified as important for the nsp 10/16 interaction; using SARS-CoV 
numbering, these include Lys 93 and Tyr 96 in nsp 10, and residues Ala 83, Val 84, Arginine 
(Arg) 86, Glutamine (Gln) 87, Ser 105, Asp 106, in nsp 16 (Decroly et al., 2011; Chen et al., 
2011; Lugari et al., 2010).  Interestingly a small peptide, p29, derived of residues 68 to 96 of 
the MHV nsp 10 was found to act as a competitive inhibitor which reduced both the in vitro 
replication of MHV and a SARS-CoV replicon. Mice inoculated with MHV and immediately 
treated with p29 did not exhibit clinical disease. It was theorised that competitive inhibition 
with p29 induced an IFN response in early infection which reduced viral replication (Wang et 
al., 2015B).       
 
1.7 Structural proteins. 
 
1.7.1 The Spike glycoprotein. 
 
The S protein is a large, ~180 kDa, highly glycosylated type I transmembrane, class I fusion 
protein. The structure of the S glycoprotein is complex as each S promoter or monomeric 
unit, 1162 aa in IBV, consists of a globular head sat upon a stalk like structure which 
complexes with two other S protomers forming a trimeric S glycoprotein (Walls et al., 2016; 
Kirchdoerfer et al., 2016; Shang et al., 2018). Literature referring to the S glycoprotein refers 
to the trimeric arrangement of three individual S promoters which as mentioned above 
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protrude outwards from the viral membrane (Figure 1.7A and 1.7B). The main role of the S 
glycoprotein during infection is to mediate attachment to the host cell receptor, and 
subsequently the fusion of host cell and viral membranes. During this process, the S 
glycoprotein undergoes major conformational changes and as such structures are divided 
into pre-fusion (Figure 1.7A) and post-fusion states (Walls et al., 2016; Walls et al., 2017; 
Kirchdoerfer et al., 2016; Shang et al., 2018, Shang et al., 2018B). A cryo-EM structure has 
been published for the IBV S glycoprotein (Shang et al., 2018), which will be discussed 
further in Chapter 3. The remainder of this section will detail the domains within each S 
protomer and the role of the S glycoprotein in tropism and pathogenicity. The S glycoprotein 
also has a major role in protective immunity which will be discussed further in a later section 
during this Chapter.  
 
 
Figure 1.7: The S glycoprotein. (A) Cryo-EM structure of IBV spike ectodomain in the pre-
fusion conformation as determined by Shang et al., (2018). Each colour represents a 
different S protomer. The pre-fusion structure contains an S1 globular head sat upon an S2 
stalk like structure. (B) Structure of a single S protomer in the pre-fusion conformation as 
determined by Shang et al., (2018). S1-NTD and S1-CTD are receptor binding domains 
located in the S1 subunit. The S2 subunit contains heptad repeats (HR1 and HR2) as well as 
the fusion peptide (FP). (C) Schematic representation of the coronavirus S gene. The S gene 
consists of a large ectodomain flanked by a single sequence (SS) and a cytoplasmic tail 
(CT). The ectodomain is divided into two subunits, S1 and S2. The exact genome location of 
FP is unknown. Highlighted gene sections are not to scale and noted amino acid location are 




Each S protomer can be broadly divided into three sections; a signal sequence (SS), a large 
ectodomain followed by a cytoplasmic tail (CT; Figure 1.7C). The ectodomain can be further 
divided in two, the amino terminal (NTD) S1 subunit and the carboxyl terminal (CTD) S2 
subunit. The S1 domain has been shown to mediate receptor binding, and is further divided 
into two subdomains (SD), both containing receptor binding abilities; the amino terminal 
domain (S1-NTD) encompassing residues 21-237 and the carboxy terminal domain (S1-
CTD) encompassing residues 269 – 414 (Shang et al., 2018). The IBV S1 subunit is noted to 
contain three hypervariable regions (HVR), which are areas of concentrated amino acid 
differences between IBV strains, with HVR1 and HVR2 located in the S1-NTD, and HVR3 in 
the S1-CTD; residues 38 – 51, 99 – 115 and 274 – 387 respectively (Niesters et al., 1986; 
Cavanagh et al., 1988; Moore et al., 1997; Valstro et al., 2016). Typically it is thought that 
S1-NTD binds sugar based receptors and S1-CTD binds protein receptors (Liu et al., 2015; 
Promkuntod et al., 2014; Wong et al., 2004). The receptors for several coronaviruses are 
known (Table 1.3) however the receptor for IBV remains undetermined although research 
has implicated sialic acids (Bingham et al., 1975; Cavanagh et al., 1986; Winter et al., 2006; 
Winter et al., 2008) and lectins (Zhang et al., 2012). Promkuntod et al., (2014) mapped the 
RBD for the M41 strains to residues 19-272 in the S1-NTD, highlighting residues Asparagine 
(Asn) 38, His 43, Pro 63 and Thr 69 as critical. This research was however completed using 
chimeric S1 subunits expressed from E.coli, and not whole S glycoproteins expressed from 
chicken cells. The glycosylation of the S glycoprotein may have a role in receptor binding 
(Jeffers et al., 2004; Jeffers et al., 2006; Han et al., 2007), and such post translational 
modifications may not be comparable between bacteria and chicken cells (reviewed by Goh 
and Ng, 2018). 
Table 1.3: Known receptors utilised for coronavirus entry.  
Genus Species Host receptor 
Alphacoronavirus 
FCoV 
Aminopeptidase N (APN) TEGV 
CCoV 
HCoV-NL63 




Carbohydrate, Neu 5,9 Ac2 
HCoV-OC43 
MHV 
Carcinoembryonic antigen-cell adhesion 
molecule (CEACAM1) 
SARS-CoV ACE 2 
MERS-CoV Dipeptidylpeptidase 4 (DPP4) 
 
Notes: Table adapted from Belouzard et al., (2012) and Raj et al., (2013). 
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Similarly to the S1 subunit, the S2 subunit also contains several subdomains and notable 
features. One such feature is the presence of two regions of extended α helices, referred to 
as heptad repeats (HR1 and HR2); a typical feature of class I fusion proteins (Bosch et al., 
2003; Shang et al., 2018). Both HR1 and HR2 have a role in cellular entry of the 
nucleocapsid by drawing the virus and cell membrane together as a result of conformational 
changes in the S glycoprotein upon receptor binding (Sainz et al., 2005, Walls et al., 2017). 
The S2 subunit also contains a transmembrane domain (TM), and a fusion peptide (FP). FPs 
are typically 15 to 25 amino acids in length, apolar, and highly conversed within virus families 
(reviewed by Belouzard et al., 2012). Experiments utilising SARS-CoV, MERS-CoV and 
MHV support the notion that the FP resides in the S2 domain (Madu et al., 2009; Basso et 
al., 2016; Ou et al., 2016). Furthermore Shang et al., (2018) identified a potential region on 
the cryo-EM structure of the S glycoprotein from M41, in which the FP is thought to be 
located. Interestingly despite the S2 not containing an RBD, the extended tropism of the 
Beaudette strain, and notably the ability to replicate in Vero cells is conferred by the S2 
subunit (Bickerton et al., 2018, Bickerton et al., 2018b).  This result has been attributed to a 
secondary cleavage site, Arg-Arg-Arg, referred to as the S2′ site, located at position 690 
therefore highlighting a role for the S2 subunit in host tropism (Madu et al., 2007; Yamada 
and Liu 2009; Bickerton et al., 2018; Bickerton et al., 2018b). As well as the secondary 
cleavage site, a primary cleavage site exists some coronaviruses, including IBV, located 
between the S1 and S2 domain. Cleavage at this site is typically mediated by furin or furin 
like host cell proteases resident in the Golgi apparatus during assembly and exocytosis (de 
Haan et al., 2004; reviewed by Belouzard et al., 2012). This means the S1 and S2 subunits 
are non-covalently linked in the pre-fusion structure. IBV is cleaved at amino acid residues 
Arg-Arg-Phe-Arg-Arg although there is some variability in this sequence between individual 
strains (Cavanagh et al., 1986; Jackwood et al., 2001). It must be noted that the S 
glycoprotein of some coronaviruses including SARS-CoV and MHV is not cleaved during 
viral exit (Rota et al., 2003; Frana et al., 1985).   
 
As expected due to its role in viral entry, and eluded to in the above paragraph, the S 
glycoprotein determines cellular tropism and host range (Sanchez et al., 1999; Tekes et al., 
2010; Casais et al., 2003; Armesto et al., 2011). This has been demonstrated for several 
coronaviruses including porcine respiratory coronavirus (PRCV), TGEV, SARS-CoV, MHV, 
feline infectious peritonitis virus (FIPV) and IBV (reviewed by Belouzard et al., 2012). The 
difference in tissue tropsim between PRCV and TGEV was the result of a deletion in the S 
gene (Rasschaert et al., 1990; Schultze et al., 1996). The ablity of SARS-CoV to jump the 
species barrier from palm civets to humans was mapped to two mutations with the S 
glycoprotein, Lys479Asn and Ser487Thr respectively (Li et al., 2005). MHV was found to be 
able to replicate in feline cells, when the ectodomain of the S gene was exchanged for the 
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counterpart seqeunce derived from FIPV (Kuo et al., 2000). In addition Haijema et al., 
(2003), generated the reciprocal virus, FIPV with the S ecotodomain from MHV which was 
found to be able to replicate in murine cells. Sequence differences between S glycoproteins 
are also responsible for the range of in vitro tropisms exhibited by IBV strains (Casais et al., 
2003; Armesto et al., 2011). Several strains, often those isolated from field conditions, are 
restricted to replication in ex vivo tracheal organ cultures (TOCs) and embryonated eggs; 
this includes strains such as 4/91 and QX (Armesto et al., 2011; Bickerton et al., 2018b). 
Laboratory strains such as M41-CK and Beaudette as well as the vaccine strain H120 are 
able to be propagated in primary chicken kidney (CK) cells (Casais et al., 2003; Bickerton et 
al., 2018b). The Beaudette strain is particularly unusual as it exhibits extended tropism and 
is able to replicate in Vero cells, a continuous cell line derived from African Green Monkey 
kidney epithelial cells, immortalized chicken embryo fibroblasts (DF1 cells) and Baby 
hamster kidney (BHK) cells (Casais et al., 2003; Keep et al., 2018).  
 
The role of the S glycoprotein in pathogenicity is less established for IBV. Research utilising 
MHV, SARS-CoV and FIPV has indicated the S gene as a pathogenicity factor (Phillips et 
al., 1999; Li et al., 2005; Miura et al., 2008; Chang et al., 2012), however both Hodgson et 
al., (2004) and Armesto et al., (2011) demonstrated that this was not necessarily the case for 
IBV. The ectodomain of recombinant IBV (rIBV) Beau-R, a Beaudette based molecular 
clone, was exchanged for either the ectodomain of a pathogenic strain M41-CK or 4/91, 
generating rIBV BeauR-M41(S) and BeauR-4/91(S) respectively; both viruses were 
apathogenic in vivo (Hodgson et al., 2004; Armesto et al., 2011). The incorporation of the S 
gene from Beau-R into a pathogenic IBV was however found to be attenuating indicating that 
the S glycoprotein of IBV is a pathogenicity factor (Stevenson-Leggett, P. 2018). 
 
1.7.2 The Envelope protein. 
 
The E protein is small, 76 to 109 aa, 12.4 kDa and contains a single hydrophobic domain 
and a charged CT (reviewed by Ruch and Machamer, 2012 and DeDiego et al., 2014). 
Unusually the protein is present in only small quantities in the viral membrane. Ion channel 
activity has been reported which is hypothesised to require the oligomerisation of individual 
E proteins (Wilson et al., 2004; Wilson et al., 2006). E is thought to be involved in several 
viral processes during infection, including virus assembly and egress (Lim and Liu, 2001; Ye 
and Hogue, 2007; reviewed by Ruch and Machamer, 2012 and DeDiego et al., 2014). The 
IBV E protein has been reported to localise to the Golgi during infection (Corse and 
Machamer, 2000). Despite the role of the E protein in viral replication not being fully 
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understood, E has been implicated in the pathogenesis of SARS-CoV (DeDiego et al., 2011; 
DeDiego et al., 2014; DeDiego et al., 2014B; Jimenez-Guarideno et al., 2014; Regla-Nava et 
al., 2014).  
 
1.7.3 The Membrane protein. 
 
The M protein is a small, 200aa, 25-30 kDa, protein that contains three hydrophobic TM 
domains as well as a short NTD that is exposed on the outside of the viral envelope. Within 
the viral envelope, a long tail, located at the CTD contains both an amphiphilic domain and a 
hydrophilic domain (Klumperman et al., 1994; reviewed by Hogue and Machamer 2008). The 
M protein is glycosylated at the NTD, is the most abundant of all the structural proteins and 
is a key player in virion assembly (de Haan et al., 1999; Neuman et al., 2011; reviewed by 
Fehr and Perlman, 2015). Virion assembly involves both M-M interactions that are thought to 
exclude host membrane proteins from the viral envelope (de Hann et al., 2000; Neuman et 
al., 2008) and M-S interactions that mediate assembly of the S protomers into the virion 
particle (de Hann et al., 1999; Neuman et al., 2011). Interactions with N and E, as well as 
genomic RNA packaging signals have also been demonstrated (Vennema et al., 1996; 
Opstelten et al., 1995; Narayanan et al., 2000; Lim and Liu, 2001; Kuo and Masters, 2002).  
It has been hypothesised that M exists in two conformations during infection with each 
conformation mediating specific interactions and/or tasks during assembly (Neuman et al., 
2011). 
 
1.7.4 The nucleocapsid protein. 
 
The N protein is a phosphorylated protein that has several functions throughout the viral life 
cycle but its primary purpose is the encapsidation of genomic RNA. Each N protein consists 
of three distinct domains; a structured NTD and CTD, with a disordered central region 
situated between the two (reviewed by McBride et al., 2014). All three domains have been 
demonstrated to bind RNA in vitro and in addition a dimerization function has been identified 
in the CTD (Surjit et al., 2004) as well as the identification of residues in the disordered 
region that interact with nsp 3 (Verheije et al., 2010; Keane et al., 2013). Two specific RNA 
substrates have been identified including TRSs as well as the genomic packaging signals 
(Stohlman et al., 1988; Molenkamp et al., 1997). In addition to a role in nucleocapsid 
formation, the N protein is therefore involved viral transcription and translation (Baric et al., 
1988; Zuniga et al., 2004).  Interestingly the development of reverse genetics systems for 
coronaviruses in the early 2000s highlighted the pivotal role of N in viral replication as it was 
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found that the N protein was either essential, or significantly enhanced the recovery of 
infectious progeny virions (Yount et al., 2000, Casais et al., 2001; Almazan et al., 2004).     
 
1.8 Accessory proteins. 
 
The coronavirus genome encodes several accessory proteins of the which the number and 
location is virus specific. IBV encodes four known accessory proteins, 3a, 3b, 5a, and 5b of 
58, 65, 66, and 83 aa in length respectively (reviewed by Cavanagh,  2007). Neither of these 
proteins is required for viral replication in cell culture or in ovo (Casais et al., 2005; Hodgson 
et al., 2006; Laconi et al., 2018; van Beurden et al., 2018). There is however some evidence 
suggesting a role of 3a and 3b during replication in ex vivo tracheal organ cultures (TOCs), 
as rIBVs not expressing these proteins exhibited lower titres 24 hpi in comparison to WT 
(Hodgson et al., 2006).  Although overall the functions of the accessory proteins are still 
poorly understood, research has identified potential roles in mediating IFN responses as well 
as in host cell translation shut off (Kint et al., 2015, Kint et al., 2016, Laconi et al., 2018). All 
four accessory proteins have been implicated as pathogenicity factors (Laconi et al., 2018). 
In addition the IBV strain H52 lacking either 3a and 3b or 5a and 5b or all four proteins, has 
been shown to protect chickens against homologous challenge with the level of protection 
determined by ciliary activity comparable to the H52 vaccinated control group (van Beurden 
et al., 2018).  
 
The genome of IBV also encodes a potential fifth accessory protein of 94 aa, termed 4b. This 
protein is translated from a sgmRNA that utilises a non-canonical TRS-B from what was 
previously considered a non-coding IR located between gene M and gene 5 (Bentley et al., 
2013B). Despite the function remaining undermined, 4b has been detected during viral 
infection and deletion of 4b has been shown to have no effect on viral replication in CK cells 
(Bentley et al., 2013B, Hall., 2017).   
 
1.9 Reverse genetics systems for coronaviruses. 
 
The advent of reverse genetics systems has opened up the possibility to investigate 
pathogenic and immunogenic determinants in the context of live viral infections. 
Subsequently this information can be used for the development of rationally designed 
vaccine viruses.  There are several technologies that have been used, and are still used to 
generate infectious clones of coronaviruses including IBV, SARS-CoV, MERS-CoV, HCoV-
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299E, HCoV-OC43, TEGV, FIPV and MHV. These systems have been independently 
developed and employ several different strategies to generate infectious recombinant virus 
including in vitro ligation, RNA recombination and the use of both Bacterial Artifical 
Chromosome (BAC) and Vaccinia virus (VV) vectors for the generation of infectious cDNA 
copies of the RNA genome (Koetaner et al., 1992; Kuo et al., 2000; Almazan et al., 2000; 
Yount et al., 2000; Casais et al., 2001; Thiel et al., 2001; Gonzalez et al., 2002; Yount et al., 
2002; Haijema et al., 2003; Yount et al., 2003; Coley et al., 2005; Youn et al., 2005; St-Jean 
et al., 2006; Tan et al., 2006;  Fang et al., 2007; Becker et al., 2008; Donaldson et al., 2008; 
Tekes et al., 2008; Pfefferle et al., 2009; Tylor et al., 2009; Balint et al., 2012; Tekes et al., 
2012; van der Worm et al., 2012; Almazan et al., 2013; Scobey et al., 2013; van Beurden et 
al., 2017). The number of reverse genetic systems in use does portray the illusion that 
development was easy, however the large size of the RNA genome paired with the toxicity of 
some virus derived cDNAs in bacteria presented a magnitude of problems that required out 
of the box thinking to solve.  As with all reverse genetics systems, there are advantages and 
disadvantages in all the developed strategies.  
 
The first reverse genetic strategy employed for a coronavirus was targeted RNA 
recombination, which involves homologous recombination events between donor RNA 
molecules and a recipient RNA molecule. One of the RNA molecules must contain a 
selective marker to differentiate between parental and recombinant virus, often this is 
temperature sensitivity or host range (Koetzner et al., 1992; Kuo et al., 2000; Haijema et al., 
2003). One of the main disadvantages of this system is it allows for only the modification of 
the structural and accessory genes, and not the replicase. Targeted RNA recombination has 
been successfully used for the H52 vaccine strain of IBV (van Beurden et al., 2017), 
however several non-coding mutations had to be incorporated into the RNA molecules for 
cloning purposes; although silent these may impact secondary RNA structure and 
transcription of viral ORFs.  
 
Another strategy used is in vitro ligation, which was originally utilised for TGEV (Yount et al., 
2000) but has also been successfully applied for the Beaudette strain of IBV (Fang et al., 
2007; Tan et al., 2006; Youn et al., 2005). The process involves the assembly of a full length 
infectious cDNA from several contiguous cDNA fragments that collectively span the entire 
genome.  Each fragment is flanked by naturally occurring or engineered restriction sites, 
which allowed ligation to proceed in an ordered fashion. The full length cDNA is under the 
control of a T7 RNA promoter allowing for in vitro transcription, and the resulting transcripts 
are transfected into a susceptible cell line along with N gene transcripts.   The in vitro cDNA 
assembly approach is both simple and straightforward; the process does however rely on 
50 
 
continuous amplification of the individual cDNA fragments either in bacteria or from PCR, 
both of which can introduce error. Also if using engineered restriction sites this may 
introduce coding or non-coding mutations into the viral genome. Finally using in vitro ligation 
for the recovery of recombinant virus is very much a one shot approach, and additionally 
cannot be used to study lethal mutations.   
 
Several groups have combined in vitro ligation with a vector such as BAC or vaccinia virus 
(VV), of which the latter has been utilised for HCoV-229E (Thiel et al., 2001), MHV (Coley et 
al., 2005), SARS-CoV (Van den Worm et al., 2012), FIPV (Tekes et al., 2008; Tekes et al., 
2012), and IBV (Casais et al., 2001). The use of a vector removes the need for plasmid 
intermediates, and allows for unlimited production of the full length cDNA with vaccinia virus 
introducing fewer errors compared to BAC. Although there is a risk of error, BAC vectors 
have been used for TGEV (Almazon et al., 2000), SARS-CoV (Almazan et al., 2006), HCoV-
OC43 (St-Jean et al., 2006), FIPV (Balint et al., 2012) and MERS-CoV (Almazan et al., 
2013). The majority of BAC based reverse genetic systems utilise a Cytomegalovirus (CMV) 
late early promoter allowing for transcription in the cell nucleus, however this process does 
come with a risk of splicing as the RNA exits the cell nucleus. An alternative approach is to 
use a T7 promoter and use in vitro transcription to produce RNA that is then subsequently 
transfected into susceptible cells (Pfefferle et al., 2009). For vaccinia vectors there are two 
strategies that have been used for the recovery of infectious virus including in vitro 
transcription followed by transfection into a susceptible cell line as well as the method used 
in this PhD project in which a fowlpox virus delivers the T7 RNA polymerase into cells that 
are subsequently transfected with IBV cDNA (Casais et al., 2001). Notably this method also 
works with a BAC vector, as Tylor et al., (2009) transfected cells infected with a vaccinia 
virus encoding the T7 polymerase.   
 
1.10 Infectious Bronchitis. 
 
Infectious bronchitis (IB) is primarily an acute highly contagious respiratory disease of 
poultry. The diesease was first descibed in the 1930s (Schalk and Hawn, 1931) though at 
this time the aetiological agent, IBV, was unknown. Classical clinical signs include snicking 
(the chicken version of a sneeze), rales (vibration in the bronchi), watery eyes, nasal 
discharge and lethargy (Dhinaker and Jones, 1997). In addition reduced cillia movement, or 
complete cessation of ciliary activity (cilostasis), is observed in trachea of infected birds. This 
IBV inflicted damage renders infected birds susceptible to secondary bacterial infections, 
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and it is often these secondary infections, for example colibacillosis, that result in mortality 
(Matthijs et al., 2003; Cavanagh and Naqi 2003). 
 
The primary replication site of IBV is epithelial cells that line the respiratory tract however 
several strains can infect epithelial cells that line the enteric tract, oviducts and kidneys 
(Jones and Jordan, 1970; Jones and Jordan, 1971; Ambali and Jones, 1990; Benyeda et al., 
2009). In addition to classical IB symptoms, extensive pathology including inflammation of 
the kidneys and oviducts is often observed in birds infected with nephropathogenic and 
enterotropic strains (Cook et al., 2001; Bayry et al., 2005; Liu and Kong, 2004). The 
nephropathogenic strain B1648 first isolated in 1984 caused large outbreaks in Belgium, 
Holland and France, with infected birds exhibiting enlarged pale kidneys with urates in 
collecting tubules (Cook et al., 2012; Reddy et al., 2016). The IBV strain QX, first identified in 
the Qingdao region in China in 1996, caused the abdomen of infected birds to swell to such 
an extent that birds developed a hunched “penguin like” posture (YuDong et al., 1998). In 
addition, infection of the oviducts of young birds resulted in false-layer syndrome (Gough et 
al., 2008; Benyeda et al., 2009). 
 
IBV and the resulting IB is not only a welfare concern but an economic concern for countries 
with industrialised poultry industries. As reviewed by Cavanagh (2007) IBV infected broilers 
exhibit reduced weight gain and poor meat quality, whilst infected layers produced fewer 
eggs, as well as poor quality eggs including those with soft shells and watery albumens.  A 
report by the Department for Envirmonent, Food and Rural Affairs (DEFRA) in 2005 
estimated the ecomonic burden of IB to the UK to be in the region of £20 million per annum 
(DEFRA, 2005).  
 
1.11 Current vaccination practices. 
 
Attempts to control IBV were employed as early as the 1940’s using a crude “controlled 
exposure” method in which birds deliberately infected with attenuated IBVs were introduced 
into the naïve flock during the rearing period. As the IBV strain naturally spread, birds were 
“protected” against IBV infection during the laying period, thereby reducing the economic 
consequences of IB (Cook et al., 2012).  Today, live attenuated vaccines administered by 
eye or nasal drop or en masse through sprays or in the drinking water are routinely used to 
control IBV infection in poultry flocks (Jordan, 2017). Breeders and layers are subsequently 
boosted at defined intervals during the course of their lifetime with a mixture of live 
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attenuated or inactivated vaccines (reviewed by de Wit et al., 2011). Inactivated vaccines are 
administered intramuscularly or via subcutaneous infection and often birds receive a series 
of vaccinations following a live-attenuated vaccination prime. Typical timings of vaccinations 
are as follows: Broilers are mass vaccinated with live attenuated vaccines at one day of age 
and may subsequently receive secondary or otherwise termed booster vaccinations between 
14 and 18 days of age.  Breeders and layers receive live attenuated vaccines at two, four 
and six weeks of age followed by the administration of inactivated vaccines after 20 weeks of 
age (Jordan, 2012).  
 
Unfortunately, a single IBV serotype vaccine does not provide adequate cross-protection 
against the wide variety of circulating strains, discussed further is section 1.14 as well as in 
Chapter 4. Poultry produces therefore use a multi-monovalent strategy for vaccination in 
which vaccinations of at least two serotypes are administered, e.g. H120 + D274, although if 
administered at the same time, there is a risk of recombination events between the vaccine 
viruses, and a risk that adequate immune responses toward both strains will not be induced 
equally. The other strategy is to vaccinate with different serotypes at different times, for 
example for broilers, one vaccine serotype, H120, will be administered at one day of age and 
then a second, CR88, at 14 days of age. Poultry producers either pick IBV vaccines suitable 
against known circulating strains or pick vaccines known to induce an adequate level of 
cross-protection (reviewed by Jordan, 2012). Both strategies require knowledge of known 
circulating strains and unfortunately may not be effective if a novel strain emerges, such as 
seen with QX in the early 2000’s (Lui and Kong, 2004). In addition, the chicks vaccinated via 
the latter method remain susceptible during the two-week period between the primary and 
secondary/booster vaccinations.  
  
Both the use of live attenuated vaccines and inactivated vaccines come with advantages and 
disadvantages. Inactivated vaccines or otherwise termed killed vaccines offer minimal risk of 
vaccine reversion or the potential for vaccine related IB-like symptoms. However, 
manufactures need to develop protocols for the optimal method of destroying virus infectivity 
whist retaining antigenicity as well as developing suitable adjuvants. As a result, killed 
vaccines typically have higher manufacturing costs than their live attenuated counterparts, 
as well as a more laborious method of administration. Despite these downsides, killed 
vaccines when administered correctly do result in the slow release of antigen and long 




All current live attenuated vaccine viruses are generated through serial passaging of a 
virulent field isolate through embryonated hens’ eggs, typically up to 100 passages (Bijenga 
et al., 2004; Geerlings et al., 2011). The most well used vaccines are H120 and H52, both of 
the Massachusetts serotype, with the respective number denoting the passage number in 
embryonated eggs, 120 and 52 passages, respectively (Bijlenga et al., 2004). Other well 
used live-attenuated strains are D1466 and D274, both of which were generated in the 
1980’s and CR88 (4/91 serotype) developed in the 1990s (reviewed by Cook et al., 2012). 
All these vaccines, and all live attenuated IBV vaccines in general, in order to be effective, 
must be able to replicate in the respiratory tract to stimulate protective immune responses 
and as a result some damage to the epithelial lining will occur. A balance needs to be 
achieved between a vaccine  virus that is attenuated to such a degree that it can no longer 
replicate sufficiently to induce the relevant immune responses and one that is not attenuated 
enough that it causes serious damage, and IB associated symptoms, after administration. 
Live attenuated vaccines therefore have varying degrees of pathology and may not be 
suitable for all flocks dependant on age and immune status; the vaccines H120 and H52 
provide a classic example of this consideration. H120 is acknowledged as a mild vaccine 
and can be used on chicks as young as one day of age, whilst H52 due to the lower number 
of passages in embryonated hens’ eggs is “hotter” and is only used for booster vaccination in 
older chicks (Hoekstra and Rispens, 1960; reviewed by Bijlenga et al., 2004 and Cook et al., 
2012).  
 
Although live attenuated vaccines are well used, cheap and relatively easy to produce and 
administer, there are some notable disadvantages including vaccines that can render the 
birds more susceptible to cobibacillosis (Smith et al., 1985; Matthijis et al., 2003) due to 
excessive epithelial damage and the process also renders the vaccine virus embryo lethal 
and therefore unsuitable for in ovo administration. In addition, and more importantly a fine 
balance needs to be achieved between the loss of pathogenicity and the retention of 
immunogenicity which can only be achieved through trial and error. Despite this process 
being a well-established method of vaccine preparation, the exact molecular mechanisms 
that result in attenuation are unknown. Each batch of vaccine virus therefore needs to be 
thoroughly tested to ensure that administration in vivo will not result in any adverse IB like 
symptoms. Recent research has indicated that only a few consensus level mutations are 
acquired over the passaging process thereby presenting a short possible route back to 
virulence (Oade et al., 2019). The risk of reversion is a notable disadvantage of current live 
attenuated vaccines and is heightened when live attenuated vaccines are administered 
incorrectly, and either accidentally or purposely overdiluted (reviewed by Bijlenga et al., 
2004). As a result of this risk, there is consequently a drive to rationally attenuate IBV, and 
subsequently rationally design IBV vaccines which have a significantly reduced risk of 
54 
 
reverting to a virulent phenotype in vivo, and the added advantage that they can be 
potentially administered in ovo, thereby allowing the chick to be protected from the point of 
hatch.  
 
1.12 Immune responses to IBV. 
 
There are several immune responses to IBV infection and IBV vaccination that despite 
several decades of research only remain partially understood. IBV vaccination is 
predominantly associated with humoral immunity and the generation of virus neutralising 
(VN) antibodies (reviewed by Bijlenga et al., 2004; Cavanagh et al., 2007, de Wit and Cook, 
2014). This immunity is largely associated with the S glycoprotein and this association will be 
discussed further in Chapter 3 and Chapter 4. In terms of humoral immunity both systemic 
IgM and IgG and mucosal IgA responses have been demonstrated to be determinants in 
viral clearance (reviewed by Bande et al., 2015). IgM has been shown to appear at five days 
post infection (dpi) and reaching a peak between eight and ten days. Viral replication in the 
Harderian Gland (HG) influence the development of mucosal IgA responses which have 
been demonstrated to be important in birds vaccinated via the intraocular route (Meir et al., 
2012). Maternally derived antibodies (MDAs) have also been shown to be important in the 
early protection of IBV with MDA shown to protect around 97% of birds at one day of age 
declining to 30% by seven days of age (Mondal and Naqi, 2001). MDA is however an 
important consideration for vaccine strategies as MDA is considered to have a negative 
impact on vaccine efficacy (Klieve and Cumming, 1988).  
 
As well as humoral immunity, cell mediated and innate immune responses also have roles 
during IBV infection. Innate immune responses are considered the first line of defence and 
include the type I and type II interferon (IFN) response, characterised by the secretion of 
both IFN alpha (IFN α) and IFN beta (IFN β), and IFN gamma (IFN γ) respectively (reviewed 
by Bande et al., 2015). The IFN I response, and specifically IFN α has been shown to inhibit 
IBV infection in vitro (Pei et al., 2004). The administration of IFN α in vivo one day prior to 
IBV challenge was shown to partially protect birds from clinical disease (Pei et al., 2004). 
The onset of IFN β production is delayed during in vitro IBV infection, and in IBV infected 
cells the early accumulation of double stranded RNA does not correlate with early onset of 
IFN β induction (Kint et al., 2015). IBV and coronaviruses in general, have employed several 
strategies of evading and modulating the host IFN responses including cellular membrane 
rearrangements that shield viral RNA replication (Maier et al., 2013; Maier et al., 2016), the 
presence of a methylated cap structure at the 5’ end of all viral RNAs, and viral proteins that 
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directly and indirectly affect the IFN response. For SARS-CoV the accessory proteins have 
been shown to modulate the IFN response (reviewed by Liu et al., 2014). Similarly, for IBV, 
the accessory proteins 3a and 3b have also been demonstrated to modify the IFN response 
at both the transcriptional and translation level (Kint et al., 2015). Roles for the coronavirus N 
and nsp 3 proteins have also been implicated in the IFN response pathways (Kuri et al., 
2011; reviewed by Zhong et al., 2012; Fehr et al., 2015).  
 
The IFN response feeds into both cell mediated immunity and humoral immunity. The type I 
IFN response provides a rapid response to viral infection through the activation of 
macrophages and natural killer (NK) cells which in turn leads to the activation of humoral 
immunity (reviewed by Bande et al., 2015). Similarly, the type II response also activates both 
cell mediated responses and humoral responses (reviewed by Bande et al., 2015). For cell 
mediated immunity, cytotoxic T cells (CTLs) have been shown to be responsible for the 
clearance of IBV infection, and both the S and N protein has been associated with the 
stimulation of such responses (Seo et al., 1997; reviewed by Collison et al., 2000; Seo et al., 
2000). Additionally, the adoptive transfer of T cells harvested from chicks 10 dpi to naïve 
chicks prior to IBV challenge demonstrated that IBV primed CD8+ lymphocytes could induce 
protection against acute infection (Seo et al., 2000). A role for NK cells has also been 
indicated in the clearance of IBV infection (Pardo et al., 2004; Vervelde et al., 2013).    
 
1.13 The role of S in protective immunity and the design of rationally 
attenuated rIBV for use in vaccination. 
 
The S glycoprotein is the main target for vaccine development as it has been demonstrated 
by several studies to induce virus neutralising (VN) antibodies (Abs; Cavanagh et al., 1984; 
Cavanagh et al., 1986; Kock et al., 1990; Kant et al., 1992; reviewed by Jordan, 2017). As 
such the serotype of any IBV is determined by the S glycoprotein. A complicated relationship 
exists, however, between the sequence of the S gene, the resulting genotype classification, 
and the serotype grouping. As reviewed by de Wit, (2011) different serotypes can have 
remarkably high similarity between their genomes and conversely viruses within the same 
serotype grouping can exhibit large variations within the S gene sequence. This complicated 
relationship is further is exacerbated by the lack of consensus to which areas of the S1 are 
compared as well as the criteria used to distinguish genotypes (Valastro et al., 2016). 
Despite advances in sequencing methods, serotype groupings remain the common method 




The S glycoprotein has been demonstrated that it is capable of inducing a protective immune 
response (reviewed by de Wit et al., 2011; Jordan,  2017).  Reverse genetics has been used 
to generate recombinant IBVs (rIBVs) based on the apathogenic Beaudette strain expressing 
heterologous S genes, from either the pathogenic strain M41-CK or 4/91  (Casais et al., 
2003; Armesto et al., 2011). Vaccination with these rIBVs, BeauR-M41(S) and BeauR-
4/91(S), was demonstrated to offer protection against homologous challenge with the wild 
type (WT) IBV corresponding to the donor S, M41-CK and 4/91(UK) respectively (Hodgson 
et al., 2004; Armesto et al., 2011). This research therefore highlighted the possibility of using 
rationally designed rIBV as a vaccine virus. Both the viruses used by Hodgson et al., (2004) 
and Armesto et al., (2011) contained the full ectodomain of the S gene from the donor virus. 
In a similar study Shirvani et al., (2018) used a recombinant Newcastle disease virus (rNDV) 
to express the IBV S glycoprotein; the authors concluded that vaccination protected the birds 
against clinical disease but had no effect on viral shedding.  
 
The two subunits that make up the S glycoprotein (Figure 1.7) however are not reported to 
play equal contributions in protective immunity. The S1 subunit has been shown to induce 
the majority of VN Abs and therefore is considered to play the dominant role (Mockett et al., 
1984; Cavanagh et al., 1986a, Cavanagh et al., 1986B, Ignjatovic and Galli, 1994; Moore et 
al., 1997; Song et al., 1998; Johnson et al., 2003). This is not unexpected as the S1 contains 
the RBD (S1-CTD and S1-NTD), and consists of 3 hyperviable regions (HVRs) which have 
been reported to correlate to VN Abs (Cavanagh et al., 1988; Shang et al., 2018). 
Predictably the amino acid sequence of the S1 subunit is less conserved between IBV 
strains than the S2 (Cavanagh et al., 1984; Cavanagh et al., 1986b; Binns et al., 1985; 
Kusters et al., 1989; Valastro et al., 2016).  
 
Several groups have demonstrated a level of protection induced in vivo by recombinant S1 
(rS1) protein (Song et al., 1998; Johnson et al., 2003; Yan et al., 2013; Toro et al., 2014; 
Zhao et al., 2017). Research groups have taken several alternative routes at producing the 
S1 antigen, with some vaccinating birds with rS1 protein (Song et al., 1998) and others 
vaccinating with S1 expression vectors including fowl adenovirus, FPV, DNA plasmids and 
NDV (Johnson et al., 2003; Chen et al., 2010; Yan et al., 2013; Toro et al., 2014; Zhao et al., 
2017; Shirvani et al., 2018); these studies will be discussed further in Chapter 3. There has 
been some investigation into the S2 subunit with Shirvani et al., (2018) vaccinating birds with 
a recombinant Newcastle disease virus (rNDV) expressing the S2 subunit; there was no 
difference in viral load in comparison to the unvaccinated control group. The potential role of 
the S2 subunit in protective immunity will also be discussed further in Chapter 3.  
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1.14 Definitions of protection. 
 
There are several methods in use to determine whether vaccinated birds are protected from 
challenge with the method used dependant on a variety of factors including whether the 
vaccine is going to be licenced in the USA and/or The European Union (reviewed by de Wit 
and Cook, 2011; Jordan, 2017). Surprisingly the assessment of clinical signs and therefore 
whether the bird is free from clinical disease is rarely taken into account for vaccine efficacy 
in licencing terms but is used by researchers in academic settings.  For license in the USA, 
vaccinated/challenged birds must be free of the challenge virus, and that is determined by 
virus re-isolation in specific pathogen free (SPF) embryonated hens’ eggs from tracheal 
swabs taken post challenge (reviewed by de Wit and Cook, 2011). Whilst virus isolation in 
embryonated hens’ eggs is regarded as the gold standard technique for determination of the 
presence of IBV, molecular methods including quantitative real time polymerase chain 
reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) are commonly used by 
researchers.  
 
Vaccines to be licenced in the European Union have to meet the standards set by the 
European Pharmacopeia (2010) which uses a ciliostasis or otherwise referred to ciliary 
activity test as a measure of tracheal cilia function. Reduced ciliary activity is a marker of the 
presence of IBV (Cavanagh et al., 1997; Cook et al., 1999) and it has been demonstrated 
that increased ciliary activity correlates to increased protection against secondary bacterial 
infections (Jackwood et al., 2015). The European Pharmacopeia (2010) states that in order 
for a chicken to be deemed fully protected at least 50% ciliary activity must be retained post 
challenge in nine out of ten tracheal rings sampled. 
 
1.15 Cross protection.  
 
One of the major problems faced by IBV vaccine manufacturers is the lack of cross 
protection induced between the different IBV serotypes (reviewed by Cavanagh, 2003; de 
Wit et al., 2011; de Wit and Cook, 2014). In a classic study, Cavanagh et al., (1997) 
challenged chickens with a variety of strains with varying sequence homology after 
vaccination with IBV 6/82. The broad conclusion was that the probabilities of successful 
vaccination decreased as the sequence difference in the S gene of the challenge and 
vaccine strain increased. However, as mentioned there is a complicated relationship 
between gene sequencing and serotyping and as expected cross protection is equally 
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complex. Abdel-Moneim et al., (2006), demonstrated that vaccination with H120 could not 
induce protection against Egypt/F/03 challenge; the sequence of the S1 subunit between the 
vaccine and challenge strains differed by only 34 nucleotides (nt; 14 aa). Hodgson et al., 
(2004) demonstrated that rIBV Beau-R could not protect against challenge with M41-CK; S1 
sequence homology is 95% and both belong to the same Massachusetts serotype grouping. 
The problems of cross protection becomes more apparent when novel variants of IBV 
unexpectantly emerge such as B1648 in the mid 1980s (Lambrechts et al., 1993) and QX in 
the late 1990s (YuDong et al., 1998). With current vaccines offering little cross protection the 
only option is to generate a new vaccine, and as discussed the generation of vaccine virus in 
embryonated hen’s eggs is time consuming and unpredicatable. As a consequence the 
industry is not able to readily react to emerging threats; a scenario that could be minimised 
by generating vaccine viruses through a reverse genetics approach.    
 
1.16 Project aims and objectives. 
 
The overall aim of this PhD project was to evaluate the protection offered by vaccine 
candidates based on rIBV Beau-R that have been rationally designed and generated by 
reverse genetics. Protection was assessed in vivo and is defined by the standards set by the 
European Pharmacopeia (2010).  
 
Objective 1: To assess whether rIBVs based on the Beau-R backbone expressing 
heterologous S1 subunits can induce a fully protective immune response against 
homologous challenge. 
 
Objective 2: To assess whether rIBVs based on the Beau-R backbone expressing 
heterologous S glycoprotein can induce a fully protective immune response against 
challenge with an IBV of a different serotype to both Beau-R and the expressed S 
glycoprotein.  
 
Objective 3: To investigate replication of Beau-R as well as other attenuated IBVs and rIBVs 








2.1.1 IBV strains. 
All IBV strains were propagated in 10 or 11 day old SPF embryonated hens’ eggs, and were 
either titrated in primary chicken kidney (CK) cells or ex vivo TOCs.  
• Beau-CK: GenBank accession number AJ311317. A laboratory strain that has been 
serially propagated in embryonated chicken eggs and in vitro (Cavanagh et al., 
1986). The exact history of Beau-CK is unknown with reports stating that Beau-CK 
has been passaged up to 300 times (Cavanagh et al., 1988). Beau-CK is attenuated 
in vivo, and displays extended tropism in vitro, notably the ability to replicate in Vero, 
DF1 and BHK-21 cells (Casais et al., 2001). Beau-CK belongs to the Massachusetts 
serotype and the GI-1 genotype (Valastro et al., 2016). 
• Beau-R: A molecular clone of Beau-CK that likewise displays extended tropism in 
cell culture (Casais et al., 2003; Bickerton et al., 2018), Beau-R is attenuated in vivo 
but is embryo lethal (Hodgson et al., 2004).  Beau-R belongs to the Massachusetts 
serotype and can be distinguished from Beau-CK by two marker mutations located 
in the nsp 16 and N genes respectively, C19666U and A27087G.  
• M41-CK: GenBank accession number MK728875.1. A laboratory pathogenic strain 
that has been adapted for propagation in primary chicken cells through an unknown 
number of passages. M41-CK does not display the extended cell culture tropism of 
Beau-R and notably is unable to replicate in Vero cells but belongs to the same 
Massachusetts serotype and the same GI-1 genotype (Casais et al., 2003; Valastro 
et al., 2016). 
• M41-R: A molecular clone of M41-CK that is attenuated in vivo as the result of four 
point mutations in nsp 10 (C12139T), 14 (G18119C), 15 (T19052A) and 16 
(G20144A).  
• M41-K: A pathogenic molecule clone of M41-CK. There are a number of non-coding 
mutations including C11682T and C11709T, both in nsp 9 that distinguish M41-CK 
and M41-K. Coding mutations in nsp 10, 14, 15 and 16 enable differentiation of M41-
K from M41-R. 
• 4/91(UK): GenBank accession number JN192154. A pathogenic field isolate that 
was a gift from Intervet (UK). Birds infected with 4/91 display classical IB respiratory 
symptoms (Armesto et al., 2011). 4/91 has restricted tropism in vitro and can only be 
propagated in embroynated hens’ eggs and ex vivo TOCs. The virus belongs to the 
4/91 serotype and the GI-13 genotype (Valastro et al., 2016). 
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• QX (L1148): GenBank accession number KY933090. The field strain QX, first 
detected in China in 1995 (Liu and Kong, 2004; Liu et al., 2006), has restricted host 
range in cell culture, and can replicate in neither CK cells nor Vero cells (Bickerton et 
al., 2018B). QX is noted for its pathogenicity in chickens, with a range of clinical 
symptoms observed including respiratory disease, nephritis and in young birds 
damage to the developing reproductive tract leading to false layer syndrome (Gough 
et al., 2008). If the latter occurs, the swelling of the oviducts leads to an extended 
abdomen often resulting in the infected bird adopting a “penguin”-like posture. QX is 
of a different serotype to 4/91, M41-CK and Beau-R, and also a different genotype, 
GI-19 (Valastro et al., 2016). This strain of QX was a gift from Professor Richard 
Jones at University of Liverpool (Worthington et al., 2008).  
• D388: A strain belonging to the QX genotype, first isolated in the Netherlands in 
2004 (de Wit et al. 2011B; Valastro et al., 2016). Induces clinical disease 
comparable to the QX strain (de Wit et al., 2011B). This strain was a gift from Sjaak 
de Wit at GD Animal Health, Deventer, The Netherlands.  
• H120: A commonly used vaccine virus of the Massachusetts serotype that was 
produced via 120 serial passages in embryonated hens’ eggs. This strain was a gift 
from Professor Richard Jones at University of Liverpool.  H120 is able to replicate in 
primary CK cells but not Vero cells (Bickerton et al., 2018B). H120 is part of the GI-1 
genotype (Valastro et al., 2016). 
• BeauR-M41(S): This rIBV has previously been described by Casais et al., (2003). 
Briefly the virus contains the 5′ UTR, replicase gene as well as the structural and 
accessory genes from Beau-R except that the signal sequence, the ectodomain and 
the transmembane domain of the S gene is derived from M41-CK. The cytoplasmic 
tail sequence of the S gene is derived from Beau-R rather than M41-CK, and was 
maintained to preserve interactions with the other Beaudette-derived viral proteins. 
This virus is attenuated in vivo and displays comparable tropism in vitro to M41-CK. 
• BeauR-M41(S1): This rIBV has the S1 domain of the S gene from M41-CK, with the 
S2 domain derived from Beau-R. All other structural, non-structural and accessory 
genes are derived from Beau-R. This virus exhibits extended tropism in vitro due to 
the incorporation of the Beaudette S2 domain, and is notably able to be propagated 
in Vero cells (Bickerton et al., 2018). 
• BeauR-M41(S2): This rIBV has the S2 domain, except the cytoplasmic tail from 
M41-CK, with the S1 domain derived from Beau-R. All other viral genes are derived 
from Beau-R (Bickerton et al. 2018). This virus displays in vitro tropism comparable 
to M41-CK.   
• BeauR-QX(S1): This virus is similar to BeauR-M41(S1) in that all viral genes except 
the S1 are derived from Beau-R. The S1 sequence is derived from QX (L1148). 
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Similarly to BeauR-M41(S1) this virus has extended tropism in vitro due to the 
presence of the Beaudette S2 domain (Bickerton et al., 2018B).  
• BeauR-4/91(S): A rIBV that contains the signal sequence, the ectodomain and 
transmembrane domain of the S gene from the field strain 4/91 (UK). The remaining 
genome sequence is derived from Beau-R. As with BeauR-M41(S) the cytoplasmic 
tail sequence of the S gene is derived from Beau-R and was maintained to preserve 
interactions with the other Beaudette-derived viral proteins. This virus is attenuated 
in vivo and has restricted tropism in vitro, in which it can only be propagated in 
embroynated hen’s eggs and ex vivo TOCs (Armesto et al., 2011). 
• BeauR-M41-Struct: A rIBV previously described by Armesto et al (2009). The 
genome of this rIBV contains Beau-R derived sequence coding for the 5′UTR 
through to, and including nsp 16. The remaining genome sequence from the S gene 
through to and including the 3′ UTR is derived from M41-CK. This virus has an 
attenuated phenotype in vivo.   
• M41-SK-106A, M41-SK-106A1, M41-SK-106C and M41-SK-106D: Serially 
passaged isolates of M41-CK. Each isolate, A, A1, C and D has been passaged 110 
times in embroynated hens’ eggs, and all isolates display an attenuated phenotype 
in vivo (Oade et al., 2019).  
 
2.1.2 Vaccinia viruses. 
• M41R-del-S: a recombinant vaccinia virus (rVV) containing a cDNA copy of the 
M41-R genome, with the S gene deleted (Keep, 2013).  
• M41R-4/91(S): an rVV containing a cDNA copy of the M41-R genome, with the 
ectodomain of the S gene of 4/91 (UK) sequence instead of M41-R.  
• M41R-4/91(S1): an rVV containing a cDNA copy of the M41-R genome with a 
chimeric S gene. The S1 domain, except from the signal sequence is derived from 
4/91 (UK) and the S2 domain consists of M41-R sequence.  
• M41-R: an rVV containing a cDNA copy of the M41-R genome. 
 
2.1.3 Fowlpox virus. 
• rFPV-T7: a recombinant fowlpox (rFPV) virus that expresses the bacteriophage T7 





2.2 Cells, eggs and tracheal organ cultures. 
All cell cultures were maintained at 37°C, 5% carbon dioxide (CO2) unless otherwise stated. 
All embryonated eggs were maintained at 37°C. TOCs were incubated at 37°C without CO2 
rotating at 7 to 8 revolutions per hour (h).  All TOCs were incubated for a full 48 h before use. 
 
2.2.1 Primary cell lines. 
• Chicken kidney (CK) cells: generated by the removal and trypsinization of kidneys 
from SPF Valo chickens or SPF Rhode Island Red (RIR) chickens, at 2- to 3-weeks 
old by a method previously described by Hennion and Hill, 2015. CK cell 
suspensions were prepared either by the Microbiological Services department of the 
Animal and Plant Agency (APHA) or the Central Services Unit (CSU) at the Pirbright 
Institute.  The suspensions provided were subsequently used to seed plates or 
flasks containing CK cell medium (Table 2.1).  
 
Table 2.1: CK cell medium. 
 
Ingredient Volume (ml) Final Concentration 
1x Eagle’s minimum essential 
medium (EMEM)  
(Sigma, M2279) 
500 0.8 x 
Newborn Calf Serum (NBBS) 
(Sigma, N4762) 
55 8.8 % 
Tryptose Phosphate Broth (TPB) 
(Sigma, T8159) 
55 8.8 % 
1 M Hepes 
(Gibco, Life Technologies, 15630-056) 
5.5 8.8 mM 
200mM L-Glutamine 
(Sigma, G7513) 
5 1.6 mM 
Penicillin/Streptomycin 
(Gibco, Life Technologies, 15140: 
Penicillin 10,000 U/ml and streptomycin 
10,000µg/ml). 
1 Penicillin 16 U/ml 
Streptomycin 16 µg/ml 
Nystatin  
(Sigma, N1638, 10,000 U/ml) 
 
2.5 40 U /ml 
Final volume 624  
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• Chicken embryo fibroblast (CEF) cells: generated from 9 day old SPF 
embryonated hens’ eggs (Valo) by CSU at The Pribright Institute. Briefly embryos 
are decapitated, eviscerated and trypsinised. The resulting cell suspensions are 
used to seed plates of flasks containing 1 x 199 medium (Table 2.2). 
 
Table 2.2: 199 medium for CEF preparation. 
Ingredient Volume (ml) Final concentration 
1 x 199 medium 
(Sigma, M4530) 
500 ml 0.8 x 
Foetal Bovine Serum (FCS) 
(Sigma, F0926) 
50 8.29 % 
TPB 50 8.29 % 
Penicillin/Streptomycin 1 16.6 U/ml Penicillin 
16.6 µg/ml Streptomycin 
Nystatin  2.5 41.4 U /ml 
Final volume 603.5  
 
 
2.2.2 Continuous cell lines. 
• Vero cells: A continuous cell line originally derived from kidney epithelial cells of the 
African Green Monkey. Cultures were maintained in 1 x EMEM supplemented with 
10% FCS and 1% L-Glutamine.  
• DF1 cells: An avian cell line derived from chicken embryo fibroblasts isolated from 
10 day old East Langsing eggs (Himly et al., 1998). Cultures were maintained in 
Dulbecco’s modified essential medium (DMEM, Sigma, D5796) supplemented with 
10% FCS.  
• BHK 21 cells: A cell line originally derived from the kidneys of five 1-day old Syrian 
golden hamsters. Cultures were maintained in Glasgow minimum essential media 
(GMEM, Sigma, G5154) supplemented with 10% FCS, 5% TPB and 1% L-
Glutamine.  
 
2.2.3 Embryonated eggs. 
SPF Valo embryonated hens’ eggs were provided by VALO Biomedia GmbH, Germany. SPF 
RIR embryonated hen’s eggs were provided by either the Poultry Production unit (PPU) at 
the Pirbright Institute, Compton Laboratory, or by the National Avian Research Facility 
(NARF) in Edinburgh. All eggs were set by Animal Services at room temperature for 24 h 
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before incubation at 37◦C. Eggs containing live embryos at the desired gestation point were 
then delivered to the laboratories.  
 
2.2.4 Ex vivo tracheal organ cultures. 
Ex vivo TOCs were prepared from 19 day old SPF RIR embryos by a method previously 
described by Hennion (2015). Briefly embryos were decapitated and the trachea removed. 
The extracted trachea was sectioned using a microtome generating rings of approximately 1 
mm. The resulting rings were separated by hand, and each ring was placed in a glass test 
tube containing 1 ml TOC medium (Table 2.3).  
 
Ex vivo TOCs were also prepared from 2 - 3 week old SPF RIR chickens. The trachea was 
removed from each bird and cleaned using a scalpel blade. Each trachea was flushed with 
Phosphate buffered saline a (PBSa) before being sectioned as above, or by hand. As 
described above either 1 ring or 3 rings depending on the experiment, were placed in glass 
test tubes with 1 ml TOC medium (Table 2.3).  
 
Table 2.3 Recipe for TOC medium.  
Ingredient Volume (ml) Final Concentration 
1 x EMEM 500 0.9 x 
1M Hepes 20 37.8 mM 
200mM L-Glutamine 5 1.9 mM 
Penicillin/Streptomycin 
 
1 Penicillin 18.9 U/ml 
Streptomycin 18.9 µg/ml 
Nystatin 2.5 47 U /ml 
Final volume 528.5  
 
2.3 Cell culture medium used for in vitro IBV, Vaccinia virus and FPV 
infections. 
 
The below tables list the recipes for all cell culture medium used during experiments utilising 




Table 2.4: N,N-bis[2-hydroxethyl]-2-Aminoethanesulfonic acid (BES) medium, 1 x and 
2 x, for IBV infections 









10 x EMEM 
(Sigma, M0275) 
50 1 x 100 2 x 
TPB 
 
50 10% 100 20% 
10% Bovine Serum 
Albumin 
(BSA, Sigma A9418) 
10 0.2 % 20 0.4 % 
1M BES 
(Sigma, B9879) 
10 20 mM 20 40 mM 
Sodium Bicarbonate 
solution, 7.5%  
14 0.21 % 28 0.42 % 
L-Glutamine, 200mM 5  2 mM 10  4 mM 
Nystatin 
 
2.5 50 U/ml 2.5 50 U/ml 
Penicillin/Streptomycin 0.5 10 U/ml penicillin, 
10 µg/ml 
streptomycin 
1 20 U/ml penicillin, 
20 µg/ml 
streptomycin 
Sterile Water 358 N/A 218.5 N/A 
Final volume 500  500  
 
Table 2.5: Recipe for 2 x EMEM for use in Vaccinia Virus infections.   
Ingredient 2 x EMEM 
Volume (ml) Final Concentration 
10 x EMEM (Sigma) 100 2 x 
FCS 50 10 % 
Sodium Bicarbonate, 7.5% 23 0.35 % 
L-Glutamine, 200 mM 10 4 mM 
Nystatin 2.5 50 U/ml 
Penicillin/Streptomycin 1 20 U/ml penicillin, 20 µg/ml streptomycin 
Sterile Water 313.5 N/A 
Final volume 500  
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Table 2.6 Recipe for 1 x GMEM for use in Vaccinia Virus infections. 
Ingredient 1 x GMEM 
Volume (ml) Final Concentration 
1 x GMEM (Sigma) 500 0.88 x 
FCS 5.5 0.96 % 
TPB 55 9.68 % 
L-Glutamine, 200 mM 5 0.88 % 
Nystatin 2.5 44 U/ml 
Penicillin/Streptomycin  0.5  8.8 U/ml penicillin, 8.8 µg/ml streptomycin 
Final volume 568  
 
 
Table 2.7 Recipe for 1 x 199 medium for FPV infections. 
Ingredient Volume (ml) Final concentration 
10 x 199  
(Sigma, M0650) 
20 1 x 
TPB 20 1% 
7.5 % sodium 
Bicarbonate 
6 0.4% 
200mM L-Glutamine 2 2 mM 
Nystatin 1 50 U/ml 
Penicillin/Streptomycin 0.2 Penicillin 10 U/ml, Streptomycin 10µg/ml 
NBBS 4* 0.02%* 
Water 146.8 N/A 
Final volume 200  
 
Notes: * For serum free 1x199, NBBS was not added and the volume was replaced with 
water. 
 
2.4 Buffers and solutions. 
 
All buffers and solutions were stored at room temperature unless otherwise stated.  
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• Phosphate buffered saline a (PBSa): 9.55 g PBSa powder (BioWhittaker), made 
up to 1 l in type 1 endotoxin free water. The solution was adjusted to pH 7.2 using 
hydrochloric acid (HCl) followed by sterilisation in an autoclave for 20 min at 115˚C. 
PBSa was prepared by Central Service Unit (CSU) at The Pirbright Institute. 
• Phosphate buffered saline (PBS): 9.55g/l DPBS powder (Sigma) adjusted to pH 
7.1 – 7.5 using HCl. The solution was sterilised in an autoclave for 20 min at 115˚C. 
PBS was prepared by CSU at The Pirbright Institute. 
• Sterile water: Type 1 endotoxin-free water was supplied by the Central Services 
Unit at The Pirbright Institute. Water was drawn from a Milli-Q system, 18.2 Ωm and 
autoclaved for 20 min at 121˚C. 
• DNA loading buffer: 2 ml Glycerol (VWR International, 24388.26), 50 mg Ficoll 400 
(Sigma, F2637), 25 mg Bromophenol blue (Sigma, 114391) and 3 ml water. 
• TE buffer, pH 9: 10mM Trizma hydrochloride (Tris-HCl) solution, pH 9, Sigma, 
T2819), 1mM Ethylenediaminetetraacetic acid, pH 9 (EDTA; Sigma; E9884) in 
water.  
• 30% sucrose: 30 g sucrose (Sigma, 16104), made up to 100 ml in sterile water. 
Final solution filtered through 0.22 µM filtration system (Sartorius Stedim, 16534-K) 
and stored at 4˚C. 
• 1% neutral red: 1 g neutral red powder (Sigma, N4638), made up to 100 ml in 
sterile water. Final solution sterilised by autoclaving for 20 min at 121˚C.  
• 2% agar: 6 g agar (Sigma, A1296) made up to 300 ml in water. Final solution was 
autoclaved for 15 min at 121˚C. 
• Mycophenolic acid (MPA): 10mg/ml MPA (Sigma, M3536) in 0.1M Sodium 
Hydroxide (NaOH; 30mM; Sigma, S5881); 400x concentrated. Final solution was 
filtered sterilised (0.22 µM filters) and stored at -20˚C. 
• Xanthine: 10mg/ml Xanthine (Sigma, X3627) in 0.1M NaOH (66mM); 40x 
concentrated. Final solution was filtered sterilised (0.22 µM filters) and stored at -
20˚C. 
• Hypoxanthine: 10mg/ml Hypoxathine (Sigma, H9636) in 0.1M NaOH (73mM); 667x 
concentrated. Final solution was filtered sterilised (0.22 µM filters) and stored at -
20˚C. 
• 10% formaldehyde: 50 ml formaldehyde solution (VWR International, 20909.29) 
was made up to 500 ml PBSa.  
• 0.1% crystal violet: 1 g crystal violet powder (Sigma, C6158), made up to 1 L in 
water. Final solution stored in the dark at room temperature (RT).  
• Proteinase K digestion buffer: 200mM Tris-HCl pH 7.5 (Sigma), 10 mM EDTA, 0.4 
% Sodium Dodecyl Sulfate (SDS; Sigma 75746), 400mM Sodium Chloride (NaCl; 
Sigma, S3014). Buffer was freshly prepared before use.  
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• Proteinase K: 20 mg proteinase K powder (Sigma, 2308) made up to 1 ml in sterile 
water. Final solution stored at -20˚C.  
• 3M sodium acetate: 24.6 g sodium anhydrous powder (Fisher Scientific, S/2080/53) 
made up to 100 ml in molecular grade water (Sigma, W4502).   
• 10% BSA: 10 g BSA powder (Sigma, A9418) made up to 100 ml in sterile water. 
Final solution was filtered (0.22µM) and stored at -20*C.  
• 1M BES: 213.25 BES powder (Sigma, B9879) made up to 1 L in sterile water. Final 
solution was filtered (0.22µM) and stored at 4*C in 250 ml aliquots.  
• Foetal Bovine Serum (FCS): Sigma, F0926. Serum was heat inactivated for 1 h at 
50°C and subsequently stored at either 4˚C or -20˚C.  
 
2.5 In vivo methods. 
 
All animal experimental protocols were carried out in strict accordance with the UK Home 
Office guidelines and under licence granted for experiments involving regulated procedures 
on animals protected under the UK Animals (Scientific Procedures) Act 1986. The 
experiments were performed in The Pirbright Institute Home Office licensed (X24684464) 
experimental animal house facilities and were approved by the animal welfare and ethical 
review committee under the terms of reference HO-ERP-01-1.  
 
All in vivo experiments used SPF RIR chickens. For experiments detailed in section 2.5.1.1 
and 2.5.1.5, chickens were hatched and reared at the PPU at The Pirbright Institute, 
Compton site, and delivered to the Experimental Animal House (EAH) at 7 days of age.  For 
experiments detailed in section 2.5.1.2 and 2.5.1.3 chickens were hatched at the National 
Avian Resource Facility (NARF) in Edinburgh and delivered to the experimental animal unit 
(BSU) at The Pirbright Institute at 1 day of age. NARF also provided eggs for the experiment 
detailed in section 2.5.1.4; these eggs were delivered to The Pirbright Institute where 




2.5.1 Study design. 
 
2.5.1.1: Homologous vaccine-challenge – Trial 1. 
SPF RIR chickens were housed in raised floor pens in separate positive pressure HEPA 
filtered rooms in groups of thirty birds. Chickens were randomly assigned to one of five 
groups, sex of the birds was not considered. Eight-day old chickens were inoculated 
(vaccinated) with 105 plaque forming units (PFU) of either BeauR-M41(S1), BeauR-QX(S1) 
or PBS for mock infection/vaccination via the ocular nasal route. Twenty-one days post 
vaccination a challenge dose, equal to the vaccination dose was administered also via the 
ocular nasal route. Birds received either 105 PFU of M41-CK, 102.73 Cilostatic dose 50 (CD50) 
of QX or PBS for mock challenge. Clinical signs were observed from days two to seven both 
post vaccination and post challenge. Blood was sampled from each bird two days prior to 
challenge (Chapter 3, Figure 3.1). Details of the groups are listed below: 
• Group A: mock vaccinated/mock challenged 
• Group B: mock vaccinated/M41-CK challenged 
• Group C: mock vaccinated/QX challenged 
• Group D: BeauR-M41(S1) vaccinated/M41 challenged 
• Group E: BeauR-QX(S1) vaccinated/QX challenged 
 
Two and four days post vaccination (dpv), and two and four days post-challenge (dpc), five 
randomly selected chickens were humanely euthanized by cervical dislocation. A sample 
size of five birds and ten tracheal rings per bird was calculated to detect a significant 
difference in mean ciliary activity of 25% (95% certainty, 80% power, two-sided) between 




2.5.1.2: Homologous vaccine-challenge – Trial 2. 
The method for trial 2 was as detailed in section 2.6.1.1 except birds were vaccinated with 
104 PFU of either BeauR-M41(S), BeauR-M41(S1), BeauR-M41(S2) or PBS. Birds were 
challenged with either 104 PFU of M41-CK or PBS for mock challenge. Two additional 
sampling points, 4 hour post vaccination (hpv) and one dpv were included in this trial 
(Chapter 3, Figure 3.2) with the aim of identifying the in vivo dissemination pattern of each 
vaccine virus. Details of the groups are listed below: 
• Group A: mock vaccinated/mock challenged 
• Group B: mock vaccinated/M41-CK challenged 
• Group C: BeauR-M41(S) vaccinated/M41-CK challenged 
• Group D: BeauR-M41(S1) vaccinated/M41-CK challenged 
• Group E: BeauR-M41(S2) vaccinated/M41-CK challenged 
 
2.5.1.3: Heterologous vaccine-challenge.  
SPF RIR chickens were housed in raised floor pens held within separate positive-pressure 
HEPA-filtered rooms in groups of 20, 30 or 35 birds. Chickens were randomly assigned to 
one of six groups (Table 4.1), sex of the birds was not considered. Eight-day old chicks were 
inoculated (classified as primary vaccination) with 104 PFU of BeauR-M41(S) or the 
equivalent dose of 3 log10 CD50 BeauR-4/91(S) via the ocular-nasal route. Mock vaccinated 
chickens were inoculated with PBS (Chapter 4, Figure 4.1). Fourteen days after the primary 
vaccination, chickens received a second vaccination of either BeauR-M41(S), BeauR-
4/91(S) or PBS, administered in the same dose and manner as the primary vaccination. 
Twenty three days after primary vaccination, a challenge dose of 3 log10 CD50 QX or PBS 
was administered in the same manner as the vaccinations to the appropriate groups. Clinical 
signs were observed from 3 – 7 days after each infection.  The groups are detailed below:  
• Group A: mock vaccinated/mock vaccinated/mock challenged 
• Group B: BeauR-M41(S) vaccinated/BeauR-M41(S) vaccinated/QX challenged 
• Group C: BeauR-4/91(S) vaccinated/BeauR-4/91(S) vaccinated/QX challenged 
• Group D: BeauR-M41(S) vaccinated/BeauR-4/91(S) vaccinated/QX challenged 
• Group E: BeauR-4/91(S) vaccinated/BeauR-M41(S) vaccinated/QX challenged 
• Group F: mock vaccinated/mock vaccinated/QX challenged 
 
On specific days post-primary vaccination (dppv) and post-challenge (dpc), 5 or 10 randomly 
selected chickens were humanely euthanized by cervical dislocation (Table 4.1). A sample 
size of five birds was used for the mock-infected group at all time points and all vaccinated 
groups on 4 dppv. This sample size of five young birds and 10 tracheal rings per bird is 
calculated to detect a significant difference in mean ciliary activity of 25% (95% certainty, 
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80% power, two-sided) between groups post IBV infection (de Wit et al., 2013).  The sample 
size was increased to 10 birds post heterologous challenge to increase the power to detect 
significant differences in protection between vaccinated groups.  
 
2.5.1.4: Pathogenicity experiment: Beau-R and M41-CK.  
SPF RIR chickens were housed in raised floor pens in separate positive pressure HEPA 
filtered rooms in groups of 24 birds. Chickens were randomly assigned to one of three 
groups (listed below), sex of the birds was not considered. At seven days of age chickens 
were inoculated with 104 PFU of rIBV Beau-R or IBV M41-CK or PBS for mock infection via 
the ocular-nasal route. The groups are detailed below. Clinical signs were observed from 
one to seven days post-infection (dpi). At specific points post infection, six randomly selected 
birds per group were humanly euthanised by cervical dislocation (Chapter 5, Figure 5.1). 
This sample size alongside 10 tracheal rings per bird was calculated to detect a significant 
difference in mean ciliary activity of 25% (95% certainty, 80% power, two-sided) between 
groups post IBV infection (de Witt et al., 2013).  All remaining birds were culled on the final 
day of the experiment, day 7.  
• Group A: mock infected 
• Group B: Beau-R infected 




2.5.1.5 Pathogencitiy experiment, M41-R. 
This experiment was completed by Dr. Erica Bickerton and I before the start of this PhD 
course. All data from the experiment has been re-analysed with the aim of this PhD project in 
mind.  
SPF RIR chickens were housed in raised floor pens in separate positive pressure HEPA 
filtered rooms in groups of 12 birds. Chickens were randomly assigned to one of three 
groups listed below with the sex of the birds not considered. At eight days of age chickens 
were inoculated with 105 PFU of rIBV Beau-R, M41-R 6, M41-R 12, IBV M41-CK or 1 x BES 
for mock infection (Figure 2.5). Clinical signs were observed from two to seven dpi.  Three 
randomly selected birds per group were humanly euthanised by cervical dislocation on 4 and 
6 dpi. All remaining birds were culled, also by cervical dislocation on the final day of the 
experiment. Ciliary activity was assessed at all sampling points.  
• Group A: mock infected 
• Group B: Beau-R infected 
• Group C: M41-R 6 infected 
• Group D: M41-R 12 infected 
• Group E: M41-CK infected 
 
2.5.2 Infection of chickens. 
RIR SPF chickens were inoculated via the intraocular and intranasal route with a total 
volume of 0.1ml PBS or 0.1 ml 1 x BES medium containing a defined quantity of IBV or rIBV. 
Mock infected birds received 0.1 ml PBS or 1 x BES medium.   
 
2.5.3 Assessment of clinical signs. 
Clinical signs were assessed by a minimum of two persons. Chickens were observed for 2 
min and the number of snicks counted by each person was recorded. The average number 
of snicks per bird per minute was calculated. Chickens were assessed individually for the 
presence of wheezing, rales, watery eyes and nasal discharge. The percentage of birds 
within each group exhibiting a particular symptom was calculated.  
 
2.5.4 Post-mortem harvesting of tissues. 
In each experiment a variety of tissues were collected, including trachea, eyelid, beak, 
Harderian gland (HG), lung, spleen, bursa and kidney. Sections of tissue were stored in 
PBS, RNAlater (ThermoFisher) or 20% sucrose depending on the downstream analysis 
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required. A set of sterile scissors and forceps were used per bird to avoid cross 
contamination of the samples.  
 
2.5.5 Assessment of ciliary activity. 
Tracheas were removed from chickens at specific time points in each study. Ten 1 mm 
sections (rings) were cut from three different regions of each trachea, 3 from the upper, 4 
from the middle and 3 from the lower section. The level of ciliary activity of each tracheal 
section was determined using light microscopy and scored as follows 0 = complete 
ciliostasis, 1 = ~ 25% of cilia beating, 2 = ~ 50% of cilia beating, 3 = ~75% and 4 = no 
ciliostasis, 100% cilia beating. The average ciliary activity of ten rings was calculated. This 
method is an adaptation of methods previously described by Cook et al., (1999) and 
Cavanagh et al., (1997).  
 
2.5.6 Blood sampling and serum collection.    
In each vaccine-challenge experiment, one day pre-vaccination and two days prior to 
challenge, blood was sampled from each bird via a wing vein. During post-mortem, blood 
was collected from each bird.  Blood was allowed to clot at room temperature and the serum 
was clarified via low speed centrifugation.  
 
2.5.7 Tissue processing. 
The tracheal rings used for the ciliary activity assay (section 2.6.5) were homogenised in 500 
µl PBSa containing penicillin, 20 U/ml, streptomycin, 20 µg/ml and nystatin, 20 U/ml, using a 
Tissuelyser II (Qiagen) with 5mm beads (Qiagen). Sections were homogenised for up to six 
min at 27 Hz, producing a tissue derived supernatant that was subsequently clarified by low 
speed centrifugation. Tracheal rings not used for ciliary activity as well as eyelids, HGs and 
nasal turbinates that had been stored in PBS were also processed in the above manner.  
The resulting tissue derived supernatants were stored at – 80°C. 
2.5.8 Viral Isolation in embryonated eggs.  
Embryonated hens’ eggs were inoculated with 100 µl of tissue-derived supernatant as 
detailed in section 2.6.1. Allantoic fluid was harvested 24 - 48 hours post infection (hpi) and 
assessed for viral presence by reverse transcription polymerase chain reaction (RT-PCR) 




2.5.9 Viral Isolation in ex vivo TOCs. 
For the pathogenicity experiment described in section 2.5.1.5 virus re-isolation from trachea 
sections was performed in ex vivo TOCs prepared from 19 day old SPF RIR embryonated 
hens’ eggs. This work was completed before the start of this PhD project but the data 
generated has been re-analysed. Briefly three tracheal rings from each bird in 120 µl PBS 
were freeze thawed three times using dry ice/ethanol and a 37°C water bath. Supernatant 
was clarified by low speed centrifugation. Tracheal suspensions were prepared by adding 
100 µl of clarified supernatant to 400 µl TOC medium. TOCs were infected with 150 µl of the 
tracheal suspension in triplicate. After infection at 37°C for 1 h, an additional 1 ml of medium 
was added per TOC. TOCs were incubated at 37°C for up to 6 days. The supernatant 
harvested was screened for IBV RNA by RT-PCR using primers BG56 and 93/100 following 
methods detailed in section 2.7.4, 2.7.5 and 2.7.7.  
 
Tissue-derived supernatant from tracheas collected post challenge during in vivo vaccine-
challenge experiments (section 2.5.1.1 to 2.5.1.3) were titrated in ex vivo TOCS as 
described by Hodgson et al., (2004) and in section 2.6.3. 
 
2.5.10 Assessment of IBV derived RNA in harvested tissues by qRT-PCR. 
 
2.5.10.1 Vaccine-challenge experiments. 
Assessment of IBV derived RNA in the trachea, Conjunctival-associated lymphoid tissue 
(CALT) and HG harvested as part of the in vivo vaccine-challenge experiments detailed in 
section 2.5.1.1 to 2.5.1.3 was carried out by Dr. Samantha Ellis at The Roslin Institute.  
 
Briefly total RNA was extracted from harvested tissues as detailed in section 2.7.1 and cDNA 
was subsequently synthesised from 1 µg of this extracted RNA using Superscript IV Reverse 
Transcriptase with a random oligo primer as detailed in section 2.7.4.  For quantification of 
viral load, quantitative real time PCR (qRT-PCR) was performed using the Taqman Universal 
PCR Master Mix (Applied Biosystems) with primers and probes specific to the 5′ UTR region, 
as described by Callison et al., 2009. Serial dilutions of M41 cDNA were included to 
generate a standard curve. The data, expressed in terms of the cycle threshold (CT) value, 
were normalized using the CT value of the 28S cDNA product for the same sample 




2.5.10.2 M41-R pathogenicity experiment. 
Assessment of IBV derived RNA in the trachea and HG harvested as part of the M41-R 
pathogenicity experiment detailed in section 2.5.1.5 was carried out by Dr. Erica Bickerton. 
Total RNA was extracted from 30 µg of tissue as detailed in section 2.7.1, and 100 ng of the 
resulting RNA was used in each real-time RT-PCR reaction  using a PrimerdesignTM 
genesig® Kit for Avian Infectious Bronchitis Virus, Advanced, per the manufacturer’s 
protocol. This data was generated before the time period of this PhD, but has been re-
analysed as part of this PhD project. 
 
2.5.11 IBV ELISA.  
Serum samples collected both pre-challenge and post-challenge, were assessed with the 
commercial IBV antibody test kit (BioChek BV).  To determine the end-point titres, pre-
challenge serum samples were diluted 1:80 and post-challenge samples were two-fold 
serially diluted in the range 1:80 – 1:2560 prior to incubation. After sample incubation, the 
remaining steps were followed directly according to the manufacturer’s instructions.  The 
sample/positive (S/P) ratio was determined by the following equation = (Mean sample – 
Mean Kit Negative)/(Mean Kit positive – Mean Kit Negative). S/P ratios above 0.2 were 
considered to be positive for IBV antibodies. Depending on the challenge virus, either anti-
M41 or anti-QX polyclonal chicken serum was included on each independent test plate as a 
reference control (GD Animal Health). All ELISA assays were performed by Dr. Samantha 
Ellis at The Roslin Institute.  
 
2.6 In vitro methods. 
 
2.6.1 Growth of IBV/rIBV in embryonated hens’ eggs. 
IBV/rIBV was propagated in either 10 or 11-day old SPF RIR or Valo embroynated hens’ 
eggs. Eggs were candled to ensure embryo viability before infection. The air sac was 
marked and a hole drilled using a Bosch Dremel Engraver approximately 0.5 cm above the 
allantoic membrane.  Each egg was inoculated with up to 300 µl IBV/rIBV using a 1 ml 
syringe and a 25G needle. Once infected, the hole in each egg was sealed with nail varnish. 
Eggs were incubated at 37°C for up to 72 h, with embryo viability being monitored regularly 
through candling. After incubation eggs were culled by refrigeration for at least 4 h at 4oC. 
The allanotic fluid from each egg was harvested and clarified by low speed centrifugation, 




2.6.1.1 Stock viruses. 
For the purpose of growing stock virus, IBV/rIBV was diluted 1:1000 in PBS prior to 
inoculation, and each egg received 100 µl. Typically 10 eggs were inoculated per stock. 
Eggs were incubated no longer than 24 h. The allantoic fluid from each egg was pooled into 
50 ml Falcon tubes prior to clarification by centrifugation at 500 x g for 5 min. Once clarified, 
all supernatant was pooled, mixed and aliquoted into 2 ml cryovial tubes before being stored 
at -80oC.  
 
2.6.1.2 Rescue passaging. 
For passaging cell lysate or allanotic fluid as part of the rescue of rIBV (section 2.9), each 
egg was typically inoculated with 300 µl and incubated for 48 to 72 h at 37°C.  
 
2.6.2 Titration via plaque assays. 
CK cells were seeded in 12 well plates, and incubated at 37°C, 5% CO2. Once confluent, 
cells were washed once with PBSa and inoculated in triplicate with 250 µl of tenfold serially 
diluted rIBV/IBV in 1 x BES medium. After incubation for 1 hour at 37°C, 5% CO2, the 
inoculum was removed and replaced with  2 ml of overlay media per well. Overlay media 
consisted of 1 x BES medium containing 1 % agar. After 72 hours incubation at 37°C, 5% 
CO2 cells were fixed at room temperature for 1 hour using 10 % formaldehyde in PBSa. The 
agar plugs were removed and cells were stained at room temperature for 20 min using 0.1% 
crystal violet (w/v in water). Plaques were counted and the number of PFU per ml calculated.   
 
2.6.3 Titration in ex vivo TOCs. 
Prior to infection each TOC was assessed individually for the presence of at least 90% ciliary 
activity; those with less were discarded.  Each TOC was washed once with PBSa and in 
replicates of five, each TOC was infected with 0.4 ml TOC medium containing tenfold serially 
diluted IBV or rIBV. Mock infected TOCs received 0.4 ml TOC medium. Inoculated TOCs 
were incubated for 6 days at 37°C, no CO2, rotating at a rate of 7 – 8 rotations per h. The 
percentage of ciliary activity of each TOC was assessed using a light microscope and was 
recorded as either active (living) or not (dead). Those TOCs displaying less than 10% ciliary 
activity were marked as dead. The dose required to cause 50% ciliostasis (CD50) was 




 2.6.4 Growth kinetic assays. 
2.6.3.1 In vitro growth kinetic assays. 
DF1 or CK cells, were seeded in either six or 12 well plates depending on the experiment 
and the multiplicity of infection (MOI) to be achieved. Once confluent cells were washed with 
PBSa and subsequently infected with a defined quantity of rIBV or IBV in 0.5 ml 1 x BES 
medium. Mock infected cells were inoculated with 0.5 ml 1 x BES medium. Infected cells 
were incubated for 1 h at 37°C or 41°C after which the inoculum was removed, and cells 
were washed twice with PBSa to remove any unbound virus. Per well, 2 or 3 ml 1 x BES was 
added, depending on whether the assay was performed in 12 or six well plates respectively. 
Cells were incubated at either 37°C or 41°C for up to 96 h. Supernatant, containing viral 
progeny, was harvested at defined intervals post infection and titrated in CK cells as detailed 
in section 2.6.2. 
 
2.6.3.2 Growth kinetic assays in ex vivo TOCs. 
TOCs prepared from 2 – 3 week-old RIR SPF chickens were inoculated in triplicate with 104 
PFU in 0.1 ml TOC medium of M41-CK, M41-R or M41-K. Inoculated TOCs were incubated 
upright for 1 h at 37°C, after which the inoculum was removed and each TOC washed twice 
with PBSa to remove residual virus. Per TOC, 1 ml TOC medium was added followed by 
incubation at 37°C rotating 7 – 8 revolutions per h. Supernatant was harvested 1, 24, 48, 72 
and 96 h post infection, and the quantity of infectious progeny virus assessed through 
titration in CK cells as described in section 2.6.2.   
 
2.6.4 Plaque reduction assays. 
All serum used for plaque reduction assays was harvested from SPF RIR chickens 14 days 
post infection.  Mock serum and anti-QX serum was harvested as part of the heterologous 
vaccine challenge experiment (section 2.5.1.3) from birds 14 dpc in group A (mock 
vaccinated and mock challenged) and group F (mock vaccinated/QX challenged). Anti-M41-
CK serum was harvested from the homologous vaccine challenge study detailed in section 
2.5.1.2. Serum was collected from birds 14 dpc in group B (mock vaccinated/M41-CK 
challenged). Anti- 4/91 serum was harvested previously from birds inoculated with 4/91. 
Serum was collected 14 dpc when the birds were 22 days of age.  
Serum was diluted 1:10 using PBS, and a subsequent two-fold dilution series generated. In 
triplicate diluted serum was incubated for 30 min at room temperature with 100 PFU of either 
rIBV Beau-R, BeauR-M41(S), BeauR-M41(S1) or IBV M41-CK with gentle agitation. Each 
plaque reduction assay contained a viral control in which no serum was added; these 
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controls were done in triplicate. The serum/virus and viral control mixes were titrated in CK 
cells as described in section 2.6.2. 
 
The difference between the PFU/ml generated in virus/serum mixes and the PFU/ml 
generated by virus incubated with mock serum was calculated. When a difference was 
identified this data was presented as percentage reduction in the number of PFU/ml in 
comparison to the relevant control samples.  
 
2.6.5 Temperature swap assays. 
CK cells were seeded in 6 well plates. Once confluent, cells were washed once with PBSa, 
and inoculated with 0.5 ml 1 x BES containing 105 PFU of rIBV or IBV. Infected cells were 
incubated at either 37°C or 41°C for 1 h (1st incubation), after which the inoculum was 
removed and the cells washed once with PBSa to remove unbound virus. Per well, 3 ml 1 x 
BES was added and infected cells were incubated for a further 23 h (2nd incubation) at either 
37°C or 41°C. Supernatant was harvested, and the quantity of progeny infectious virus was 
determined by plaque assay as detailed in section 2.6.2. The list below details the group 
involved in each assay: 
• 1st incubation at 37◦C/ 2nd incubation 37◦C 
• 1st incubation at 37◦C/ 2nd incubation 41◦C 
• 1st incubation at 41◦C/ 2nd incubation 41◦C 
• 1st incubation at 41◦C/ 2nd incubation 37◦C 
 
2.6.6 Growth of rFPV-T7 in CEF cells. 
T150 flasks seeded with 2 x 107 CEF cells were inoculated with 2 ml serum free 1 x 199 
media containing rFPV-T7 at a MOI of 0.01 to 0.1. The virus was allowed to attach for 1 h at 
37°C, after which 20 ml 1 x 199 medium was added per flask. Infected cells were further 
incubated until extensive rFPV-T7 induced cytopathic effect (CPE) could be observed, 
typically 4 dpi.  The cells and supernatant were harvested and in order to lyse the collected 
cells, all harvested material underwent 3 rounds of a -80°C freeze followed by a 37°C thaw.  
Cell debris was removed by low speed centrifugation, 500 x g, 15 min, 4°C. The clarified 




2.7 Molecular biology methods. 
 
2.7.1 RNA extraction. 
RNA was extracted from cell culture supernatant and allanotic fluid using an RNeasy mini kit 
(Qiagen, 74104) following the manufacturer’s protocol for RNA clean-up. Intracellular RNA 
from cell lystate was extracted using the same Qiagen kit following the animal cells spin 
protocol with the accompanying DNase treatment step. RNA was extracted from tissues 
harvested as part of in vivo studies using the same Qiagen kit following the animal tissues 
spin protocol. RNA was typically eluted in 40 µl RNase free water (H2O) and stored at -20˚C. 
 
2.7.2 Small scale DNA extraction. 
DNA was extracted from re-suspended cell pellets using the QlAamp DNA mini kit following 
the manufacturer’s (Qiagen) blood or bodily fluids spin protocol. All DNA extracted by this 
method was stored at -20˚C. 
 
2.7.3 Large scale DNA extraction. 
An equal volume of proteinase K digestion buffer (section 2.5) was added per sample 
alongside 0.1 % proteinase K (section 2.5). For example, 5 ml sample was added to 5 ml 
proteinase K digestion buffer with 0.1 ml proteinase K.  The reaction was incubated for 2.5 h 
at 50°C after which an equal volume of phenol-chloroform-isoamyl alcohol (25:24:1) 
containing 8-hydroxy-quioline was added, mixed through inversion 5-10 times and 
centrifuged for 15 min at 1,200 x g, 4°C. The upper phase was separated into a clean 50 ml 
tube and a second phenol-chloroform extraction carried out, followed by a final chloroform 
extraction. DNA was precipitated using 2.5 volumes of -20°C ethanol and 0.1 volumes of 3 M 
sodium acetate followed by centrifugation for 90 min at 2,300 x g, 4°C. The supernatant was 
removed and the pellet was washed with 10ml -20°C 70% ethanol. In order to dissolve the 
salts the sample was incubated on ice for 5 min before centrifugation for 1 h at 2,300 x g, 
4°C. Once the ethanol had been removed the DNA pellet was re-suspended in 100µl water, 
molecular biology grade (Sigma) and incubated overnight at 4◦C. Once the DNA had fully 
dissolved, the quantity and purity was assessed using a Nanodrop 1000 (ThermoScientific). 
DNA extracted by this method was stored at 4˚C.  
 
2.7.4 Reverse Transcription (RT). 
IBV cDNA was generated from RNA isolated via section 2.7.1. To 5µl RNA (< 500ng) the 
following reagents were added. The final concentration of each reagent is highlighted in (). 
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• 1 µl 10mM dNTPs (Invitrogen by Life Technologies, 18427-013, 0.5 mM of each) 
•  1 µl 50 µM random primer (GTTTCCCAGTCACGATCNNNNNNNNNNNNNNN, 
Sigma; 2.5 µM) 
•  6 µl molecular grade water  
 
The sample was incubated at 65°C for 5 min before the reaction was cooled on ice for 2 min. 
Once cool the following reagents were then added: 
• 4 µl Superscript IV (SSIV) buffer/ First strand buffer for superscript III (SIII; 1x) 
• 1 µl 100 mM DTT (5mM) 
• 1 µl Recombinant Ribonuclease Inhibitor (RNaseOut, Invitrogen by Life 
Technologies, 10777-019; 2U/µl) 
• 1 µl SSIV (Invitrogen by Life Technologies, 108090010; 20 U/µl) or 1 µl Superscript 
III ( Invitrogen by Life Technologies, 18080093; 20 U/µl) 
 
The reaction was incubated in a thermo-cycler for either 10 min at 23°C, 10 min at 55°C and 
10 min at 80°C if using SSIV or 5 min 25°C, 1 h at 50°C and 15 min at 70°C for SSIII. The 
resulting cDNA was either stored at -20°C or taken forward immediately for PCR analysis as 
detailed in section 2.7.5.  
 
2.7.5 PCR analysis. 
 
2.7.5.1 Non high fidelity PCR.  
Each PCR reaction contained the following reagents made up to a final volume of 50 µl in 
Nuclease-free water (Sigma, W4502). The final concentration of each reagent is highlighted 
in (). 
• 5 µl 10 x PCR buffer – Magnesium  (Mg); (1x) 
• 2 µl 50mM MgCl2  (Magnesium Chloride); (2 mM) 
• 1 µl 10mM dNTP mix (200 µM) 
• 1 µl 10µM forward oligonucleotide (0.2 µM) 
• 1 µl 10µM reverse oligonucleotide (0.2 µM)  
• 5 µl template DNA/cDNA (< 500 ng) or 1 bacterial colony 





PCRs were performed using a thermal cycler (2720 Thermal Cycler, Applied Biosystems) 
with the following cycles: 95°C for 3 min followed by 25 cycles of 95°C for 30 seconds (s), 
X°C for 30 s and 72°C for 1 min per kb of DNA amplified and a final cycle of 72°C for 3 min. 
The annealing temperature, X, was dependent upon the melting temperatures of the 
oligonucleotide primers used and the extension times were dependant on the size of the 
PCR product amplified. 
 
2.7.5.2 High fidelity PCR. 
Each PCR reaction contained the following and was made up to a total reaction volume of 50 
µl using Nuclease-free water. The final concentration of each reagent is shown in (). 
• 2.5 µl 10 µM forward oligonucleotide (0.5 µM) 
• 2.5 µl 10 µM reverse oligonucleotide  (0.5 µM) 
• 10 µl 5 x Q5 reaction buffer (1x) 
• 1 µl 10mM dNTP mix (200 µM) 
• Up to 5 µl Template DNA (< 1000 ng) 
• 0.5 µl Q5 high fidelity DNA polymerase (New England Biolabs, M0491S, 0.02 U/µl) 
 
PCRs were performed using a thermal cycler (2720 Thermal Cycler, Applied 
Biosystems) with the following cycles: 98°C for 1 min followed by 25 cycles of 98°C for 
10 s, X°C for 30 s and 72°C for 30 s per kb of DNA amplified and a final cycle of 72°C 
for 2 min. The annealing temperature, X, was dependent upon the melting temperatures 
of the oligonucleotide primers used and the extension times were dependent on the size 
of the PCR product amplified. 
 
2.7.5.3 PCR primer sets.  
All primers were synthesised by Sigma, and re-suspended in molecular grade water to give a 




Table 2.8: Details of primer sets. 


























2.7.6 Restriction digest. 
The following restriction endonuclease enzymes were used in this project including Sal I – 
HF® (NEB, R3138S), Not I (NEB, R0189S), Kpn I (NEB, R01425) and Xhol I (NEB, 
R0146S). All reactions were prepared following the manufacturers’ protocol. Typically each 
50 µl reaction contained 1 x the appropriate buffer, 1 unit (U) of restriction enzyme and up to 
1 µg of DNA. Reactions were incubated for 1 h at 37˚C and heat inactivated for 20 min at 
65°C.  
 
2.7.7 Agarose gel electrophoresis.  
PCR products were separated and visualised by agarose gel electrophoresis. Agarose gels 
contained 1 - 0.8% agarose in 50 ml 1 x Tris borate EDTA (TBE) buffer (Invitrogen by Life 
Technologies, CH5022) as well as 5 µl SYBR safe DNA gel stain (Invitrogen by Life 
Technologies, S33102). Each sample, 5 µl, was mixed with 2 µl DNA loading buffer. Gels 
were run in 1 x TBE buffer using a 9 x 11 horizontal submarine gel apparatus (Galileo 
Bioscience) at approximately 5 V/cm gel length. A 1kb+ DNA ladder (Invitrogen) was used to 
estimate DNA band sizes. The gel was visualised using a Bio-Rad Gel Doc EZ as per the 
manufacturer’s protocol.  
 
2.7.8 Pulsed field gel electrophoresis. 
Large fragments of DNA were examined by pulsed field gel electrophoresis. Up to 1 µg of 
DNA was digested with restriction enzyme Sal I as described in section 2.7.6. Per sample, 5 
µl of DNA loading buffer was added followed by incubation at 65˚C for 10 min. The digested 
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and denatured DNA was subsequently separated on 0.8% agarose gel (Pulsed Field 
Certified Agarose, Bio-Rad Laboratories, 1620137) prepared in 0.5 X TBE buffer. Gels were 
run in 0.5 x TBE buffer using pulsed field gel apparatus (BioRad) under the following 
conditions: initial pulse time of 0.1 s, final pulse time of 1.0 s, 6.0 V/cm for 12 h. To 
approximate size of fragments a CHEF DNA Size Standards 8-48 Kb marker was run 
alongside the samples (Bio-Rad Laboratories, 170-3707). Before visualization the gel was 
stained in sterile water containing 0.1g/mL ethidium bromide (C21H20BrN3), at room 
temperature for 30 min with gentle agitation. To remove excess dye, and to provide a clear 
picture, gels were also partially de-stained in sterile water for 30 min with gentle agitation. 
The gel was visualised using a Bio-Rad Gel Doc EZ as per the manufacturer’s protocol.  
 
2.7.9 PCR purification. 
PCR products or those products from restriction digest (section 2.7.6) that required less than 
20 nucleotides removed were purified using the Monarch PCR and DNA clean up kit 
following the manufacturer’s protocol (NEB, T1030S). Products were typically eluted in 10 µl 
and stored at -20˚C.   
 
2.7.10 Gel purification. 
Up to 5 µg of DNA was separated by agarose gel electrophoresis (section 2.7.7) using 1 x 
Tris-acetate-EDTA (TAE) buffer (Invitrogen by Life Technologies, 15558026) instead of 1 x 
TBE. Fragments were excised using a scalpel blade. The DNA was recovered from the 
excised fragment using a Monarch DNA gel extraction kit, (NEB, T1020S). Products were 
typically eluted in 10 µl and stored at -20˚C.  
 
2.7.11 Ligation. 
DNA fragments were ligated in a 3:1 vector/insert ratio using T4 DNA ligase (NEB, M0202). 
Each reaction contained the following reagents. The final concentration is highlighted (). 
• 2 µl 10 x T4 DNA ligase buffer (1x) 
• X µl Vector DNA 
• Y µl Insert DNA 
• 1 µl T4 DNA ligase (20 U/µl) 
• Up to 20 µl molecular grade water  
Reactions were incubated at RT for 10 - 30 min, after which the sample was used to 




2.7.12 Transformation of E.coli. 
One ShotTM MAX EfficiencyTM DH5αTM-T1R chemically competent cells (Invitrogen by Life 
Technologies, 12297016) were transformed according to the manufacturer’s protocol. Per 
reaction, up to 150 µl was subsequently spread onto Luria-Bertani broth (LB) agar plates 
containing ampicillin (100 µl/ml); plates were produced by the CSU department at The 
Pirbright Institute. Plates were incubated overnight at 37°C after which they were wrapped in 
cling film and stored, for up to 2 weeks, at 4°C. 
 
2.7.13 Bacterial overnight cultures. 
Transformed E coli generated from section 2.7.12 was amplified for mini or maxi preps of 
plasmid DNA. For mini preps, 1 bacterial colony was added to 5 ml LB broth (Sigma, L2542) 
plus ampicillin (100 µl/ml) and was incubated overnight at 37°C, 120 rpm. For maxi cultures 
1 bacterial colony was added to 1 ml LB plus ampicillin and incubated for 8 h at 37°C, 120 
rpm, after which the starter culture was added to 100 ml LB plus ampicillin. This large culture 
was incubated overnight at 37°C, 120 rpm.  
 
2.7.14 Minipreps. 
1 ml of the 5 ml overnight cultures resulting from section 2.7.13 were centrifuged for 5 min at 
14,000 x g. Plasmid DNA in the resulting bacterial pellet was isolated using either a QlAprep 
Spin Miniprep Kit (Qiagen, 27106) or a Monarch Plasmid Miniprep Kit (NEB, T1010S) 
following the manufacturer’s protocol. Samples were typically eluted in 30 – 50 µl and stored 
at -20˚C.  
 
2.7.15 Maxipreps. 
The large 100 ml cultures of transformed E coli resulting from section 2.7.13 were 
centrifuged for 15 min at x 500 x g. Plasmid DNA was isolated in the resulting pellet using 
the QlAfilter Plasmid Maxi Kit (Qiagen, 12263) following the manufacturer’s protocol. The 
DNA pellet was typically suspended in 100 to 200 µl molecular grade water.  
 
2.7.16 Sequencing. 
All sequencing was outsourced. PCR products or plasmid DNA along with the relevant DNA 
primers were either sent to GATC (Germany) or Source Bioscience (UK). All samples were 
diluted to the quantities stated by the relevant company. The data generated from each 
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sequencing reaction was analysed by either Dr. Erica Bickerton or Michael Oade using 
Staden sequencing software, version 1.7.0. 
 
2.8 Reverse genetic system utilising vaccinia virus for the generation 
of recombinant IBV. 
 
An IBV reverse genetics system previously described by Britton et al. (2005), Casais et al. 
(2001) and Keep et al., (2015) was used to modify the IBV genome allowing for the 
generation of novel rIBV. Briefly a complete cDNA copy of the Beaudette (Beau-R) or the 
M41-CK genome (M41-R, M41-K) has been assembled within the genome of a recombinant 
vaccinia virus (rVV) in place of the Thymidine Kinase (TK) gene (Figure 2.6). The 5′ UTR 
sequence of the IBV cDNA is preceded by a T7 polymerase promotor, and following the 
poly(A) tail is a hepatitis delta antigenome ribozyme site.  The IBV cDNA can be modified 
through transient dominant selection (TDS, Figure 2.7), a method that takes advantage of 
recombination events between homologous sequences (Falkner and Moss, 1988, Falkner 
and Moss, 1990). The TDS method requires a plasmid containing the selective marker gene, 
Escherichia coli guanine phosphoribosyltransferase (GPT) gene, which confers resistance to 
MPA in the presence of xanthine and hypoxanthine, as well the IBV sequence to be inserted 
into the full length IBV cDNA. These plasmids are referred to as pGPT plasmids. Once the 
desired cDNA copy of IBV has been assembled within the rVV genome, the rescue of 
infectious rIBVs is carried out in primary CK cells (Casais et al., 2001; section 2.9). The 
generation of a rIBV is therefore a multistep process that is summarised in Figure 2.8. 





Figure 2.1: A full-length copy of the IBV genome is expressed by Vaccinia Virus. A 
cDNA copy of the IBV genome has been inserted within the TK gene of VV vNotI/tk via an 
introduced Not I restriction site (Casais et al., 2003). The inserted sequence is flanked at 
either end by Sal I restriction sites. The IBV derived sequence is preceded by a T7 RNA 
polymerase promotor and is followed by hepatitis delta antigenome ribozyme (HδR) site and 
a T7 termination sequence. A full length mRNA can be produced by a T7 RNA polymerase 
which alongside the self-cleavage action of the incorporated ribozyme site produces an 






Figure 2.2: The incorporation of the IBV S gene using transient dominant selection. 
Transient Dominant selection is used to modify the cDNA copy of the IBV genome encoded 
by an rVV. (1) To modify the IBV genome, a plasmid is required that contains a GPT gene as 
well as the desired IBV derived sequence. For the insertion of the S gene into an IBV 
genome missing the S gene, the plasmid contains the S gene flanked by neighbouring 
sequence in nsp 16 and gene 3. (2) Recombination occurs between the homologous IBV 
sequences in the plasmid vector and the IBV cDNA, resulting in the complete plasmid 
sequence inserting into the rVV genome thereby creating, due to the presence of duplicate 
sequences, a highly unstable intermediate. (3) The presence of the GPT gene allows for the 
selection and isolation of this highly unstable intermediate through plaque purification in the 
presence of selection agents MPA, Xanthine and Hypoxanthine. (4) Once the selective 
pressure is removed a second homologous recombination event occurs that either results in 
the generation of an rVV containing the original unmodified IBV sequence or the generation 





Figure 2.3: Flow chart detailing the multistep process used for the generation of 
rIBVs. 
 
Since the reverse genetic system was first developed in 2001, many rIBVs have been 
successfully rescued. In addition there is a vast number of rVVs, not all of which served to 
directly produce rIBV but rather served as intermediate steps; once such rVV is M41R-del-S, 
which contains the M41-R genome but with the S gene deleted (Keep, 2013). These 
intermediate rVVs allow for targeted modification of the IBV genome in multiple stages.  
 
The aim of this project was to construct two rIBVs, which required the construction of two 
rVVs. The first rVV was M41R-4/91(S1) which contained the M41-R genome with the S1 
subunit of the S gene derived from the UK field strain 4/91. To construct an rVV containing 
this construct, a pGPT plasmid encoding the 4/91 S1 subunit flanked by M41-R derived nsp 
16 and gene 3 sequence was used in a homologous recombination event alongside a 
receiver rVV encoding the full M41-R genome, rVV M41-R.  In theory this approach could 




The second rVV, M41R-4/91(S), contained the M41-R genome with the ectodomain of the S 
gene derived from 4/91. The signal sequence and cytoplasmic tail of the S gene are derived 
from M41-R sequence, and these were maintained to conserve the nsp 16 sequence and the 
interaction of the S glycoprotein with the other M41-R derived structural proteins 
respectively. To construct rVV M41R-4/91(S) a pGPT plasmid encoding the 4/91(S) 
ectodomain flanked by M41-R nsp 16 and gene 3 sequence was used alongside the 
intermediate receiver rVV M41R-del-S.  
 
The following sections will detail the construction of the plasmids used, and the methods 
used for constructing an rVV.  Before use, each rVV was freeze-thawed up to three times 
using dry ice and a water bath set at 37°C. This was followed by sonication using a Branson 
Digital Cup Horn Sonifier 450, continuous pulse at 70 % output for 2 min. All rVV viruses 
were stored at -20◦C unless otherwise stated. 
 
2.8.1 Generation of pGPT vectors.  
 
2.8.1.1 pGPT-M41-4/91(S1). 
This generation of plasmid pGPT-M41-4/91(S1) was contracted to GeneArt® (Invitrogen by 
Thermo Fisher Scientific). The sequence of the desired insert (Appendix, Figure 8.1) was 
chemically synthesised and the resulting fragment cloned into pGPTNEB193. The plasmid 
DNA was provided at a concentration of 1 µg/ml. 
 
2.8.1.2 pGPT-M41-R-4/91(S). 
This vector was assembled in house using over lapping PCR methodology to generate the 
4/91(S) sequence flanked by M41-R derived nsp 16 and 3a regions (Appendix, Figure 8.2). 
Once the fragment was complete this was cloned into pGPTNEB193 (Figure 2.9).  
 
Briefly to generate the M41-R derived nsp 16 fragment primers Sal-M40 and BG131 (Table 
2.8) were used to amplify rVV M41-R DNA. To generate the 4/91(S)-M41R-(3a) fragment, 
primers S-FOR and 3A-REV-SalI (Table 2.8) were used alongside the template pGPT-M41-
4/91(S) (GeneArt). The plasmid used as a template was actually utilised in the reverse 
genetic system to successfully generate rIBV M41K-4/91(S) (Stevenson-Leggett, 2018) but 
due to the differences between M41-K and M41-R in nsp 16 it was not appropriate for the 
construction of M41R-4/91(S).  
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Once both fragments were generated, both acted as templates in an overlapping PCR 
utilising primers Sal-M40 and 3A-REV-SalI (Tbale 2.8). The reaction contained a 4:1 ratio of 
the smaller PCR fragment encoding nsp 16 to the larger fragment encoding the 4/91 S and 
M41-R 3a genes. The resulting PCR product was gel purified, digested with Sal I and 
subsequently ligated into the Sal I digested pGPTNEB193 vector.  Figure 2.9 details the 
process of generating pGPT-M41R-4/91(S) and the relevant section numbers for the exact 
molecular biology methods used. 
 
 
Figure 2.4: Schematic detailing the methods used to construct pGPT-M41-R-4/91(S) (1) 
To generate the M41-R derived nsp 16 fragment (yellow) primers (red arrows) Sal-M40 and 
BG131 were used to amplify rVV M41-R DNA. (2) To generate a fragment containing M41-R 
nsp 16, 4/91 S ectodomain (green) and the M41-R gene 3a (blue) primers S-FOR and 3A-
REV-SalI were used to amplify the template pGPT-M41-4/91(S) (GeneArt). Once both 
fragments were generated, both acted as templates in an overlapping PCR (3) utilising 
primers Sal-M40 and 3A-REV-SalI. Steps 4 to 11 describe the order of methods used for 
cloning the overlapping PCR product. The section numbers highlighted in blue refer to the 
corresponding methods in this chapter.   
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2.8.2 Infection/transfection of Vero cells:  the generation of rVVs containing GPT 
gene by homologous recombination. 
 
Vero cells were seeded in 6 well plates, and once at approximately 60% confluency were 
washed once with PBSa. Cell were infected with rVV at an MOI of 0.2, and incubated for 2 h 
at 37°C.  The inoculum was removed and the cells washed twice with Opti-MEM with 
Glutamax-1 (Gibco by Life Technologies, 51985026). Each well was transfected with a 
solution containing 3 ml Opti-MEM with Glutamax-1, 5 µg pGPT plasmid, and 12 µl lipofectin 
(Invitrogen by Life Technologies, 18292011). After 1 h at 37°C, 5% CO2, the transfection 
solution was removed and replaced with 5 ml 1 X BES medium.  Infected/transfected cells 
were incubated overnight before the addition of GPT selection agents. This prolonged 
incubation period allowed for the occurrence of recombination events between homologous 
sequences of the IBV cDNA within the rVV genome and the IBV sequence within the pGPT 
plasmid.   
 
Following overnight incubation GPT selection agents in the following quantities were added 
per well: 12.5 µl MPA, 125 µl xanthine and 7.4 µl hypoxanthine. Cells were incubated at 
37˚C until extensive CPE was observed, typically 2 to 3 days, after which both the cells and 
supernatant were harvested. The cells were pelleted by low speed centrifugation and re-
suspended in 400 µl 1 x BES medium. 
 
2.8.3 Transient dominant selection (TDS). 
Vero cells were seeded in 6 well plates, and once confluent were washed once with PBSa. 
Each rVV was serially diluted in 1 x EMEM, 10-1 to 10-3. Each well of cells was inoculated 
with 500µl serially diluted rVV and incubated for 1 - 2 h at 37˚C, 5% CO2. The inoculum was 
removed and replaced with 3ml of overlay mixture; 1 x EMEM containing 1% agar. If GPT 
positive viruses were being plaque purified, GPT selection agents were added to the overlay 
mixture; 250 µl MPA, 2.5 ml xanthine and 149 µl hypoxanthine per 100 ml. Infected cells 
were incubated for 3 to 4 days at 37°C, 5% CO2. Plaques were visualised using neutral red 
staining; 2 ml overlay mixture containing  0.01% (w/v) neutral red was added per well. 
Plaques could be visualised after a minimum of 6 to 7 h incubation at 37°C, 5% CO2. Well 
isolated plaques, 2 to 10, were picked per rVV and re-suspended individually in 400µl 1 x 




2.8.4 Preparation of rVV mini-stocks. 
Vero cells were seeded in 6 well plates, and once confluent were washed once with PBSa. 
Each well was inoculated with 500µl 1 x BES medium containing 150 µl rVV.  After 1 hour 
incubation at 37°C, 2.5ml 1 x BES medium was added per well. The cells were incubated at 
37°C, 5% CO2 until extensive CPE was observed. The infected cells were pelleted by low 
speed centrifugation and re-suspended in 700 µl 1 x BES. 
 
DNA was extracted from rVV mini-stocks as described in section 2.7.6. DNA was screened 
by PCR analysis (section 2.7.5.1) for the presence of GPT using primers GPT for and GPT 
rev, as well as the desired insert using primers S for* and S rev* (Table 2.8). The sequence 
of the latter PCR product was confirmed (section 2.7.16). Once the desired rVV ministocks 
had been identified, these ministocks were used to inoculate BHK-21 cells for the 
preparation of large rVV stocks (section 2.8.5).  
 
2.8.5 Infection of BHK-21 cells for the preparation of large stocks of rVV. 
BHK-21 cells were seeded in T150 flasks. Once confluent the growth media was removed 
from each flask and replaced with 18 ml 1 X GMEM. A further 2 ml 1 X GMEM containing 10 
to 20 µl rVV was added. Infected cells were incubated at 37°C, until extensive VV-induced 
CPE was observed, typically 72 to 96 hpi. Both cells and supernatant were harvested into 50 
ml Falcon tubes, and the infected cells pelleted by low speed centrifugation for 15 min, 4°C.  
Each pellet was re-suspended in TE buffer, pH 9 to produce a total of volume of 11 ml. Two 
0.5 ml aliquots were kept for stock virus and stored at -80°C, whilst the remaining 10 ml was 
purified using ultracentrifugation (section 2.8.6). 
 
2.8.6 Purification of large stocks of rVV. 
Recombinant vaccinia virus, 10 ml, harvested as part of section 2.8.5 was centrifuged for 10 
min at 500 x g, 4˚C, to pellet the nuclei. The cell pellet was discarded and the supernatant 
collected and made up to 13 ml using TE buffer pH 9. This was layered on top of 16 ml 30% 
sucrose solution in Beckman ultra-clear (25 x 89 mm) ultracentrifuge tubes. Using a 
Superspin 630 rotor and a Sorvall OTD65B ultracentrifuge, the sample was centrifuged at 
4°C for 1 to 2 h at 14 k rpm (36,000 x g). The supernatant was carefully removed and the 





2.9 Recovery of recombinant IBV in CK cells. 
 
The rescue of infectious rIBVs was carried out in primary CK cells (Figure 2.10) and has 
been described previously (Casais et al., 2001, Britton et al., 2005, Keep et al., 2015). Briefly 
CK cells are infected with a rFPV-T7 that encodes a bacteriophage T7 RNA polymerase 
(Britton et al., 1996). The cells are then transfected with rVV DNA containing a cDNA copy of 
the desired rIBV genome as well as a plasmid expressing the IBV N protein. The presence of 
the N protein has been found to be essential for efficient recovery of infectious virus (Casais 
et al., 2001). The IBV N gene and the IBV cDNA are under the control of T7 promoters, and 
once transcribed in the cell cytoplasm by the T7 RNA polymerase encoded by rFPV-T7, an 
IBV replication cycle is initiated. Translation and genome replication follow and infectious 
virus is assembled and released.  
 
Figure 2.5: Schematic detailing the recovery of infectious rIBV in CK cells. (1) Primary 
CK cells are infected with a recombinant fowlpox virus which expresses a T7 RNA 
polymerase (rFPV-T7). (2) Cells are subsequently co-transfected with recombinant vaccinia 
DNA encoding the desired IBV cDNA under the control of a T7 RNA promotor, and a plasmid 
(pCI-Neo-N) expressing the IBV N protein under the control of both a cytomegalovirus (CMV) 
RNA polymerase II promoter and a T7 RNA promoter. (3) The rFPV-T7 derived RNA 
polymerase generates both the N protein from pCi-Neo-N, and infectious IBV RNA from the 
rVV DNA. This in turn (4) initiates an IBV replication cycle resulting (5) in the generation of 
recombinant IBV (rIBV). 
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2.9.1 Infection and transfection of CK cells. 
CK cells were seeded in 6 well plates with the aim of achieving 40 – 50 % confluency. Prior 
to use the cells were washed twice in PBSa to ensure removal of unattached and/or dead 
cells.  In replicates of 10, each well of CK cells were inoculated with 500 µl rFPV-T7 (MOI of 
5 - 10) and incubated for 1 h at 37°C. Replicates of 10 are chosen as the successful 
recovery of rIBV is considered a low probability event. During the incubation period, 
transfection solutions A and B were prepared. Each solution was incubated at RT for 30 min 
before being combined to form solution AB. Solution AB was incubated for a further 15 min 
at RT before use.  
Per well,  
• Solution A: 1.5 ml Opti-MEM with Glutamax-1, 10 µg rVV DNA containing the 
modified IBV cDNA, 5 µg of plasmid expressing IBV N protein (pCi-Neo-N). 
• Solution B: 1.5 ml Opti-MEM with Glutamax-1, 30 µl lipofectin.  
 
After the 1 h incubation period, rFPV-T7 was removed from each well, and cells washed 
twice with Opti-MEM with Glutamax-1. Each well of cells was transfected with 3 ml solution 
AB, and incubated overnight at 37˚C after which solution AB was replaced with 5 ml 1 x BES 
medium. Cells were incubated at 37°C until extensive rFPV-T7 induced CPE was observed, 
typically 3 days.  
 
The supernatant from each well was harvested and filtered (0.22µm filter) to remove rFPV-
T7 and stored at -80°C. It was not expected that rIBV would be able to exit the cell so 
infected/transfected cells were frozen in 500 µl 1 x BES medium at -80˚C, and thawed at RT 
followed by turation 10 – 20 x using 1 ml syringes and needles. Once filtered (0.22µM), up to 
300µl cell lysate was used to infect an embryonated hens’ egg as detailed in section 2.6.1. 
Cell lysate was passaged twice in embryonated hens’ eggs before the allantoic fluid was 
screened for the presence of rIBV by RT-PCR analysis using primers BG56 and 93/100 as 




Each figure in the results section of this PhD thesis details the statistical tests used to 
analysis the data set presented. Graphpad Prism, version 7.0, was used for all statistical 
analysis. Prior to each statistical test the normality of each data set was assessed using a 
Shapiro-Wilk test.   
95 
 
Chapter 3: Recombinant IBV Beau-R expressing either 
heterologous S1 or S2 subunits is unable to confer complete 




Previous research has identified that vaccination with a Beau-R vector expressing either the 
M41 or 4/91 S ectodomain can induce a protective immune response against homologous 
challenge (Hodgson et al., 2004; Armesto et al., 2011). One of the drawbacks of expressing 
the complete S ectodomain is that its removes the unique ability of Beau-R to replicate in 
Vero cells; an ability conferred by the Beau-R S2 subunit (Bickerton et al., 2018). Efficient 
replication in Vero cells is a desirable characteristic of vaccine viruses, as Vero cells are both 
licenced and routinely used by vaccine manufacturers (Montagnon et al., 1981; Frazatti-
Gallina et al., 2004). As discussed in chapter 1 each individual S glycoprotein consists of two 
subunits, S1 and S2, of which the S1 forms the globular head and the S2 the stalk like 
structure (Doms et al., 1993, Walls et al., 2016; Kirchdoerfer et al., 2016). Two rIBVs have 
been constructed that contain the S2 subunit from Beau-R and the S1 subunit from either 
M41 or QX; rIBV BeauR-M41(S1) and BeauR-QX(S1) respectively. Both rIBVs replicate to 
high titres in Vero cells (Bickerton et al., 2018, Bickerton et al., 2018B), consequently 
identifying both viruses as desirable vaccine candidates.    
 
The role of the S glycoprotein in protective immunity is well documented (Cavanagh, 2007; 
de Wit and Cook, 2014; Jordan,  2017) and it is the S1 subunit that is reported to induce the 
majority of virus neutralising antibodies (Cavanagh and Davies, 1986; Cavanagh et al., 1986, 
Ignjatovic and Galli, 1994; Johnson et al., 2003; Song et al., 1998; Mockett et al., 1984). 
Previous research has reported varying degrees of success in both homologous and 
heterologous in vivo vaccine-challenge experiments that utilise a variety of expression 
systems for the S1 subunit (Johnson et al., 2003; Yan et al., 2013; Makadiya et al., 2016; 
Song et al., 1998).   
 
Recombinant IBV vectors have the distinct advantage of mimicking the natural route of WT 
infection. Consequently local protective immune responses will be induced in vivo in areas 
that mirror the WT virus life cycle. The S glycoprotein is also a dynamic trimeric-protein 
structure that undergoes conformational changes during the replication cycle (Walls et al., 
2017). In WT infection epitopes will be presented to the immune system in both the pre-
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fusion and post-fusion conformations. Non-IBV vectors such as recombinant fowl adenovirus 
(Johnson et al., 2003), rNDV (Shirvani et al., 2018) and recombinant baculovirus (Song et 
al., 1998) that express the S1 subunit will not have the ability to present the S1 antigen as 
part of a trimeric structure nor in multiple forms thus limiting the induced immune response to 
a number of fixed epitopes. An IBV vector has capacity to allow both the pre-fusion and post-
fusion forms of the S1 subunit to be presented, thereby allowing a variety of epitopes to be 
presented throughout the duration of the rIBV vaccine virus replication cycle.     
 
To establish whether vaccination with a rIBV expressing heterologous S1 subunits, in which 
the S1 subunit is derived from a different genetic isolate and the S2 subunit is derived from 
the same genetic background as the vector IBV genome, could induce homologous 
protection against the donor S1 strain, an in vivo vaccine challenge experiment was carried 
out (Figure 3.1, Table 3.1).  The results of this experiment are published in the research 
article (Ellis et al., 2018) that forms the results section of this chapter. As an overview neither 
vaccination with the vaccine viruses, BeauR-M41(S1) or BeauR-QX(S1) protected birds 
against IB induced by challenge with IBV strains M41-CK or QX, respectively, as defined by 
the European Pharmacopoeia. This result lead to a second homologous vaccine-challenge 
experiment (Figure 3.2, Chapter 3 Table 3.2) utilising vaccine viruses, BeauR-M41(S1), 
BeauR-M41(S2) alongside a control rIBV vaccine BeauR-M41(S) which had previously been 
demonstrated to protect birds against challenge (Hodgson et al., 2004). This experiment 
aimed to investigate the role of the individual subunits in vaccine induced immunity; the 
results of this are also presented in the enclosed research article (Ellis et al., 2018). It was 
concluded that only BeauR-M41(S) induced a protective response, however this still fell 





Figure 3.1: Schematic detailing protocol for in vivo homologous vaccine-challenge 
experiment – trial 1. Groups of eight day old SPF RIR chickens were vaccinated with 
BeauR-M41(S1), BeauR-QX(S1) or PBS. Three weeks (21 days) post vaccination birds were 
challenged with either M41-CK, QX or mock challenged with PBS. Clinical signs were 
assessed both post vaccination and post challenge. At defined intervals five randomly 
chosen birds were culled from each group and a variety of tissues harvested. Serum was 
collected pre-vaccination, post-vaccination (pre-challenge) and post-challenge. Tracheal 
ciliary activity was assessed on 4 dpv and 4 dpc.  The experiment ended 14 dpc with all 
remaining birds culled.  
 
Table 3.1: Groups, sampling points and numbers for the vaccine-challenge 
experiment assessing vaccine viruses BeauR-M41(S1) and BeauR-QX(S1) against 
homologous challenge. 
 
Note:* one bird was culled due to poor health unrelated to the IBV infection resulting in a 






Figure 2.2: Schematic detailing protocol for in vivo homologous vaccine-challenge 
experiment – trial 2. Groups of eight-day old SPF RIR chickens were vaccinated with 
BeauR-M41(S1), BeauR-M41(S2), BeauR-M41(S) or PBS. Three weeks (21 days) post 
vaccination birds were challenged (homologous challenge) with M41-CK or mock challenged 
with PBS. Clinical signs were assessed both post vaccination and post challenge birds. At 
defined intervals, including 4 hpv, five randomly chosen birds were culled from each group 
and a variety of tissues harvested. Serum was collected pre-vaccination, post-vaccination 
(pre-challenge) and post-challenge. Tracheal ciliary activity was assessed 4 dpv and 4 dpc.  
The experiment ended 14 dpc with all remaining birds culled.  
 
Table 3.2: Groups, sampling points and numbers for the vaccine-challenge 
experiment assessing vaccine viruses BeauR-M41(S1) and BeauR-M41(S2) and 
BeauR-M41(S) against homologous challenge. 
 
Note: * one bird was culled due to poor health unrelated to the IBV infection resulting in a 




To clarify my contribution to the enclosed research article, I planned and organised both in 
vivo vaccine challenge experiments. I assessed clinical signs in both the experiments, Figure 
2 and 6 in the enclosed article and took blood samples both pre-vaccination and pre-
challenge that were used in ELISA assays, Figure 5 and 8. I also carried out post mortem 
examinations and generated the ciliary activity data presented in Table 1 and 2. I 
investigated viral load post-challenge through titrations of tracheal derived supernatant in ex 
vivo TOCs; this data is presented in Figure 4E and 7E. Tissues including eyelid, beak (nasal 
turbinates) and trachea were assessed for viral presence both post vaccination and post 
challenge; a selection of this data is presented in Table 3 of the enclosed article as well as 
Tables 3.3 and 3.4 of this chapter. Finally, I investigated the replication kinetics of the 




The results section of this chapter consists of the following research article:  
Recombinant Infectious Bronchitis Viruses expressing chimeric spike glycoproteins induce 
partial protective immunity against homologous challenge despite limited replication in vivo. 
 
Authors:  Samantha Ellis, Sarah Keep, Paul Britton, Sjaak de Wit, Erica Bickerton, Lonneke 
Vervelde. 
 
Journal Details:  Journal of Virology, December 2018, Volume 92, Issue 23, e01473-18. 
 




























































The inability of vaccination with either BeauR-M41(S1) or BeauR-QX(S1) to induce a fully 
protective immune response to homologous challenge with M41-CK or QX respectively, was 
unexpected. Both vaccine viruses are able to replicate in Vero cells to high titres (Bickerton 
et al., 2018, Bickerton et al., 2018b) which offers the ability to bulk manufacture without a 
dependency on embryonated hens’ eggs. However, this advantage does not compensate for 
the lack of protection induced. The mean ciliary activity in both the BeauR-M41(S1) 
vaccinated/M41-CK challenged and BeauR-QX(S1) vaccinated/QX challenged chickens at 4 
dpc was less than 10%; comparable to the mock vaccinated/M41-CK challenged and mock 
vaccinated/QX challenged control groups (Table 1 in the enclosed article). In addition, post 
challenge both rIBV vaccinated groups displayed IB related clinical signs (Figure 2 in the 
enclosed article), although birds vaccinated with BeauR-QX(S1) and challenged with IBV QX 
appeared to have recovered 1 day earlier.  Previous research had eluded that the S1 subunit 
alone could induce a protective immune response (Cavanagh et al., 1986, Ignjatovic and 
Galli, 1994; Johnson et al., 2003; Song et al., 1998; Yan et al., 2013, Toro et al., 2014).  
 
Several research groups have vaccinated chickens with viral vectors expressing the IBV S1 
subunits or with recombinant S1 (rS1) glycoprotein. Johnson et al., (2003) investigated the 
use of a single dose of recombinant fowl adenovirus expressing the S1 gene from the IBV 
strain Vic S. The authors concluded that vaccination of commercial broiler chicks at one day 
of age protected four of eight birds against homologous challenge, and vaccination at six 
days of age protected six of thirteen birds. Unlike the studies presented in this chapter, 
Johnson et al. (2003) defined protection by the absence of challenge virus derived RNA in 
the trachea 6 dpc. Using this definition two of the five birds vaccinated with BeauR-M41(S1) 
would have been deemed protected against homologous challenge with M41-CK (Table 3.3). 
Unlike the study presented in this chapter, Johnson et al., (2003) reported no ciliary activity 
data nor conclusive IB related clinical signs data therefore making it difficult to compare the 
level of protection induced. Johnson et al., (2003) also concluded that the S1 subunit of Vic 
S could offer protection against heterologous challenge with the IBV strain N1/62, reporting a 
protection rate of 100% when using a vaccine dose of 106 TCID50 compared to 80% with 103 
TCID50. The presence of challenge virus was however determined via virus isolation in 
embryonated hens’ eggs with a read out of embryo dwarfing and IBV antigen ELISA on the 
harvested allanotic fluid. Similarly to the homologous vaccine-challenge study, there were 




Table 3.3: Number of birds positive for IBV derived RNA in the eyelid and trachea 4 
dpc. 
 
Note: IBV RNA was detected in the upper eyelids and trachea sections harvested 4 dpc 
using RT-PCR utilising primers BG56 and 93/100 that amplify the 3′ UTR. *Two birds in 
group D would be classified as protected according to the criteria set by Johnson et al., 
(2003) due to the lack of challenge virus derived RNA present in the trachea. 
 
The study by Johnson et al., (2003) highlights the difference in techniques used and the 
differences in the definition of protection. These differences are not isolated to one study but 
are common throughout the IBV vaccination field (de Wit and Cook, 2014). Further studies, 
Song et al., (1998), Chen et al., (2010), Yan et al., (2013) and Toro et al., (2014) which are 
commonly cited as evidence that the S1 can induced a protective immune response, have 
notable technical differences to the study presented by Ellis et al., (2018). These differences 
not only included the definition of protection but also include age of bird, the type of 
vaccination, whether it is live attenuated or a subunit vaccine, route of vaccine 
administration, vaccination dose and whether birds received a single vaccine dose or 
multiple. 
  
Song et al., (1998) vaccinated six week old chickens with rS1 derived from the 
nephrophathogenic IBV strain KM91 which had been expressed from a baculovirus vector. 
After three intramuscular (i.m.) vaccinations of the rS1 protein, 50% protection as defined by 
the absence of challenge virus derived RNA, was observed in the kidney and 25% in the 
trachea after homologous challenge. Similarly Yan et al., (2013) used three doses of an i.m. 
vaccination of a plasmid encoding the S1 gene, reporting protection rate, also defined by the 
absence of IBV derived RNA, upon homologous challenge of 75%. These birds were i.m. 
vaccinated at 7, 21 and 35 days of age, and then challenged via the intra-ocular and intra-
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nasal route 3 weeks later. Toro et al., (2014) used a recombinant adenovirus expressing the 
S1 subunits of strains of the Ark IBV serotype; birds received an i.m vaccination at 3 days of 
age, and a booster, deliver via the intraocular route, at 20 days of age. A small reduction in 
viral load in tears as well as a reduction in tracheal mucosal damage was reported.  
 
Chen et al., (2010) vaccinated one day old SPF chickens with rFPV expressing either the S1 
subunit from the nephropathogenic HN99 strain of IBV, rFPV-S1, or the S1 subunit alongside 
chicken interleukin 18 (Il18), rFPV-S1/Il18. Birds were vaccinated via wing prick and 
homologously challenged 43 days later via the ocular nasal route. Chen et al., (2010) 
reported that 100% of those vaccinated with rFPV-S1/Il18 displayed no IB related clinical 
symptoms post challenge; 75% vaccinated with rFPV-S1 also presented no clinical 
symptoms.  Kidney tissue extracted 14 dpc was assessed for viral presence with 100% and 
75% of birds testing negative that had been vaccinated with rFPV-S1/Il 18 and rFPV-S1 
respectively. Whilst the data presented does indicate the vaccines have induced protection 
against kidney infection and clinical disease it is unclear whether the respiratory tract is free 
of viral infection. Chen et al., (2010) only sampled birds at 14 dpc and did not assess viral 
presence in tracheal tissue nor ciliary activity, and it is likely at this time point respiratory 
infection may have cleared. Whilst the results of this study are interesting, the difference in 
technical methodology and sampling points make it difficult to directly draw comparisons with 
the studies detailed in the chapter.  Similarly the studies detailed by Song et al., (1998), Yan 
et al., (2013) and Toro et al., (2014) are all very different to those presented in this chapter. It 
is very challenging therefore to conclusively assess whether the S1 subunit can induce a 
protective immune response, and whether the study presented in this chapter compares to 
previous research or is an anomaly.  
 
As well as studies in which the authors suggest expression of the S1 subunit can induce 
protection, there have been studies published in which the authors conclude the S1 is 
insufficient. Zhao et al., (2017) vaccinated 14 day old SPF birds with rNDV expressing the 
S1 subunit of IBV strain ck/CH/LDL/091022, rLaSota-S1. Vaccinated birds were 
homologlously challenged three weeks later.  The presence of IBV in oral swabs collected 4, 
8 and 12 dpc was determined via qRT-PCR, with those birds mock vaccinated reported to 
have a higher viral load in comparison to the vaccinated birds. Zhao et al., (2017) concluded 
due to the presence of IBV RNA in oral swabs from vaccinated birds, that a single vaccine 
with rLaSota-S1 was insufficient to induce a fully protective immune response against 
homologous challenge. Despite the technical differences this is a similar conclusion to Ellis 
et al., (2018). Zhao et al., (2017) also investigated a prime-boost vaccination schedule with 
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birds receiving vaccinations at 14 and 28 days of age; birds were homologously challenged 7 
dpsv. Tissues harvested 5 dpc showed a reduction in viral load in comparison to the 
unvaccinated control group. Despite this reduction however the tissues were positive for IBV 
indicating that similarly to a single vaccination, a prime-boost vaccination with rLaSota-S1 
was insufficient to induce a fully protective immune response against homologous challenge.  
Similarly Shirvani et al., (2018) also used an rNDV to express the IBV S1 subunit, rNDV-S1. 
Birds were vaccinated at one day of age and homologously challenged three weeks later. 
Viral load in tracheal swabs collected 5 dpc was assessed, with vaccinated birds 
demonstrated to have similar viral load as the unvaccinated control birds. This observation, 
alongside the presence of IB related clinical signs indicated that vaccination with rNDV-S1 
was unable to induce a fully protective immune response.  
 
The inability of Beau-R vaccines expressing heterologous S1 subunits to induce a fully 
protective immune response raised a number of questions regarding the role of the S2 
subunit which has been shown in IBV, MHV and SARS-CoV to contain immunogenic regions 
(Kusters et al., 1989; Koch et al., 1990; Daniel et al., 1993; Zhang et al., 2004; Elshabrawy et 
al., 2012).  In comparison to the S1 subunit, the sequence of the S2 subunit is relatively 
conserved between IBV strains, with Toro et al., (2014) reporting 74.4 – 99.7% amino acid 
identity of 251 complete sequences available in GenBank. To evaluate the role of the S2 
subunit a second in vivo vaccine challenge experiment was carried out, which is also 
presented in the enclosed research article. Chickens were vaccinated at 8 days of age with 
BeauR-M41(S1), BeauR-M41(S2) or BeauR-M41(S) and challenged three weeks later with 
M41-CK. Only vaccination with BeauR-M41(S) offered protection against homologous 
challenge, however this protection fell short of the standards set by the European 
Pharmacopeia (Table 2 in the enclosed article). The conclusion that the expression of a full 
S ectodomain was required to elicit a protective immune response against homologous 
challenge raised a number of questions regarding the role of protective epitopes across both 
subunits, and also whether the chimeric S glycoproteins were folded in a comparable way to 
WT and therefore whether structural conformational epitopes had been affected. 
 
Similar to Ellis et al., (2018), research by Eldemery et al., (2017) and Shirvani et al., (2018) 
has also indicated a role for the S2 subunit in protective immunity. Eldemery et al., (2017) 
vaccinated SPF chickens at 12 days of age with recombinant trimerised S (rS) or rS1 protein 
by subcutaneous injection, boosted three weeks later and challenged a further three weeks 
post boost. Viral load was assessed in tears and trachea at 5 dpc, with a reduction in tears 
observed in those birds vaccinated with rS and rS1 in comparison to the mock vaccinated 
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control group. Only those birds vaccinated with rS presented with reduced viral load in 
harvested tracheas and also reduced tracheal damage as determined by histopathology. 
Unfortunately no data is presented regarding clinical signs or ciliary activity so it cannot be 
stated for certain that vaccination with rS protected against clinical disease. The authors 
concluded that only rS could induce a protective immune response and hypothesised this 
was due to a number of reasons including epitopes present on the S2 subunit and a 
conformational stabilisation effect of the S2 subunit on the S1 subunit which could affect the 
structure of protective epitopes and/or receptor binding. Interestingly rS demonstrated higher 
affinity binding to chicken tissues including the trachea in comparison to rS1, with rS1 
notably unable to bind to lung and kidney tissue.   
 
Shirvani et al., (2018) vaccinated one day old SPF chickens with rNDV expressing either S1 
(rNDV-S1), S2 (rNDV-S2) or the S ectodomain (rNDV-S), and challenged three weeks later. 
Clinical signs were observed twice a day in the ten days after challenge with the average 
severity score presented; birds vaccinated with rNDV-S appear to have fewer clinical signs 
than those mock vaccinated and those vaccinated with rNDV-S1 and rNDV-S2. Tracheal 
swabs were collected 5 dpc and assessed by qRT-PCR for viral genome; the viral load 
appears similar in all vaccinated groups. Viral isolation from tracheal swabs in embryonated 
eggs however indicated that 93.3% of chickens vaccinated with rNDV-S were protected as 
no viable virus was re-isolated; 100% of chickens in all other vaccinated groups were 
positive for re-isolated challenge virus. The authors hypothesised that rNDV-S gave better 
protection due to the inclusion of the S2 subunit which may act as a chaperone, assisting 
folding of the S1 protein and therefore assisting presentation of conformational epitopes. 
 
The S glycoprotein is a complex homo-trimeric structure that exists in both pre-fusion and 
post-fusion conformations. Until recently the structure of the IBV S glycoprotein could only be 
assumed using data generated from other coronaviruses such as MHV, PDCoV and HCoV-
HKU1 (Kirchdoerfer et al., 2016; Walls et al., 2017; Shang et al., 2018B); the pre-fusion 
conformation of the S glycoprotein of M41 was published in 2018 (Shang et al., 2018). 
Similarly, to MHV and HKU1, the pre-fusion conformation of the IBV S exhibited on mature 
virions has a clove-like shape, with three S1 heads forming a crown-like structure that sits 
upon a trimeric S2 stalk structure (Shang et al., 2018). As discussed in the Chapter 1 both 
the S1 and S2 subunits consist of several domains (Chapter 1, Figure 1.6). Shang et al., 
(2018B) identified that the S1-CTD domains from three S protomers sit centrally on top of the 
spike trimer, with the three S1-NTD domains sitting lower on the outer edge, closer to the S2 
subunit. The S2 contains three central helices, one from each protomer which form an 
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interface between the S1 and S2. The S1 located subdomains, SD1 and SD2, connect the 
S1 subunit to S2 and the S2 HR2 region is notably disordered. 
  
 
To complicate the structure, the trimeric S1 exhibits quaternary packing (Figure 3.3); from 
one S protomer, the S1-CTD domain interacts with a S1-CTD domain located on another,  
as well as a S1-CTD domain and a S1-NTD domain located on a third protomer (Shang et 
al., 2018). This quaternary packing of the S1 subunit partially conceals the RBD in the S1-
NTD (Promkuntod et al., 2014) as well as the putative RBD residing in the S1-CTD.  It also 
locks the S2 into the pre-fusion state; the HR1 region and the FP of each S2 subunit is 
locked in place by a S1-CTD domain located on a different S protomer, as well as an S1-
CTD domain and a SD1 subdomain located on the third S protomer (Shang et al., 2018). 
Given the complexity of the structure it is not difficult to see why a chimeric S1/S2 





Figure 3.3: Quaternary packing of three S protomers into the trimeric S glycoprotein. (A) 
Schematic drawing of IBV S1 detailing the presence of two subdomains, SD1 and SD2.  (B) 
Structure of monomeric S2 subunit. (C) Structure of the monomeric S1 subunit. (D) Structure 
of trimeric S1 subunit. The S1 subunit from each monomeric unit (protomer) are represented 
in green, blue or purple. (E) Structure of trimeric S2 subunit.  The S2 subunit from each 
monomeric unit (protomer) are represented in grey, pink or purple. Figure adapted from 





There are a number of amino acid differences in S1-NTD domains of M41-CK, Beau-R and 
QX (Appendix, Figure 8.3), and notably this domain includes the HVR 1 and 2 identified by 
Cavanagh et al., (1988). The S1-CTD domains also exhibit several amino acid differences 
most of which are concentrated in the HVR 3 region identified by Moore et al., (1997). There 
is a difference of four amino acids between the SD1 subdomain of Beau-R and M41-CK and 
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18 between Beau-R and QX. There are 17 amino acid differences in the SD2 subdomain 
between Beau-R and QX and no differences between M41-CK and Beau-R. As discussed by 
Ellis et al., (2018), the S2 subunits between Beau-R, QX and M41-CK are relatively 
conserved however there are a number of differences in the HR1 region, a region structurally 
restrained by the quaternary packing of the S1 subunits.  Whilst it is unknown which residues 
play critical roles in the assembly of the trimeric S glycoprotein, the analysis of the amino 
acid sequences of the S protomers does indicate that there is potential for conformational 
changes with a chimeric S1/S2 glycoprotein. If, however, there are conformation changes 
these have not detrimentally affected the replication of the rIBV BeauR-M41(S1), BeauR-
M41(S2) nor BeauR-QX(S1) in vitro. This indicates there have not been massive structural 
changes in the chimeric S glycoproteins, as these proteins are clearly functioning to allow 
virus entry and fusion. It is possible that small conformational changes have 
distorted/changed conformational epitopes accounting for the lack of protection induced by 
these rIBV vaccines.  
 
The structure of the M41 S glycoprotein (Shang et al., 2018) as well as the solved structures 
from other coronaviruses (Kirchdoerfer et al., 2016; Walls et al., 2016; Shang et al., 2018B; 
Walls et al., 2017; Shang et al., 2018) raises questions about how the S1 subunit is 
presented to the immune system when delivered in vector vaccines, as a DNA vaccine or 
rS1 subunit vaccine (Johnson et al., 2003; Song et al., 1998; Toro et al., 2014, Yan et al., 
2012). Given the complexity of the trimeric S glycoprotein structure it is unlikely an S1 
subunit expressed on its own assembles comparably to an S1 expressed as part of WT 
infection. Furthermore the S2 subunit anchors the S1 to the viral membrane, therefore aiding 
in conformational presentation of the S1 subunit (Shang et al., 2018). Neither Johnson et al., 
(2003), Song et al., (1998), Yan et al., (2013) nor Toro et al., (2014) address this issue and 
therefore it is unclear how the S1 subunit is assembled and what conformation is presented 
to the immune system.  Using an IBV vector allows the S glycoprotein to be presented as in 
WT infection, and additionally allows for the structural changes of the S glycoprotein 
throughout the replication cycle. 
 
The structure of S described by Shang et al., (2018), discussed above is the pre-fusion 
conformation however the structure is remarkably different post-fusion, with the trimeric S 
exhibiting an elongated cone like shape (Walls et al., 2016; Walls et al., 2017; Shang et al., 
2018). Once the conformational restraint of the S1 is lifted through proteolytic processing, 
the three HR1 and HR2 regions in the trimeric S2 subunit refold into a 6-helix bundle 
structure exposing the FP (Walls et al., 2016, Walls et al., 2017; Shang et al., 2018). These 
major conformational changes will result in the exposure of epitopes previously unseen in 
the pre-fusion structure (Walls et al., 2017). The FP region is one such area that has been 
identified as an antigenic determinant in both MHV and SARS-CoV (Daniel et al., 1993; 
126 
 
Zhang et al., 2004). It is possible therefore that “hidden” epitopes in the S2, that become 
accessible after fusion, play a fundamental role in protective immunity. Subsequently it is 
therefore possible that epitopes in both the S1 and S2 subunit are required for the induction 
of a fully protective immune response, and this may account for why neither BeauR-M41(S1) 
nor BeauR-QX(S1) could induce such a robust response against homologous challenge.  
 
The results of this chapter have raised questions regarding the possible mis-folding of a 
chimeric S glycoprotein, as well as the potential role of epitopes across both the S1 and S2 
subunits in vaccine induced immunity. One other question that this chapter has raised 
regards the level of in vivo vaccine virus replication that is required to induce a protective 
immune response when utilising live attenuated vaccines. The rIBV Beau-R is a molecular 
clone of the apathogenic Beaudette-CK strain (Casais et al., 2001). Whilst rIBV BeauR-
M41(S) did induce protective immunity, as previously reported by Hodgson et al., (2004), the 
response was not as robust as expected, with the vaccine virus inducing poor levels of local 
immunity within the trachea. In addition, ciliary activity post challenge fell short of the 
European Pharmacopeia standards, a finding comparable to Hodgson et al., (2004). 
Armesto et al., (2011) investigated rIBV BeauR-4/91(S) as a vaccine against homologous 
challenge; ciliary activity at ~65% 4 dpc also fell short of the European Pharmacopeia 
standards. One possible explanation for this, and also of the failure of BeauR-M41(S1) and 
BeauR-QX(S1) to elicit a protective immune response is the potentially limited in vivo 
replication of the vaccine viruses.  
 
In the studies presented in this chapter neither rIBV BeauR-M41(S), BeauR-M41(S1), 
BeauR-M41(S2) nor BeauR-QX(S1) could be consistently detected at the sites of inoculation 
or in the trachea post vaccination (Table 3.4 and Table 3 in the enclosed article). It has long 
been established that the Beaudette strain cannot establish a long lasting productive 
infection in vivo, with the molecular clone Beau-R behaving similarly (Casais et al., 2001). 
Interestingly chickens inoculated with Beaudette do produce virus neutralising antibodies, 
however these rapidly decrease over time (Geilhausen et al., 1973), presumably due to the 
lack of or some limitation in viral replication. The lack of detectable in vivo replication of IBV 
Beaudette has been attributed to an unknown number of attenuating mutations accumulated 
during repeated passaging in both cell culture and embryonated hens’ eggs (Cavanagh et 
al., 1988). These unknown mutations may play a significant role in the failure of the vaccine 
viruses to replicate efficiently in vivo and subsequently to induce a robust immune response. 
The replication of Beau-R in vivo is therefore important to investigate for the future of 
rationally designed vaccines and will be discussed further in Chapter 5 and 6. It remains a 
possibility therefore that both the S1 subunit and the S ectodomain could elicit a stronger 




Table 3.4: IBV derived RNA could not be detected after vaccination with BeauR-
M41(S1) or BeauR-QX(S1). 
 
Note: Upper eyelids and trachea sections harvested 2 and 4 dpv were assessed for the 
presence of IBV derived RNA by RT-PCR utilising primers BG56 and 93/100 which amplify 
the 3′ UTR.  
 
The full length S glycoprotein has been used to vaccinate against SARS-CoV with reported 
success. Bukreyev et al., (2004) vaccinated monkeys with a parainfluenza virus encoding 
the full length SARS-CoV S glycoprotein; vaccinated animals had reduced viral load in 
trachea swabs compared to unvaccinated animals. Buchholz et al., (2004) also investigated 
the use of a parainfluenza virus expressing the SARS-CoV S glycoprotein; similarly to 
Bukreyev et al., (2004) vaccinated hamsters exhibited a reduction in challenge viral load. 
Mouse models have also been used to demonstrate the protective ability of the SARS-CoV 
spike when expressed from a vaccinia virus vector, a baculovirus and also as a DNA vaccine 
(Bisht et al., 2004, Yang et al., 2004; He et al., 2006). Whilst it is clear that the S glycoprotein 
is a very potent antigen, due to the use of animal models it is not conclusive whether the S 
glycoprotein alone can induce a fully protective immune response in the natural host. It is 
possible that other viral proteins are required. Interestingly whilst both BeauR-M41(S) and 
BeauR-4/91(S) can induce a protective immune response, as discussed above this response 
cannot be classified as fully protective against homologous challenge (Hodgson et al., 2004; 
Armesto et al., 2011); it may also be possible that other viral proteins are required to enable 
the rIBV to have closer resemblance to the challenge virus. The potential role of other viral 




In summary the results presented in this chapter demonstrate that neither rIBV BeauR-
M41(S1), BeauR-QX(S1) nor BeauR-M41(S2) can induce a fully protective immune 
response against homologous challenge. This could be due to a number of reasons 
including the potential mis-folding of chimeric S glycoproteins, the need for protective 
epitopes across both subunits, and the inability of the vaccine viruses to establish a 
productive infection in vivo.  A rIBV expressing the full length S ectodomain from M41-CK, 
BeauR-M41(S), can elicit a protective immune response against homologous challenge, 
however this response fell short of the European Pharmacopeia standards. This raises 
further questions regarding the level of replication of rIBV vaccines required to induce a 
protective immune response, and also whether additional viral proteins are required to 






Chapter 4: Investigating the role of the S glycoprotein in the 





The results discussed in Chapter 3 demonstrate the ability of the S glycoprotein, when 
expressed in a rIBV vector, to induce protective immune responses against homologous 
challenge. These results alongside  those reported by Hodgson et al., (2004) and Armesto et 
al., (2011) demonstrate that it is possible to rationally design live attenuated rIBV vaccine 
viruses. Whilst results of homologous vaccine-challenge experiments are encouraging, the 
major challenge in the control of IBV is that vaccination against one serotype often offers 
limited cross protection towards another (reviewed by de Wit and Cook, 2014). Cavanagh et 
al., (1997), concluded that there is a general a negative correlation between the level of 
protection afforded by a vaccine and the level of homology between the S genes of 
challenge and vaccine strain.  
 
The mechanism of cross protection is not clear cut, with several studies demonstrating a 
degree of cross protection between unrelated vaccine and challenge strains (Cavanagh et 
al., 1992; Cook et al., 2001; Terregino et al., 2008;  Armesto et al., 2011; Lim et al., 2012; 
Bru et al., 2017). Terregino et al., (2008) evaluated the use of two commercial vaccines of 
different serotypes, Ma5 and 4/91, against challenge with a third serotype, QX. No challenge 
virus could be re-isolated from the tracheas of vaccinated birds indicating to the authors that 
a fully protected immune response against QX had been induced by vaccination with the two 
unrelated serotypes. Low sequence homologies between the hypervariable region of the S1 
subunits were reported; 77.1% between Ma5 and QX and 81% between 4/91 and QX 
(Terregino et al., 2008). Conversely, other studies have demonstrated limited cross 
protection between strains with high sequence homology (Cook et al., 2001, Ladman et al., 
2006; Liu et al., 2009). Vaccination with a Beaudette strain does not confer protection 
against a M41-CK challenge; despite the > 95% sequence homology between the S genes 
(Hodgson et al., 2004); and the fact that both viruses belong to the Massachusetts serotype. 
Previous work has hypothesised that a small number of virus neutralising epitopes play a 
disproportionate role in cross-protection, which makes it difficult to predict effective vaccine 




Effective vaccination against IBV is proving an increasing challenge to the global poultry 
industry due to the continuing emergence of novel strains, such as QX which was first 
isolated in China in 1995 (Wang et al., 1998) and has subsequently spread worldwide (Beato 
et al., 2005; Worthington et al., 2008; Amin et al., 2012; Valastro et al., 2016). Commercial 
live IBV vaccines are generated through multiple passages, typically 80 – 100 times, of a 
pathogenic field isolate through embryonated hens’ eggs with the aim of generating a virus 
that is attenuated but still retains immunogenicity (Geerligs et al., 2011). Given the nature of 
this process, it is challenging to readily react to emerging strains in a time appropriate 
manner. The development of a reverse genetic system for IBV (Casais et al., 2001), opened 
up the possibility of using rIBVs as vaccines that can be rationally designed and readily 
manufactured, removing the cumbersome trial and error prone method of attenuation by 
multiple passage through embryonated hens’ eggs. 
 
In this chapter, two rIBVs, BeauR-M41(S) and BeauR-4/91(S) were investigated as potential 
vaccines against heterologous challenge with a QX strain of IBV. Both rIBVs have been 
described previously and have been demonstrated to offer protection against homologous 
challenge (Hodgson et al., 2004, Armesto et al., 2011; Ellis et al., 2018). The rIBV BeauR-
4/91(S) has also been demonstrated to offer limited cross protection against a heterologous 
M41-CK challenge (Armesto et al., 2011). Whilst cross protection studies are not novel, 
previous research has largely utilised traditional vaccine strains, such that the vaccine virus 
closely resembles the challenge virus and therefore it is difficult to assess just the role of the 
S glycoprotein. As discussed in the Chapter 3, those studies that utilised non IBV vectors as 
vaccines for the expression of the S glycoprotein or S1 subunit also come with limitations, 
making it difficult to fully assess the sole role of the S glycoprotein in the generation of a 
protective immune response against natural infection. In addition, rIBV vectors have the 
distinct advantage of mimicking the natural route of WT IBV infection.  
 
The two rIBVs, BeauR-M41(S) and BeauR-4/91(S) used in this chapter as potential vaccine 
viruses are genetically based on the Beaudette genome with only the S gene derived from a 
different strain, either M41-CK or 4/91 (UK), respectively. The use of these rIBVs therefore 
allowed for the assessment of the M41-CK and 4/91 S glycoproteins alone, when delivered 
in a manner that mimics a WT virus infection, in vaccine induced immunity against a 
heterologous QX challenge. This chapter will detail the results of the in vivo vaccine-






4.2.1 Confirmation that the S gene from a pathogenic strain does not confer 
virulence to a non-pathogenic strain.  
 
To elucidate if rIBV expressing the S gene from either 4/91 or M41-CK could induce a level 
of cross protection against a heterologous challenge with the IBV strain QX, a vaccination 
challenge experiment in SPF RIR chicks was conducted (Figure 4.1). Briefly eight-day-old 
chicks received a primary vaccination of PBS (mock vaccination), BeauR-4/91(S) or BeauR-
M41(S) as per grouping in Table 4.1. Fourteen days post primary vaccination (dppv) the 
birds received a secondary vaccination of either PBS (mock vaccination), BeauR-4/91(S) or 
BeauR-M41(S). Nine days post-secondary vaccination (dpsv) the birds were then challenged 
with either QX or mock challenged with PBS. Samples were harvested 4 dppv and 2, 4 and 








Figure 4.1: Schematic detailing protocol for in vivo heterologous vaccine-challenge 
experiment. Groups of eight day old SPF RIR chickens received a primary vaccination of 
BeauR-M41(S), BeauR-4/91(S), or PBS. Two weeks (14 days) later birds received a second 
vaccination of either BeauR-M41(S), BeauR-4/91(S) or PBS. Nine days post-secondary 
vaccination (dpsv) birds were challenged with QX or mock challenged with PBS. Clinical 
signs were assessed both post vaccination and post challenge birds. At defined intervals 
randomly chosen birds were culled from each group and a variety of tissues harvested. 
Serum was collected pre-vaccination, post-vaccination (pre-challenge) and post-challenge. 
Tracheal ciliary activity was assessed on 4 dpv and 4 dpc.  The experiment ended 14 dpc 








Clinical signs were assessed 2 to 7 dppv, with no IBV related clinical signs observed. The 
levels of snicking were comparable between all vaccinated groups and the unvaccinated 
control groups, remaining below 0.05 snicks per bird per min (Figure 4.2). No rales were 




Figure 4.2: BeauR-4/91(S) and BeauR-M41(S) vaccinated chickens displayed rates of 
snicking comparable to mock vaccinated groups. SPF RIR chickens were vaccinated 
with either BeauR-M41(S), BeauR-4/91(S) or mock vaccinated with PBS at eight days of 
age. The number of snicks was assessed from day 3 to 7 dppv. Snicks were independently 
counted by two or three persons over a 2 min period with the average of these scores 
presented.   
  
Primary No. of birds Secondary Total no. of 
vaccination sampled 4 dppv vaccination 2 dpc 4 dpc 14 dpc birds per group
A PBS (mock) 5 PBS (mock) PBS (mock) 5 5 5 20
B BeauR-M41(S) 5 BeauR-M41(S) QX 10 10 9 34
C BeauR-4/91(S) 5 BeauR-4/91(S) QX 10 10 9 34
D BeauR-M41(S) 0 BeauR-4/91(S) QX 10 10 10 30
E BeauR-4/91(S) 0 BeauR-M41(S) QX 10 10 10 30
F PBS (mock) 0 PBS (mock) QX 10 10 12 32
Group Challenge
No. of birds sampled
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Tracheal ciliary activity was assessed in five randomly chosen birds in groups A (Mock), B 
(BeauR-M41(S)) and C (BeauR-4/91(S)) at 4 dppv. Ciliary activity in BeauR-4/91(S) and 
BeauR-M41(S) infected birds was comparable to those mock vaccinated; the group means 
were 87%, 95% and 87.5% respectively (Figure 4.3). The tracheal rings used for the ciliary 
activity assay were homogenised resulting in a tissue derived supernatant which was used to 
inoculate embryonated hen’s eggs. Allanotic fluid was screened by RT-PCR utilising IBV 
specific primers BG56 and 93/100, which amplify the 3′ UTR. No PCR product was detected 






Figure 4.3 BeauR-4/91(S) and BeauR-M41(S) vaccinated chickens displayed tracheal 
ciliary activity comparable to mock vaccinated chickens. Tracheas were harvested from 
five randomly selected birds per group on four dppv. Each trachea was sectioned in 10 x 
1mm rings and the ciliary activity of each ring was assessed by light microscopy and the 
percentage activity calculated. Plotted points represent individual animals and the mean 
activity of the 10 rings assessed. Error bars represent standard deviation (SD). Statistical 
differences between groups was evaluated using Kruskal-Wallis test followed by post Hoc 






Figure 4.4: No infectious vaccine virus could be re-isolated from trachea sections 
harvested 4 dppv. SPF embryonated hen’s eggs were inoculated with tissue derived 
supernatant generated from trachea harvested 4 dppv. A positive (V+) control of BeauR-
M41(S) was included in the re-isolation experiment as was a PBS negative control (V-). 
Allantoic fluid harvested was screened for IBV related RNA by RT-PCR utilising primers 
BG56 and 93/100. A positive and negative RT-PCR control was included and denoted by + 
and – respectively. All samples were run on a 0.8% agarose gel alongside 1 KB+ ladder (L; 
Life Technologies).  
 
 
The lack of infectious virus re-isolated from tracheas harvested 4 dppv alongside the lack of 
pathology as denoted by the comparative ciliary activities to mock infected birds, and the 
lack of IBV related clinical signs, demonstrates that both BeauR-M41(S) and BeauR-4/91(S) 
have an attenuated phenotype in vivo. These observations support previous reports that the 
S genes from the two pathogenic isolates do not confer virulence to the apathogenic rIBV 
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Beau-R therefore providing a strategy for the rational design of potential vaccine viruses 
(Hodgson et al., 2004; Armesto et al., 2011; Ellis et al., 2018).  
 
4.2.2 Neither the S glycoprotein from 4/91 nor M41-CK can induce a fully 
protective immune response against a QX challenge. 
 
Fourteen days following primary vaccination each group received a second vaccination of 
BeauR-M41(S), BeauR-4/91(S) or PBS as per the groupings detailed in Table 4.1. The 
vaccination scheme included both homologous, e.g. BeauR-M41(S) followed by BeauR-
M41(S) and heterologous vaccinations, e.g. BeauR-M41(S) followed by BeauR-4/91(S). The 
order in which the heterologous vaccination was administered was also investigated as 
previous research has suggested that vaccination order has an effect on the level of 
protection induced (Cook et al., 1999). As with post primary vaccination, clinical signs were 
observed from 3 to 7 dpsv. No rales were observed in any of the groups. Levels of snicking 
(Figure 4.5) were largely comparable between vaccinated groups and unvaccinated control 
groups, remaining, bar two exceptions, below 0.1 snicks per bird per min. The two 
exceptions to this were observed 4 dpsv in those birds vaccinated with BeauR-
4/91(S)/BeauR-4/91(S), 0.19 snicks per bird per min, and on day 7 in the BeauR-






Figure 4.5: Vaccinated chickens displayed comparable rates of snicking to mock 
vaccinated chickens post-secondary vaccination. SPF RIR chickens received a 
secondary vaccination of BeauR-M41(S), BeauR-4/91(S) or PBS for mock vaccination. 
Vaccinated birds had 14 days prior received a primary vaccination of BeauR-M41(S), 
BeauR-4/91(S) or PBS for mock vaccination. The number of snicks was assessed from day 
3 to 7 dspv. Snicks were independently counted by two or three persons over a 2 min period 
with the average of these scores presented. 
 
Nine dpsv, birds were either challenged with QX, a different serotype to both M41-CK and 
4/91, or mock challenged with PBS. From 2–7 dpc clinical signs were observed in all groups 
except the mock vaccinated/mock challenged control group (Mock/Mock/Mock). Up until 5 
dpc there was no difference in the numbers of snicks between all vaccinated/challenged 
groups and the mock vaccinated/QX challenged group (Mock/Mock/QX) (Figure 4.6). On 6 
dpc the snicks in the group vaccinated with BeauR-M41(S)/BeauR-M41(S) and the mock 
vaccinated/QX challenged control group increased whereas in all other vaccinated groups 
the number of snicks decreased. The peak of the number of snicks per bird per min in the 
mock vaccinated/QX challenged control bird group, 1 snick per bird per min, was at 7 dpc.  
At this time point all vaccinated/challenged groups except BeauR-4/91(S)/BeauR-4/91(S)/QX 
exhibited less than 0.25 snicks per bird per min, with the latter exhibiting 0.6 snick/bird/min. 
At 14 dpc snicking in all the vaccinated/QX challenges groups was comparable to the mock 
vaccinated/mock challenged control group indicating that all birds had recovered from the 






Figure 4.6: Assessment of snicking post challenge.  SPF RIR chickens were vaccinated 
with either BeauR-M41(S), BeauR-4/91(S) or PBS for mock vaccination. Fourteen days later 
birds received a secondary vaccination of either BeauR-M41(S), BeauR-4/91(S) or PBS for 
mock. Nine days post-secondary vaccination birds were challenged with QX or mock 
challenged with PBS.  The number of snicks was assessed from 2 to 7 dpc and the resulting 
number of snicks per bird per min calculated. Snicks were independently counted by two or 
three persons over a 2 min period with the average of these scores presented. 
 
 
Rales were observed on days 3 to 5 dpc in all groups except unvaccinated/unchallenged 
(Figure 4.7) and followed a similar trend to the snicking in that the vaccinated birds appeared 
to recover more rapidly than the mock vaccinated/QX challenged control birds. On day 7 dpc 
only birds in the mock vaccinated/QX challenged group exhibited rales. Of the vaccinated 
groups, interestingly on 6 dpc only birds vaccinated with BeauR-4/91(S)/BeauR-4/91(S) and 
BeauR-M41(S)/BeauR-4/91(S) exhibited rales, although the numbers were reduced in 
comparison to the mock vaccinated/QX challenged control group; 22.2%, 20% and 41.7% 
respectively. Chickens that received vaccination BeauR-M41(S)/BeauR-M41(S) and BeauR-







Figure 4.7: Vaccinated chickens exhibited in fewer rales post challenge in comparison 
to unvaccinated chickens. SPF RIR chickens were vaccinated with either BeauR-M41(S), 
BeauR-4/91(S) or PBS for mock vaccination. Fourteen days later birds received a secondary 
vaccination of either BeauR-M41(S), BeauR-4/91(S) or PBS for mock. Nine days post-
secondary vaccination birds were challenged with QX or mock challenged with PBS. 
Chickens were checked individually for the presence of tracheal rales 2 – 7 dpc. The 
percentage of birds per group positive for rales was calculated.  
 
 
Tracheal ciliary activity was assessed on 4 dpc in tracheas harvested from 10 randomly 
selected chickens in all groups except the mock vaccinated/mock challenged control group 
in which five birds were randomly sampled (Table 4.2, Figure 4.8). The industry standard for 
the assessment of IBV vaccines set by the European Pharmacopeia states that in order for a 
chicken to be protected at least 50% ciliary activity must be retained post challenge in nine 
out of ten rings sampled from a trachea (European Pharmacopeia, 2010). The mean ciliary 
activities for the vaccinated groups ranged from 2.25% to 18.75% (Table 4.2). The mock 
vaccinated/QX challenged control group displayed a mean activity of 1.0%, and the 
unvaccinated/unchallenged group a mean activity of 80.5%. Ciliary activities in the mock 
vaccinated/QX challenged control group as well as all vaccinated groups, except the BeauR-
4/91(S)/BeauR-4/91(S) vaccinated group, were significantly different to the 
unvaccinated/unchallenged group (p<0.05, Figure 4.8). Interestingly, two birds vaccinated 
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with BeauR-4/91(S)/BeauR-4/91(S) retained ciliary activities comparable to 
unvaccinated/unchallenged birds, with one bird classified as fully protected with 10/10 
tracheal rings retaining 50% or more ciliary activity (Table 4.2). The second bird displayed an 
average ciliary activity of 72.5%, with 7/10 rings retaining 50% or more activity.  
 
Table 4.2 Percentage ciliary activities in tracheal samples harvested at 4 dpc. 
 
Notes: Birds considered protected if at least 50% ciliary activity is retained post challenge in 
nine out of ten rings sampled (European Pharmacopeia, 2010). 
  
No. of Standard 
protected birds Deviation
72.50 97.50 75.00 87.50 70.00
5.00 7.50 10.00 2.50 0.00 7.50 5.00 5.00 10.00 5.00
2.50 0.00 2.50 95.00 72.50 7.50 2.50 2.50 0.00 2.50
0.00 0.00 0.00 30.00 0.00 5.00 17.50 0.00 10.00 0.00
5.00 15.00 0.00 0.00 0.00 0.00 0.00 0.00 2.50 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.00
E
F
































Figure 4.8: Vaccination strategies did not offer protection against the loss of ciliary 
activity post challenge. Ciliary activity was assessed in trachea extracted four days post 
challenge in five or ten randomly selected chickens as per post vaccination. Ciliary activity in 
all groups except BeauR-4/91(S)/BeauR-4/91(S)/QX was statistically reduced in comparison 
to the mock vaccinated/mock challenged control group. Ciliary activity in all vaccinated 
groups was comparable to the mock vaccinated/QX challenge control group. Statistical 
differences between groups were evaluated using Kruskal-Wallis test followed by post Hoc 
Mann Whitney test corrected for multiple comparisons. Error bars represent SD.  
 
 
Whilst one vaccinated group, BeauR-4/91(S)/BeauR-4/91(S), did display some evidence of 
retained ciliary activity and it appears that the birds in all vaccinated groups recovered in 
terms of the clinical signs (rales and snicking) more rapidly than the mock vaccinated/QX 
challenged control birds, overall none of the vaccination strategies successfully offered full 
protection against heterologous challenge with QX. 
 
4.2.3 Vaccination has resulted in a reduction of viral load post challenge.  
 
To assess the implications of the vaccine strategies on viral load, tissue derived 
supernatants prepared from tracheas harvested 4 dpc, were titrated in ex vivo TOCs (Figure 
4.9). Viral loads from all vaccinated/challenged groups were statistically higher than those 
from birds in the mock vaccinated/mock challenged control group, in which no virus was re-
isolated. In birds vaccinated with BeauR-M41(S)/BeauR-M41(S) the viral loads were 
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statistically lower (p<0.05) than those observed from the mock vaccinated/QX challenged 
control group. Similarly, viral load in birds vaccinated with BeauR-4/91(S)/BeauR-4/91(S) 
was also lower (p<0.05). Overall, the results showed that birds which received homologous 
primary and secondary vaccinations had a lower viral load in comparison to mock 
vaccinated/QX challenged birds. However, there were no differences in viral loads between 
the mock vaccinated/QX challenged control group and those vaccinated with heterologous 
vaccines, BeauR-M41(S)/BeauR-4/91(S) or BeauR-4/91(S)/BeauR-M41(S). It therefore 
appears that a vaccination schedule with homologous primary and secondary vaccines had 
a greater effect on viral load than one involving heterologous primary and secondary 
vaccinations. In addition, interestingly the two birds vaccinated with BeauR-4/91(S)/BeauR-
4/91(S) which retained ciliary activity post challenge comparable to mock vaccinated/mock 
challenged birds, had viral load comparable to the group average (mean), 3.5, 3.8 and 3.13 
log10 CD50/ml respectively, and to the group average of the unvaccinated/QX challenged 
control group, at 4.06 log10 CD50/ml. This observation therefore indicates that viral load and 





Figure 4.9: Infectious viral load in the trachea 4 days post challenge. Tissue derived 
supernatant prepared from trachea sections harvested four dpc was titrated in ex vivo TOCs. 
Data points represent individual animals, with lines representing the mean and standard 
error of the mean (SEM). Statistical differences in viral load were evaluated by a parametric 
one-way ANOVA with a Tukey test for multiple comparisons. Statistical differences are 




Viral RNA loads in the head-associated lymphoid tissues at 2 and 4 dpc were also 
investigated and were determined by qPCR (Figure 4.10). This experiment was carried out 
by Dr. Samantha Ellis at The Roslin Institute. CALT extracted 4 dpc from chickens 
vaccinated with BeauR-M41(S)/BeauR-4/91(S) and BeauR-4/91(S)/BeauR-M41(S) showed 
a significant reduction (p<0.05) in viral RNA load compared to the mock vaccinated/QX 
challenged control group (Figure 4.10D). Interestingly, there was no significant reduction in 
viral load in the group vaccinated with BeauR-M41(S)/BeauR-M41(S) nor the group 
vaccinated with BeauR-4/91(S)/BeauR-4/91(S), both of which had lower infectious viral load 
in the trachea (Figure 4.9). There were no significant differences in viral RNA load between 
the vaccinated groups and the mock vaccinated/QX challenged control group in the head-
associated lymphoid tissues (harderian gland) at any of the post-challenge time points 







Figure 4.10: Viral load in the CALT and Harderian gland 2 and 4 days post challenge. 
Relative viral RNA load (expressed as corrected 40- cycle threshold, Ct) was assessed at 
specific time-points: (A) Harderian gland at 2 dpc, (B) CALT at 2 dpc, (C) Harderian gland at 
4 dpc and (D) CALT at 4 dpc.  Data points are shown as individual animals (three technical 
replicates per animal; n= 6 – 10 per group), lines represent the group mean and error bars 
represent the SEM. Statistical differences between groups were evaluated using one-way 
ANOVA with Tukey’s multiple comparisons. Significant differences are highlighted by * 




4.2.4 Vaccination with a rIBV induces the production of IBV-specific antibodies. 
 
Serum IBV-specific antibodies were assessed, using a commercial ELISA assay, 2 days pre-
challenge (21 days post primary vaccination), by Dr. Samatha Ellis at The Roslin Institute. 
Antibody titres in the vaccinated groups were compared to the mock vaccinated control 
group (Figure 4.11). Mean titres were significantly higher in all the vaccinated groups in 
comparison to the mock vaccinated group (p<0.0001), indicating that vaccination had 
resulted in the generation of anti-IBV antibodies. There were no significant differences 




Figure 4.11: Vaccination with rIBV induced the production of anti-IBV antibodies. 
Serum anti-IBV titres were assessed by commercial ELISA (BioChek). Pre-challenge serum 
samples were diluted 1:80. The mean S/P from each group (n=20 or 30) is presented and 
this includes four technical replicates per sample. The dashed line indicates the cut-off 
threshold for positive samples (S/P ratio=0.2). The error bars represent the SD. Statistical 
differences between the group antibody titre means at pre-challenge were assessed using 
Kruskal Wallis and Dunn’s multiple comparison tests. Significant differences are highlighted 
by **** (p<0.0001). This work was completed by Dr. Samantha Ellis at The Roslin Institute. 
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4.2.5 Vaccination with rIBV primed chickens for a boosted humoral response to 
challenge. 
 
Using the same methodology anti-IBV serum antibody titres were also investigated at 4 dpc, 
also by Dr. Samantha Ellis at The Roslin Institute. At dilutions 1:80 through to and including 
1:320, titres were significantly higher in all of the vaccinated groups compared to the mock 
vaccinated/QX challenge control group (Figure 4.12, p<0.05, Table 4.3). Serum dilution 
1:640 displayed the same pattern except there were no significant differences between titres 
in the group vaccinated with BeauR-M41(S)/BeauR-M41(S) and the unvaccinated/QX 
challenged control group. At all dilutions the titres in the mock vaccinated/QX challenge 
control group remained below detection level. Overall the higher titres of anti-IBV antibody 
observed, indicates that vaccination with rIBV BeauR-M41(S) and/or BeauR-4/91(S) primed 
the birds for a boosted humoral response to challenge. 
 
Further analysis highlighted significant differences observed between the vaccinated groups, 
indicating variations in the capability of the vaccine strategies to induce humoral responses. 
Serum anti-IBV titres were significantly higher in the BeauR-4/91(S)/BeauR-M41(S) 
vaccinated group compared to all the other vaccinated groups (Figure 4.12, Table 4.3, 
p<0.05). Interestingly, in comparison, when the birds were vaccinated in the reverse order, 
i.e. BeauR-M41(S)/BeauR-4/91(S), the titres were significantly lower. At all dilutions titres 
observed in the BeauR-M41(S)/BeauR-4/91(S) and the BeauR-4/91(S)/BeauR-4/91(S) group 
were similar suggesting the generation of a comparable humoral response to vaccination. At 
dilutions 1:80 through to and including 1:320, vaccination with BeauR-M41(S)/BeauR-





Figure 4.12: Vaccination with rIBV boosts the humoral response to heterologous QX 
challenge at 4pc. Serum anti-IBV titres were assessed by commercial ELISA (BioChek) at 4 
dpc. Serum samples were diluted from 1:80 to 1:2560. The mean S/P of four technical 
replicates of each bird from each group is presented. The dashed line indicates the cut-off 
threshold for positive samples (S/P ratio=0.2). The error bars represent SD. Statistical 
differences between the groups were assessed two-way ANOVA with a Tukey multiple 
comparison test.  Statistical differences are displayed Table 4.3. This work was completed 





Table 4.3: Statistical analysis of serum antibody titres at day 4 dpc. 
 
Notes: Serum anti-IBV titres were assessed by commercial ELISA (BioChek) at 4 dpc 
(Figure 4.12). Statistical differences between the groups were assessed two-way ANOVA 
with a Tukey multiple comparison test.  This work was completed by Dr. Samantha Ellis at 
The Roslin Institute. 
• Purple:  Titres in vaccinated groups are higher than the unvaccinated/QX challenged 
control group. 
• Orange: Titres observed in BeauR-4/91(S)/BeauR-M41(S) group are higher in 
comparison to all other vaccinated groups.  
• Green: There is no difference in serum antibody titres between groups vaccinated 
with BeauR-M41(S)/BeauR-4/91(S) and BeauR-4/91(S)/BeauR-4/91(S).  
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-4/91(S) *** 0.0008
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-M41(S)/BeauR-4/91(S) *** 0.0003
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-M41(S) **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. Mock/QX **** <0.0001
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-M41(S)/BeauR-4/91(S) ns 0.9987
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) ** 0.0074
BeauR-4/91(S)/BeauR-4/91(S) vs. Mock/QX **** <0.0001
BeauR-M41(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) * 0.0181
BeauR-M41(S)/BeauR-4/91(S) vs. Mock/QX **** <0.0001
BeauR-4/91(S)/BeauR-M41(S) vs. Mock/QX **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-4/91(S) ** 0.0015
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-M41(S)/BeauR-4/91(S) *** 0.0007
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-M41(S) **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. Mock/QX **** <0.0001
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-M41(S)/BeauR-4/91(S) ns 0.9997
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) *** 0.0005
BeauR-4/91(S)/BeauR-4/91(S) vs. Mock/QX **** <0.0001
BeauR-M41(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) ** 0.001
BeauR-M41(S)/BeauR-4/91(S) vs. Mock/QX **** <0.0001
BeauR-4/91(S)/BeauR-M41(S) vs. Mock/QX **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-4/91(S) * 0.0295
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-M41(S)/BeauR-4/91(S) ** 0.0042
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-M41(S) **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. Mock/QX * 0.0276
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-M41(S)/BeauR-4/91(S) ns 0.9744
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) ** 0.002
BeauR-4/91(S)/BeauR-4/91(S) vs. Mock/QX **** <0.0001
BeauR-M41(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) * 0.0162
BeauR-M41(S)/BeauR-4/91(S) vs. Mock/QX **** <0.0001
BeauR-4/91(S)/BeauR-M41(S) vs. Mock/QX **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-4/91(S) ns 0.1909
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-M41(S)/BeauR-4/91(S) ns 0.134
BeauR-M41(S)/BeauR-M41(S) vs. BeauR-4/91(S)/BeauR-M41(S) **** <0.0001
BeauR-M41(S)/BeauR-M41(S) vs. Mock/QX ns 0.4115
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-M41(S)/BeauR-4/91(S) ns 0.9998
BeauR-4/91(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) * 0.0108
BeauR-4/91(S)/BeauR-4/91(S) vs. Mock/QX ** 0.0071
BeauR-M41(S)/BeauR-4/91(S) vs. BeauR-4/91(S)/BeauR-M41(S) * 0.0182
BeauR-M41(S)/BeauR-4/91(S) vs. Mock/QX ** 0.0046
BeauR-4/91(S)/BeauR-M41(S) vs. Mock/QX **** <0.0001
1:640






Anti-IBV serum titres were assessed, also by Dr. Samantha Ellis at The Roslin Institute, at 
14 dpc, the final day of the in vivo experiment (Figure 4.13). At this point birds were 
considered to have recovered from the QX challenge infection as no clinical signs were 
observed (Figure 4.6 and 4.7). Similarly to 4 dpc, serum antibody titres were significantly 
higher in all of the vaccinated groups in comparison to the unvaccinated/QX challenged 
control group (p<0.0001). This observation provides further evidence that the vaccination 
strategies have primed the birds for a boosted humoral antibody in response. Unlike serum 
titres at 4 dpc, however, there were no significant differences between the anti-IBV titres 
observed between the vaccinated groups, indicating at this stage of infection no one 
vaccination strategy was more effective than the others. 
 
 
Figure 4.13: At 14 dpc all vaccinated groups displayed a boosted humoral response to 
challenge with QX. Serum anti-IBV titres were assessed by commercial ELISA (BioChek) at 
14 dpc. Serum samples were diluted from 1:80 to 1:2560. The mean S/P of four technical 
replicates of each bird from each group is presented. The dashed line indicates the cut-off 
threshold for positive samples (S/P ratio=0.2). The error bars represent SD. Statistical 
differences between the groups were assessed one-way ANOVA with a Friedman test and 
Dunn’s multiple comparison test.  Statistical differences in comparison to the mock 
vaccinated/QX challenge control group (Mock/Mock/QX) are highlighted by **** (p<0.0001). 
This work was completed by Dr. Samantha Ellis at The Roslin Institute. 
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4.2.6 Shared epitopes between M41-CK and QX or 4/91 may not be neutralising 
to M41-CK infection.  
 
Sequence alignment of the S glycoproteins of M41-CK, QX and 4/91 (Appendix, Figure 8.3) 
highlight shared regions of amino acid sequences and therefore the potential for shared 
epitopes, and in turn the potential for cross reactive antibodies. A series of plaque reduction 
assays was used to investigate the cross neutralising ability of specific anti-IBV sera. If sera 
raised against one strain of IBV were able to neutralise infection with a different strain of IBV, 
the sera would be considered to be cross neutralising, and therefore contain cross-reactive 
antibodies. In turn, this would indicate the presence of shared neutralising epitopes between 
the IBV strain in which the sera was raised against and the IBV strain used in the plaque 
reduction assay.   
 
The IBV QX challenge strain used in the in vivo vaccine-challenge experiment is not able to 
be propagated in vitro (Bickerton et al., 2018b) limiting the ability to assess whether 
neutralising antibody against QX is present in anti-M41, anti-4/91 and anti-QX sera. 
However, the neutralising ability of these sera against the IBV M41-CK and rIBVs BeauR-
M41(S) and Beau-R is possible to assess in vitro. To investigate this, sera harvested from 
QX (anti-QX), 4/91 (anti-4/91), M41-CK (anti-M41-CK) and mock infected chickens was 
incubated with either Beau-R, BeauR-M41(S) or M41-CK. After a defined incubation period, 
the quantity of remaining infectious particles was determined through titration in CK cells. In 
this assay, if the sera contained antibodies capable of fully neutralising viral infection, no 
infectious particles would remain therefore resulting in a 100% plaque reduction. 
 
The anti-M41-CK serum was neutralising to both M41-CK and BeauR-M41(S) with both 
viruses exhibiting comparable % plaque reduction profiles (Figure 4.14). At sera dilutions 
1:20 to 1:80 both M41-CK and BeauR-M41(S) exhibited a greater than 50% reduction in 
PFU, indicating that at these dilutions anti-M41-CK sera was able to neutralise at least 50% 
of infectious particles. A less than 25% reduction in PFU was observed with both 1:160 and 
1:320 dilutions. This would indicate that individual populations of neutralising antibody 
present in the un-diluted anti-M41-CK sera, and in the sera at dilutions 1:20 to 1:80, had 
possibly been diluted out thereby reducing the overall neutralising ability of that sera dilution. 
It is also possible that whilst no individual antibody population was missing from the sera at 
dilution 1:160 and 1:320 that populations of individual antibodies had instead been diluted to 
levels that were only partially effective, which would again reduce the overall neutralising 
ability of that sera dilution.  
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The similarity of the response of both M41-CK and BeauR-M41(S) to anti-M41-CK sera 
supports the notion that the majority of neutralising antibodies are directed against the S 
glycoprotein. If neutralising antibodies against other IBV proteins were present at detectable 
levels it would be expected that there would be a difference between the neutralisation 
profiles of M41-CK and BeauR-M41(S). Supporting this, Beau-R which contains a different S 
glycoprotein did not display a comparable neutralisation profile in response to anti-M41-CK 
sera (Figure 4.14). No plaques were observed after infection with Beau-R that had been 
incubated with 1:20, 1:40 and 1:80 dilutions of anti-M41-CK sera. At dilution 1:160 the mean 
reduction in PFU was 76% indicating that over 75% of infectious viral particles had been 
neutralised. The neutralisation observed at this dilution was greater than that exhibited for 
both M41-CK at 23% and BeauR-M41(S) at 16% (p<0.001). Interestingly, both M41-CK and 
Beau-R belong to the Massachusetts serotype and amino acid identity between the S 
glycoprotein is high at >95% (appendix). The difference in neutralisation profiles is therefore 




Figure 4.14: An Anti-M41-CK serum is able to neutralise M41-CK, BeauR-M41(S) and 
Beau-R infection in vitro. 100 PFU of M41-CK, BeauR-M41(S) or Beau-R was incubated 
with dilutions of either anti-M41-CK sera or mock sera. The quantity of infectious virus 
neutralised was assessed through titration in CK cells in triplicate. The percentage difference 
in the number of PFU/ml between the samples incubated with mock sera and those 
incubated with anti-M41-CK sera was calculated. Each point represents the mean of three 
independent replicates, with error bars representing the SEM.  Differences were evaluated 
using a 2way ANOVA with a Tukey test for multiple comparisons. Significant differences 
(p<0.005) between neutralisation of Beau-R in comparison to both M41-CK and BeauR-
M41(S) in response to anti-M41-CK sera are highlighted by ***.  
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The ability of anti-QX and anti-4/91 sera to neutralise M41-CK infection was also 
investigated. Beau-R, BeauR-M41(S) or M41-CK was incubated with decreasing quantities 
of either anti-QX, anti-4/91 or mock sera. Neutralisation was assessed through titration in CK 
cells. Decreasing quantities of sera had minimal effect on viral titre, indicating that antibodies 
present in the anti-QX and anti-4/91 serum were incapable of neutralising BeauR-M41(S), 
M41-CK or Beau-R infections at the dilutions assessed (Figure 4.15A to 4.15F). A small 
difference was observed between the response of Beau-R to anti-QX sera and to mock sera 
at dilution 1/20 (p<0.005). The titre of Beau-R at this dilution was approximately 0.5 log10 
lower after incubation with anti-QX sera in comparison to after incubation with mock sera 
(Figure 4.15F). Similarly a small difference was observed at dilution 1/320 when comparing 
M41-CK infection in response to mock and anti-4/91 sera (p<0.05) (Figure 4.15A). In this 
case viral titre was higher in those samples incubated with anti-4/91 sera than those 
incubated with mock sera so whilst statistically different the biological relevance may be 






Figure 4.15: Anti-QX and anti-4/91 sera are not able to prevent M41-CK, BeauR-M41(S) 
nor Beau-R infection in vitro. 100 PFU of M41-CK, BeauR-M41(S) or Beau-R was 
incubated with 2 fold serial dilutions of either anti-QX, anti-4/91 sera or mock sera. The 
quantity of infectious virus neutralised was assessed through titration in CK cells in triplicate. 
The titre (PFU/ml) resulting from each dilution is shown. Each point represents the mean of 
three independent replicates, with error bars representing the SEM.  Differences were 
evaluated using a Two-way ANOVA with a Tukey test for multiple comparisons. Significant 





There have been numerous studies that have addressed the question of cross protective 
immunity against IBV reporting varying degrees of success (Wang et al., 1996; Cavanagh et 
al., 1997; Cook et al., 1999; Terregino et al., 2008; Lim et al., 2012; Bru et al., 2017). It is 
thought that the chances of a successful vaccination decrease as the amino acid homology 
between the S glycoprotein of the vaccine and challenge strain also decreases (Cavanagh et 
al., 1997; Cook et al., 1999). As homology decreases, the likelihood of differences in 
important neutralising epitopes increases. It is possible, however for vaccines to offer 
successful protection against heterologous challenge when sequence homology between the 
vaccine and challenge strain is deemed low (as reviewed in de Wit et al., 2011), presumably 
due to conserved structural homology of important neutralising epitopes. It is likely therefore 
a small number of virus neutralising epitopes play a disproportionate role in cross-protection 
(Cavanagh et al., 1997). Although the location of some neutralising monoclonal antibody 
epitopes are known (Mockett et al., 1984, Mockett et al., 1988; Kant et al., 1992) it remains 
unknown which epitopes are required for the successful induction of cross-protective 
immunity. It therefore continues to be important to assess vaccine strategies against 
heterologous challenge.   
 
Several previous studies have utilised commercial vaccines produced via the traditional 
method of passaging a field isolate through embryonated hens’ eggs to produce an 
attenuated virus. As such, these commercial vaccines closely resemble the challenge 
strains, and it is therefore difficult to assess the individual contribution of each viral protein 
towards both homologous and heterologous immunity. As discussed in Chapter 3 the S 
glycoprotein or the S1 subunit has been expressed in a number of viral or bacterial vectors 
(Song et al., 1998; Johnson et al., 2003; Hodgson et al., 2004; Chen et al., 2010; Armesto et 
al., 2011; Yan et al., 2013; Zhoa et al., 2017; Ellis et al., 2018; Shirvani et al., 2018) however 
there is no consensus in the field of the markers of protection and therefore it is difficult to 
compare levels of protection achieved against either homologous or heterologous challenge. 
It is also unclear how the expressed protein is presented, whether it assembles into trimers, 
whether it is anchored to a membrane thereby aiding conformation or whether the S1 is only 
expressed as a monomeric unit. The recombinant viruses used in this chapter and also used 
by Hodgson et al., (2004), Armesto et al., (2011) and Ellis et al., (2018) express 
heterologous S glycoproteins from a rIBV vector. As such the S glycoproteins are expected 
to be trimeric and anchored into a viral membrane. Host processing of the S glycoprotein, 
such as glycosylation and palmitoylation, should also occur as in a natural WT IBV infection. 
The presentation of the expressed S glycoprotein to the host immune system should also be 
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comparable to WT infection. Alongside these benefits, vaccination with rIBV BeauR-M41(S) 
and BeauR-4/91(S) allowed for characterisation of the role of the 4/91 and M41-CK S 
glycoproteins in the induction of a protective immune response against a heterologous QX 
challenge as all other proteins in the vaccine viruses are Beaudette derived. Amino acid 
sequence identity of M, E and N between QX and Beau-R is 92%, 88% and 90% 
respectively (Appendix 8.4, 8.5, 8.6). In previous studies that have investigated vaccination 
with both Massachusetts and 4/91 serotypes against a QX challenge it is difficult to be as 
certain whether the protective response induced is solely the result of the presence of the S 
glycoprotein of either the Massachusetts strain or 4/91 strain (Terrenigo et al., 2008; Awad et 
al., 2016, de Wit et al., 2011B).  
 
Vaccination with BeauR-M41(S) or with BeauR-4/91(S) in any combination did not induce a 
fully protective immune response, as defined by the European Pharamacopeia (2010), 
against the QX challenge, as ciliary activity in all vaccinated groups was largely reduced to 
less than 25% by the QX infection (Figure 4.8). Two birds that were vaccinated with BeauR-
4/91(S)/BeauR-491(S) were observed to retain more ciliary activity, however, only one 
sample would be deemed as protected by the European Pharamacopeia (2010) standards. 
To determine whether this vaccination combination offers protection to 10% of birds or 
whether this bird was an anomaly would require a much larger sample size. However, 
despite the overall reductions in ciliary activities observed, there are indications that each of 
the vaccination strategies induced an immune response that resulted in positive differences 
post challenge. All vaccinated groups appeared to recover more rapidly from clinical signs 
than the mock vaccinated/QX challenged control group (Figure 4.6 and 4.7). In groups which 
received the same primary and secondary vaccination, BeauR-M41(S)/BeauR-M41(S) or 
BeauR-4/91(S)/BeauR-4/91(S), less infectious challenge virus was present in the tracheas of 
the vaccinated birds at 4 dpc than in the mock vaccinated/QX challenged control group 
(Figure 4.9). Also in comparison to the mock vaccinated/QX challenge control group, lower 
viral RNA loads were detected in the CALT at 4 dpc (Figure 4.10) in birds vaccinated with 
different primary and secondary vaccinations, BeauR-M41 (S)/BeauR-4/91(S) or BeauR-
4/91(S)/BeauR-M41(S). In addition all vaccinated groups at 4 dpc had higher titres of serum 
anti-IBV antibody than the mock vaccinated/mock challenged control group (Figure 4.12). 
 
Previous research has suggested that the order in which live attenuated IBV vaccines are 
administered affects the outcome of heterologous challenge. Cook et al., (1999) concluded 
that better cross protection was seen when a Ma5 (Massachusetts serotype) vaccine was 
administered before a 4/91 vaccine. It must be noted that both Beau-R and M41-CK are of 
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the Massachusetts serotype. Bourogaa et al., (2014), Awad et al., (2016) and Bru et al., 
(2017) have all demonstrated a degree of cross protection using a Massachusetts vaccine 
followed by a secondary vaccine of a different serotype. These studies, however, did not 
directly compare the reverse order. In this study at 4 dpc whilst in terms of ciliary activity 
there was no difference between those birds vaccinated with BeauR-M41(S)/BeauR-4/91(S) 
and BeauR-4/91(S)/BeauR-M41(S), the order in which the BeauR-M41(S) (Massachusetts 
serotype) and BeauR-4/91(S) (4/91 serotype) were administered did appear to have affected 
serum antibody levels. Serum antibody titres were significantly higher in the group 
vaccinated with BeauR-4/91(S)/BeauR-M41(S) suggesting in this study, in terms of 
seropositivity, a 4/91 vaccine followed by an Massachusetts vaccine gave a better result. 
One possible explanation for this observation is that vaccination with BeauR-M41(S) may 
have induced an immune response that was partially neutralising toward BeauR-4/91(S).This 
in turn may have limited the replication of BeauR-4/91(S) and consequently impacted on the 
effectiveness of the second vaccination. Conversely BeauR-4/91(S) may not elicit a cross 
neutralising response toward BeauR-M41(S). Further work therefore could involve 
neutralisation assays investigating the response of BeauR-M41(S) and BeauR-4/91(S) to 
anti-BeauR-M41(S) and BeauR-4/91(S) sera.    
 
Despite the indication that the vaccination strategies employed in this study have induced an 
immune response, ultimately the vaccines did not offer full protection against a QX 
challenge. This was unexpected as it contradicts previous work that has demonstrated that 
commercially available Massachusetts and 4/91 vaccines could offer protection against a QX 
challenge (Terregino et al., 2008, de Wit et al., 2011B, Awad et al., 2016,). Awad et al., 
(2016) investigated combinations of Ma5 (Massachusetts serotype) or H120, also of the 
Massachusetts serotype alongside 793B vaccines (4/91 serotype) against heterologous QX 
challenge; ciliary activity was reported at 68 and 92% respectively. Similarly de Wit et al., 
(2011B) used a combination of Massachusetts vaccines or a mixture of Massachusetts 
combined with a D274 serotype, followed by a 793B vaccine reporting protection, as defined 
by ciliary activities, of 51% and 89% respectively. Terregino et al., (2008) also evaluated 
vaccination with Ma5 and 4/91, against a QX challenge. Unlike this study in which challenge 
virus could be detected in the tracheas from all vaccinated/challenged chickens, Terregino et 
al., (2008) detected no challenge virus in those SPF chickens that received vaccination. It is 
difficult to directly compare vaccine-challenge experiments due to differences in age of bird, 
breed, the SPF status of the birds, and the definition of protection, whether that be ciliary 
activity, viral load or seropositivity (reviewed by de Wit and Cook, 2014). Terregino et al., 
(2008) did not assess ciliary activity and it is well documented that viral load and ciliary 
activity do not always correlate (Hodgson et al., 2004; Armesto et al., 2011; reviwed by de 
Wit and Cook, 2014; Ellis et al., 2018). Similarly seropositivity and protection do not always 
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correlate (reviwed by de Wit and Cook, 2014). Whilst de Wit et al., (2011B) did assess ciliary 
activity, the sampling points were 5, 8 and 11 dpc, and therefore not exactly comparable to 
the sampling point used in this study, 4 dpc. In addition, no clinical signs data was reported, 
and the age of the chickens, at both vaccination and challenge were also not comparable. It 
is also worth noting that both Terregino et al., (2008) and Awad et al., (2016) vaccinated 
birds that contained maternally derived antibody although this is thought to have a negative 
impact on vaccination (Klieve and Cumming, 1988). The inability of BeauR-M41(S) and 
BeauR-4/91(S) to induce a protective immune response against heterologous virus 
challenge, in terms of both ciliary activity and clinical disease (Figure 4.6 – 4.8) as well as 
challenge virus replication (Figure 4.9 – 4.10) is a notably different result to that published by 
Terregino et al., (2008), de Wit et al., (2011B) and Awad et al., (2016). This raises some 
interesting questions, and may suggest that the S glycoprotein from either M41-CK and/or 
4/91 alone may not be sufficient to elicit a protective immune response against a 
heterologous QX challenge.   
 
Protective immunity against IBV is thought to largely involve the presence of antibodies 
capable of neutralising viral infection, and it has been demonstrated that the majority of 
these antibodies are directed against the S glycoprotein (Cavanagh et al., 1986, Cavanagh 
and Davis, 1986;   Ignjatovic and Galli, 1994). The comparative response of BeauR-M41(S) 
and M41-CK to anti-M41-CK sera supports this (Figure 4.14). The vaccine viruses used 
within this study did elicit an anti-IBV antibody response, with a boosted (memory) humoral 
response identified in response to the QX challenge in all vaccinated groups at 4 dpc (Figure 
4.12). It remains to be determined whether the antibody response induced by BeauR-M41(S) 
and BeauR-4/91(S) elicited antibodies capable of neutralising the QX challenge virus. The 
restricted tropism of the QX strain used in this study (Bickerton et al., 2018B) makes this 
question difficult to comprehensively answer. In vitro plaque reduction assays however 
identified that anti-QX and anti-4/91 sera could not fully neutralise M41-CK, BeauR-M41(S) 
nor Beau-R infection at dilutions 1:20 through to 1:320 (Figure 4.15). These assays, 
however, cannot definitely conclude that potential shared epitopes are not neutralising as it 
is possible that antibody directed against these epitopes has been diluted to a point where 
the effect is minimal. The small but significant difference between Beau-R infection after 
incubation with 1:20 mock sera and 1:20 anti-QX sera may support this. In a previous study, 
two-way cross neutralisation assays including a comparison between M41 and D388 as well 
as M41 and 4/91 have identified very low titres of neutralising antibody (de Wit et al., 2011B). 
It is, unfortunately, not possible to assess less diluted sera largely due to limited quantity of 
sera paired with the relatively sizable quantities needed for plaque reduction based 
neutralisation assays.  
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Whether anti-M41-CK or anti-4/91 sera can neutralise QX infection in vitro remains an 
unanswered question. There are two possible alternatives to QX for the in vitro assessment 
of neutralising antibody presence in sera harvested as part of this in vivo vaccine-challenge 
experiment. One possible alternative is to utilise rIBV BeauR-QX(S1) as the majority of 
neutralising antibodies are thought to be directed against the S1 subunit (Mockett et al., 
1984; Cavanagh et al., 1986, Cavanagh and Davis, 1986). This rIBV expresses the QX S1 
subunit and the Beau-R S2 subunit which enables the virus to replicate in Vero cells 
(Bickerton et al., 2018B). Vero cells would offer a number of advantages for use in 
neutralisation assays over the current protocol that uses primary CK cells, including a less 
limited supply and the ability to reliably seed in 96 well plates producing a clear monolayer. 
This would allow neutralisation to be defined by presence or absence of IBV induced CPE, 
rather than the more labour intensive and time consuming method of titration in CK cells to 
determine the PFU. BeauR-QX(S1) was however used as a vaccine virus in Chapter 3 and 
was unable to induce a protective immune response to a homologous QX challenge with 
possible misfolding of the chimeric S glycoprotein hypothesised as a potential reason.  
Further research is required to investigate this possibility which this could include 
neutralisation assays using monoclonal antibodies targeted toward the S1 and S2 subunits.  
 
The second possible alternative to QX is the IBV strain D388 which was isolated in The 
Netherlands in 2004, and is deemed QX like. Sequencing results have reported that it is of 
the QX genotype with 98% sequence homology in the S1 subunit (de Wit et al., 2011b; 
YuDong et al., 1998; Liu and Kong, 2004). Virus neutralisation assays have yet to directly 
compare the original Chinese QX isolate to D388, and therefore as a result D388 cannot be 
defined as a QX serotype, and instead is referred to as D388 (QX) serotype. In house 
sequencing data identifies that D388 only has two amino acid differences in the S 
glycoprotein to the QX strain used in this study (unpublished data). In addition, across the 
whole genome there are only a further 41 nucleotide differences. This sequence similarity 
alongside the ability of D388 to replicate in CK cells (Chapter 5, Figure 5.8) identifies D388 
as a possible suitable alternative to QX in the assessment of neutralising antibody generated 
through the vaccination strategies employed in this study. However, further research is 
required to demonstrate whether the sera raised against QX has the ability to neutralise 
D388 in vitro comparably to sera raised against D388. 
 
Despite the limitations, the plaque reduction assays presented in this study alongside the 
inability of the vaccine viruses BeauR-M41(S) and BeauR-4/91(S) to elicit a protective 
immune response against a heterologous IBV could suggest that potential shared epitopes 
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on the S glycoprotein when expressed by a Beaudette vaccine vector do not generate cross 
protective antibodies, or do not do so in a quantity that positively affects the outcome after 
challenge. As stated, both Awad et al., (2016) and Terregino et al., (2008) did report a 
protective immune response using 4/91 serotype vaccines and Massachusetts vaccines, 
indicating the presence of shared neutralising epitopes. In both studies, however, the 
presence of neutralising antibody was not directly assessed. Amino acid sequence identity 
between the S glycoproteins of 4/91 and QX is 83.5% with M41-CK and QX sharing a similar 
percentage at 81.8%. The difference of 20% may therefore have removed neutralising 
epitopes. Further work utilising D388 as an alternative to QX in neutralisation assays is 
required to establish whether the vaccination with BeauR-M41(S) and/or BeauR-4/91(S) did 
elicit the generation of neutralising antibodies against QX. The results of these assays would 
therefore help to inform whether the 20% difference in sequence has in fact removed cross 
protective neutralising epitopes.  
 
One important factor to note is that, there are many different strains within a serotype all with 
sequence differences across the genome, including within the S gene (Adzhar et al., 1995; 
Adhzar and Gough, 1997; Cavanagh et al., 1992; Cavanagh et al., 2005). Using the 
Massachusetts serotype as an example, the S glycoprotein of Ma5, used by both Terregino 
et al., (2008) and Awad et al., (2016) has a 4% difference in amino acid sequence identity to 
M41-CK (Appendix, Figure 8.3). Similarly the sequence difference between the H120 and 
M41-CK S glycoproteins is also 4% as is the difference between Beau-CK and H120. There 
is an approximate 4% sequence difference between the 793B vaccine, also known as CR88 
(4/91 serotype) and the S glycoprotein of 4/91. Plaque reduction assays in this chapter 
assessing the neutralisation profile of Beau-R and M41-CK in response to anti-M41-CK sera, 
have demonstrated that even small differences between S glycoproteins, approximately 4%, 
can have quite a noticeable effect on neutralisation.  
 
The same logic also applies to the challenge virus; this study used an isolate of QX derived 
from The Netherlands in 2004 (Worthington et al., 2008) whereas Terregino et al., (2008) 
used an isolate of QX derived from Italy in 2005. Although both isolates are classified as QX-
like, the sequence diversity between these two isolates is unknown and may, alongside the 
differences of the S glycoproteins of the vaccine strains discussed above, may have 
contributed to the differences observed in the level of cross-protection between the studies. 
In addition, de Wit et al., (2011B) used D388 and not QX; as discussed in the results section 
there are differences across the genome. In addition, passaging, even one passage to 
produce a stock virus from a master seed vial, in cells or embryonated hen’s eggs, is enough 
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to result in consensus level changes (Cavanagh et al., 2005). One final thought to consider 
regarding sequence differences is that both BeauR-M41(S) and BeauR-4/91(S) are clonal 
therefore decreasing the variety of epitopes that exist on a sub consensus level; it is possible 
that sequence diversity has a role in successful vaccination. Questions therefore remain as 
to whether neutralising epitopes to QX do exist within BeauR-4/91(S) and BeauR-M41(S), 
and if they do, why these vaccine viruses did not elicit a stronger humoral response.   
 
One interesting question that has arisen from this study is regarding the role of the other 
structural proteins in vaccine acquired immunity. As well as humoral responses, innate and 
cell mediated responses have been demonstrated to play a vital role in the clearance of IBV 
infection as well as in vaccine induced protection (Seo and Collisson 1997; Vervelde et al., 
2013; Collisson et al., 2000; Gurjar et al., 2013). Meir et al., (2012) investigated vaccination 
with recombinant N (rN) protein and S1 (rS1) expressed in E.coli. 40% of birds vaccinated 
with rS1 were negative for IBV post challenge compared to 10% vaccinated with rN. 
Interestingly an increased cell mediated response was seen in those birds vaccinated with 
rN than rS1. Several other studies have linked the N protein to cell mediated immunity (Seo 
et al., 1997B; Boots et al., 1991; Ignjatovic and Sapats, 2005) as well as identifying B cell 
epitopes (Ignjatovic and Sapats, 2005). In addition, partial protection has been demonstrated 
using adoptive transfer of memory CD8+ T cells (Pei et al., 2003). Analysis of the N protein 
identifies variation in sequence identity across IBV strains; Beau-R and QX share a 90% 
amino acid identity, QX and Ma5 share 92%, QX and CR88 (4/91 serotype vaccine) share 
91% (Appendix, Figure 8.6). Although it has been demonstrated that the coronavirus M or N 
proteins alone cannot induce a protective immune response (Ignjatovic and Galli, 1994; 
Buchholz et al., 2004; Meir et al., 2012), it does not mean that neither protein has a role.  
Buchholz et al., (2004) investigated the contributions of the structural proteins of SARS-CoV, 
through expression in a parainfluenza vector (Buchholz et al., 2004). Vaccination with a 
vector expressing S, M and E resulted in a 2000 fold reduction of challenge virus, whilst S 
alone resulted in a 500 fold decrease. It is possible that the inclusion of M and E led to the 
formation of virus like particles and broader stimulation of the immune system. It is therefore 
plausible that immune responses to other structural proteins play a role in the induction of 
protective IBV immune responses, and without these responses neutralising antibodies 
induced by the S glycoprotein are either insufficient alone or not generated in sufficient 
quantities to offer a fully protective immune response against either homologous or 
heterologous challenge. Ultimately, it is also possible that as homology between S 
glycoproteins of vaccine and challenge viruses decreases, the collaborative role of shared 
epitopes within the other structural proteins may play a larger role in protective immunity.  
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Another question that this study raises, the same question raised in Chapter 3, is what level 
of vaccine virus in vivo replication is required to induce a protective immune response? As 
discussed in Chapter 3, the rIBV Beau-R is a molecular clone of the apathogenic Beaudette-
CK strain (Casais et al., 2001). Chapter 3 investigated the ability of Beau-R expressing 
heterologous S1 and/or S2 subunits to induce protective immune responses against 
homologous challenge (Ellis et al., 2018). Whilst rIBV BeauR-M41(S) induced protective 
immunity, as also reported by Hodgson et al., (2004), the response was not as robust as 
expected, with vaccine viruses inducing poor levels of local immunity within the trachea. In 
addition, ciliary activity post challenge at 65%, fell short of the European Pharmacopeia 
standard for vaccines, a finding comparable to both Hodgson et al., (2004), and Armesto et 
al., (2011) who investigated homologous and heterologous challenge using BeauR-4/91(S). 
As discussed in Chapter 3, one possible explanation for this is the limited in vivo replication 
of the Beau-R based vaccine viruses. In this study, as in previous studies (Hodgson et al., 
2004; Armesto et al., 2011; Ellis et al., 2018) neither rIBV BeauR-M41(S) nor BeauR-4/91(S) 
could be detected in the trachea post vaccination. The inability of Beau-R and subsequently 
the Beau-R based vaccine viruses to replicate in vivo is therefore important to investigate, 
and will be discussed further in Chapter 5. 
 
In conclusion, this chapter has raised a number of interesting questions that will be important 
to answer to enable the design of the next generation of rationally attenuated vaccines. It is 
important to establish whether a less attenuated IBV vaccine backbone with improved 
replication in vivo, could potentially induce a more robust humoral response that includes the 
generation of long lasting neutralising antibodies. If this is achieved, it will be interesting to 
investigate whether the S glycoprotein from M41 and/or 4/91 could induce a more robust 
immune response to a heterologous QX challenge or whether the effects of improved in vivo 
replication would only be of benefit in response to homologous challenge. Alternatively, it is 
possible that improved in vivo replication will have minimal effect and that the inclusions of 
other IBV structural proteins resulting in the vaccine virus having a closer resemblance to the 
challenge virus, is required. Further work is required to investigate this. Of course, it is 
entirely possible that a mixture of improved in vivo replication as well as additional viral 
proteins derived from the challenge virus is ultimately required to optimise the protective 




Chapter 5: Replication of the recombinant Infectious Bronchitis 




As discussed in Chapter 1, there is a large variety of IBV strains that all inflict varying 
degrees of disease severity in vivo. Infection of chickens with M41, a Massachusetts 
serotype results in classical IB symptoms including snicking, rales, watery eyes, nasal 
discharge, lethargy, and reduced weight gain. Viral replication is largely confined to the 
respiratory tract. Nephropathogenic strains, such as QX, are able to disseminate further and 
infect the enteric tract, oviducts and kidneys, often resulting in severe disease under field 
conditions (Cook et al., 2001; Liu and Kong, 2004, Bayry et al., 2005; de Wit et al., 2011B). 
In contrast several strains, including vaccines such as H120 and the laboratory strain 
Beaudette, are considered apathogenic and infection of chickens does not result in IB 
(Bijlenga et al., 2004). The Beaudette strain, first isolated in the 1937 (Beaudette and 
Hudson, 1937), has, in particular, been an enigma for several decades with the site of in vivo 
viral replication undetermined.  
 
As discussed in the previous chapters, the advent of reverse genetics systems has opened 
the possibility for the development of rationally attenuated IBV that have the potential to be 
used as vaccines. In the two previous chapters the rIBV Beau-R, a molecular clone of the 
Beaudette strain, Beau-CK, has been investigated as a vaccine backbone. It has been 
demonstrated, under experimental conditions, that Beau-R expressing an S gene from a 
pathogenic isolate, can induce a protective immune response against the wild type IBV strain 
of which the “donor” S sequence was derived (Hodgson et al., 2004, Armesto et al., 2011, 
Ellis et al., 2018). However, the protection level induced, around 65%, does not meet the 
European Pharmacopeia standard of 80%, and questions have been raised regarding the 
replication of these Beaudette-based vaccine viruses in vivo, and whether this accounts for 
the unexpectedly low protection rate.   
 
In this chapter the in vivo dissemination pattern of the rIBV Beau-R in comparison to the 
pathogenic strain M41-CK is evaluated. The in vivo study confirms previous reports that 
infection with Beau-R does not result in clinical signs, and that replication in vivo is highly 
restricted. In vitro studies identify that whilst Beau-R can replicate at 37°C, replication is 
temperature sensitive and cannot be maintained at 41°C, the core body temperature of a 
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chicken. Further experiments utilising a panel of rIBVs, identified the replicase gene as a 
potential defining factor in the restriction of replication at non-permissive temperatures. The 
inability of rIBV Beau-R to replicate at 41°C likely has a contributory role in the attenuated 
phenotype observed in vivo, and has implications for the use of Beau-R as a backbone for 




5.2.1 The replication of rIBV Beau-R is restricted in vivo.  
 
To establish the sites of viral replication and therefore the areas to which Beau-R based 
vaccines could deliver antigen, groups of seven-day old SPF RIR chickens were inoculated 
with either M41-CK, Beau-R or mock infected with PBS (Figure 5.1, Table 5.1). Samples 
from randomly chosen birds were harvested 1, 4, 6 and 7 days post infection (dpi), and 
assessed for viral presence. Birds were observed for IB related clinical signs, including 
snicking and rales 1 to 7 dpi, and ciliary activity was observed in extracted tracheal sections 
4 and 6 dpi. 
 
Figure 5.1: Schematic of experimental protocol: pathogenicity experiment Beau-R and 
M41-CK. Groups of seven-day old SPF RIR chickens were inoculated with Beau-R, M41-CK 
or PBS. The birds were assessed daily for the presence of clinical signs. At defined intervals 
randomly chosen birds were culled from each group and a variety of tissues harvested. 
Tracheal ciliary activity was assessed on 4 and 6 dpi.  The experiment ended on 7 dpi with 
all remaining birds culled.  
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Table 5.1: Details of groups, sample days and numbers during the in vivo study 
assessing the dissemination pattern of rIBV Beau-R. 
 
Notes: *Two birds in group B were culled due to poor health unrelated to IBV resulting in a 
lower number of birds sampled 7 dpi.  
 
IB related clinical signs including snicking and rales (Figure 5.2) were assessed from one to 
seven days post infection (dpi). Birds infected with Beau-R exhibited rates of snicking 
comparable to mock infected birds, both peaking on 7 dpi at 0.25 and 0.17 snicks per bird 
per min, respectively (Figure 5.2A). In contrast, on 7 dpi, M41-CK infected birds exhibited a 
snicking rate of 1.67 snicks per bird per min, and a maximal rate of 3.21 snicks per bird per 
min at 5 dpi. Rales were not observed in Beau-R or mock infected birds, but were observed 
in 94 and 100% of birds infected with M41-CK on 4 and 6 dpi, respectively (Figure 5.2B). 
 
Figure 5.1 Beau-R infected chickens display clinical signs comparable to mock 
infected chickens. SPF chickens were inoculated at 7 days of age with 104 PFU of either 
Beau-R, M41-CK or PBS for mock infection. (A) Snicking was assessed from 1 to 7 dpi, with 
the number of snicks in a 2 min time period counted independently by 2 or 3 persons. The 
average of these scores are presented. (B) Chickens were assessed individually for the 




Tracheas were harvested from six randomly selected birds per group on 4 and 6 dpi and the 
ciliary activities were assessed (Figure 5.3). Mean ciliary activities were comparable between 
mock and Beau-R infected birds, 99% and 95%, respectively, at 4 dpi and of 95% and 96% 
at 6 dpi. In contrast, M41-CK infected birds exhibited lower scores of 1% and 0.4% at the 
same time points, respectively (p<0.0001). All birds within a group exhibited similar ciliary 
activity scores, with no outliers detected. Tracheal ciliary activity is used as a marker to 
determine whether a pathogenic isolate of IBV is present, with a ciliary activity score of less 
than 50% being deemed positive (European Pharmacopoeia, 2010; Cavanagh et al., 1997). 
All birds infected with Beau-R retained over 85% ciliary activity, which alongside the absence 
of clinical signs (Figure 5.2) confirms previous reports that Beau-R has an attenuated 
phenotype in vivo (Hodgson et al., 2004, Armesto et al., 2011, Keep et al., 2018). Birds 
infected with M41-CK exhibited less than 50% ciliary activity, and also presented IB related 
clinical signs (Figure 5.2), confirming previous reports that M41-CK exhibits a pathogenic 
phenotype in vivo (Hodgson et al., 2004, Armesto et al., 2011, Keep et al., 2018). 
 
 
Figure 5.3: Tracheal ciliary activities in Beau-R infected birds were comparable to 
mock infected birds. SPF chickens were inoculated at 7 days of age with 104 PFU of either 
Beau-R, M41-CK or PBS for mock infection. Tracheas were removed from six randomly 
chosen birds per group at 4 and 6 dpi. Each trachea was sectioned in 10 x 1mm rings and 
the ciliary activities of each ring was assessed by light microscopy and the percentage 
activity calculated. Plotted points represent individual animals and the mean activity of the 10 
rings assessed. Error bars represent SD. Statistical differences between groups were 
evaluated using a One-Way ANOVA followed by Tukey test for multiple comparisons, and 
are represented ****(p<0.0001). There was no significant difference between the ciliary 
activities observed in mock and Beau-R infected birds on neither 4 nor 6 dpi. 
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5.2.2 Beau-R can be re-isolated from nasal turbinates.  
 
To establish the sites of viral replication, a panel of tissues were harvested from six randomly 
selected chickens per group at 1, 4, 6 and 7 dpi. To establish whether the tissue contained 
IBV, each tissue was homogenised producing a tissue derived supernatant which was 
subsequently used to infect 9 or 10 day old embryonated hens’ eggs. RNA was extracted 
from allantoic fluid and investigated by RT-PCR analysis using a random primer for the RT 
step and primers, BG56 and 93/100, specific for the IBV 3′UTR, for the PCR step. The 
genome of M41-CK contains a deletion in the 3′UTR (Casais et al., 2003), allowing for 
differentiation of Beau-R derived PCR products (~650 bp) from M41-CK (~450 bp). 
Identification of IBV derived RNA in allantoic fluid indicates the presence of infectious virus in 
the tissue derived supernatant and therefore in the harvested tissue. Tissues harvested from 
mock infected birds were included in the experiment as negative controls.  
 
Both infectious Beau-R and M41-CK were detected at 1 dpi, with both viruses re-isolated 
from nasal turbinates harvested from all sampled birds (Table 5.2). However, infectious 
Beau-R was not detected in tracheal tissue or in eyelids. In contrast, eyelids and tracheas 
from the M41-CK infected birds were virus positive; in four and six birds, respectively. Beau-
R was sporadically detected in nasal turbinates, trachea and eyelid from 4 to 7 dpi. 
Interestingly, there was no consistency; one bird 6 dpi was positive for virus in the trachea 
but negative in eyelid and nasal turbinates and on 7 dpi two birds were positive in nasal 
turbinates and a third in the eyelid. In contrast to Beau-R, M41-CK was consistently detected 
in all sampled birds from 4 to 7 dpi, with all birds on 4 and 6 dpi positive for infectious virus in 
the eyelids. Additionally, nasal turbinates harvested from all M41-CK infected birds at 4 dpi 
were positive and five birds were positive in the trachea 4 and 6 dpi. No infectious virus was 
re-isolated from tissues extracted from mock infected birds. The virus isolation data suggests 
that productive replication of Beau-R, unlike M41-CK is largely restricted to early infection in 





Table 5.2: Virus re-isolation from tissues harvested from mock, Beau-R and M41-CK 
infected birds. 
 
Notes: Tissue derived supernatant was used to infect 9 or 10 day old embryonated hen’s 
eggs. RNA was extracted from allantoic fluid and investigated by RT-PCR analysis using a 
random primer for the RT step and primers, BG56 and 93/100, specific for the IBV 3′UTR, for 
the PCR step. * Samples from trachea of one bird, and nasal turbinates from two birds were 
damaged and therefore were unable to be included in the experiment, resulting in a group of 
four or five samples assessed instead of six.  
 
5.2.3 Replication of rIBV Beau-R in vitro is sensitive to temperature.  
 
The finding of Beau-R in tissue harvested from nasal turbinates raised an interesting 
question regarding the potential for temperature to affect virus dissemination. The 
continuous movement of air in the upper respiratory tract will inevitably cool this area of the 
bird, and it has been demonstrated for several respiratory viruses including Influenza virus, 
Rhinoviruses and Respiratory Syncytial Virus (RSV) that replication can be confined to the 
upper respiratory tract as a consequence of viral replication being sensitive to the 
comparatively higher temperatures in the lower respiratory tract (Alford et al., 1966; 
Maassah, 1967; Maassah,  1968; Juhasz et al., 1999; Hatta et al., 2007; Da Costal et al., 
2015; Foxman et al., 2014). A growth kinetic experiment was therefore used to assess 
whether the replication of Beau-R was detrimentally affected by higher temperatures, 
specifically at 41°C, the core body temperature of a chicken. CK cells were infected with 
either Beau-R or M41-CK and incubated at either 41°C or 37°C, with supernatant harvested 
Group Dpi Nasal Turbinates Eyelid Trachea
Mock 0/6 0/6 0/6
Beau-R 6/6 0/6 0/6
M41-CK 6/6 4/6 6/6
Mock 0/6 0/6 0/6
Beau-R 2/6 0/6 0/6
M41-CK 6/6 6/6 5/6
Mock 0/6 0/6 0/6
Beau-R 0/6 0/6 1/6
M41-CK 0/6 6/6 5/6
Mock 0/6 0/6 0/6
Beau-R 2/4 1/4 0/4







at regular intervals. The quantity (titre) of viable infectious viral progeny in this harvested 
supernatant was assessed through titration in CK cells (Figure 5.4).  
 
At all the time points assessed, except 1 hpi, the PFU/ml of Beau-R generated at 41°C was 
lower (p<0.0001) than at 37°C (Figure 5.4B), with very little viable infectious progeny virus 
detected at the higher temperature. In contrast, the PFU/ml of M41-CK was similar at both 
temperatures at 1, 12 and 24 hpi, after which at 48, 72 and 96 hpi, the titre was lower 
(p<0.0001) at 41°C (Figure 5.4C). Although both viruses exhibited reduced titres at 41°C, the 
difference between Beau-R and M41-CK is considerable (Figure 5.4D). At 41°C Beau-R 
generated significantly lower titres in comparison to M41-CK at all the time points except 1 
hpi (p<0.0001). This is notably a different pattern to 37°C in which Beau-R generates higher 
titres of infectious progeny virus than M41-CK at 12 and 24 hpi (p<0.005). From 48 h titres of 
Beau-R are lower than M41-CK, with the difference at 72 and 96 h reaching statistical 
significance (p<0.005).   
 
The reduction in PFU/ml observed during Beau-R infection at 41°C in comparison to 37°C 
identifies that Beau-R replication is sensitive to increased temperature, and specifically is 
detrimentally affected. The replication of M41-CK also seems to be negatively affected by 
the increased temperature, but only at later time points. Whilst titres of infectious progeny 
virus are statistically lower at 41°C, the replication of M41-CK is still sustained generating 
titres of approximately 104 PFU/ml. The results of this growth kinetics assay therefore 
indicate that unlike M41-CK, Beau-R is unable to establish a productive infection in vitro at 
41°C, demonstrating that this temperature can be classified as non-permissive and that 






Figure 5.4: Assessment of M41-CK and Beau-R replication at 37°C and 41°C. CK cells 
seeded in 6 well plates were inoculated with 104 PFU of M41-CK or Beau-R, and incubated 
at either 37°C or 41°C. Supernatant was harvested at 24 h intervals and the quantity of 
infectious progeny was determined via titration in triplicate in CK cells. Each point represents 
the mean of three independent experiments with error bars representing SEM. Graph (A) 
represents all data gathered during the experiment, graph (B) displays the data generated 
from Beau-R infection, graph (C) the data generated from M41-CK infection, and graph (D) 
and (E) the data generated through incubation at 41°C and 37°C respectively. Statistical 
differences were assessed using a two-way ANOVA stating time and temperature as 
independent factors, followed by a Tukey test for multiple comparisons. Statistical 




To confirm that the temperature sensitive in vitro replication phenotype of Beau-R was not 
specific to CK cells, the growth of both Beau-R and M41-CK in DF1 cells, a continuous cell 
line derived from chicken embryo fibroblasts, was assessed. DF1 cells were infected with 
either Beau-R or M41-CK, and incubated at either 37°C or 41°C. The supernatant was 
harvested at 24h intervals, and the quantity of infectious progeny virus was assessed 
through titration in CK cells (Figure 5.5). A BSc placement student, Jamie Stuart, carried out 
this experiment under my supervision and direction.  
 
The titres of M41-CK produced at 37°C and 41°C were below 10 PFU/ml indicating that 
extremely little infectious progeny, if any, had been produced. This strongly indicated that 
M41-CK was unable to establish a productive infection in DF1 cells at either temperature 
(Figure 5.4A), which was not unexpected as the M41-CK S glycoprotein restricts cell tropism 
(Casais et al., 2003). Whilst it may seem counterintuitive, M41-CK was included in the 
experiment in case the higher temperature affected S mediated entry resulting in M41-CK 
being able to establish an infection in cells previously non-permissive. 
 
Similarly, to M41-CK, the titres of Beau-R at 41°C were also below 10 PFU/ml suggesting 
that Beau-R was also unable to establish a productive infection. However, titres of Beau-R at 
37°C reached approximately 105 PFU/ml at 24 through to 72 hpi only decreasing to 104 
PFU/ml at 96 hpi. The difference between the PFU/ml generated at 41°C and 37°C was 
significant at all time points assessed (p<0.0001). The significantly lower titres of progeny 
virus produced from Beau-R infected DF1 cells at 41°C in comparison to 37°C demonstrates 
that the temperature sensitive replication phenotype is not restricted to CK cells, and may be 






Figure 5.5: Beau-R replication is highly restricted at 41°C in DF1 cells in comparison 
to 37°C. DF1 cells seeded in six well plates were inoculated with 105 PFU of M41-CK or 
Beau-R, and incubated at either 37°C or 41°C. Supernatant was harvested at 24 h intervals 
and the quantity of infectious progeny was determined via titration in triplicate in CK cells. 
Each point represents the mean of three independent experiments with error bars 
representing SEM. Statistical differences at each time point were assessed using a two-way 
ANOVA followed by a Tukey test for multiple comparisons. Statistical differences at each 
time point between Beau-R at 37°C and Beau-R at 41°C as well as between Beau-R at 37°C 
and M41-CK at 37°C as well as at 41°C are highlighted by **** (p<0.0001). There were no 
statistical differences between M41-CK infection at 37°C and 41°C nor between M41-CK 
infection at either 37°C and 41°C with Beau-R infection at 41°C at any of the time points 
assessed. The experimental data was generated by Jamie Stuart under my supervision and I 
analysed the data.  
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5.2.4 Temperature sensitivity is not a shared characteristic of attenuated strains.  
 
It was an interesting observation that the replication of the apathogenic rIBV Beau-R was 
limited at 41°C yet the pathogenic strain M41-CK could establish a sustained productive 
infection. To establish whether temperature sensitivity was a shared characteristic of 
attenuated strains the vaccine virus H120 was investigated. Alongside H120, the replication 
phenotype of serially passaged M41-CK isolates, M41-SK-106A, M41-SK-106A1, M41-SK-
106C and M41-SK-106D that have been passaged 110 times through embryonated hen’s 
eggs and are attenuated in vivo (Oade et al., 2019), was also assessed. Passaging a 
pathogenic isolate through embryonated hens’ eggs is a known method of attenuation, 
although the molecular mechanism remains unknown (Geerligs et al., 2011; Oade et al., 
2019). The process of serially passaging in embryonated hens’ eggs typically occurs at 
37°C, and therefore it was possible that this process whilst attenuating the virus also 
rendered the replication of the virus temperature sensitive.  
 
The growth of H120, M41-SK-106A, M41-SK-106A1, M41-SK-106C and M41-SK-106D was 
assessed in CK cells at both 37°C and 41°C and compared to both M41-CK and Beau-R. As 
in previous assays CK cells were infected and incubated at either 37°C or 41°C. The 
supernatants were harvested at 24 h intervals and titrated in CK cells to quantify the amount 
of viral progeny. This work was completed by Michael Oade, under my direction and the data 
generated has been analysed by me. The dataset is presented in Figures 5.6 and Figure 5.7 
to allow clear representation of the findings.  
 
The vaccine strain H120 was observed to initiate and maintain a productive infection at 37°C 
with the pattern of replication mirroring that of M41-CK (Figure 5.6B); both viruses reached 
peak titres at 48 h after which titres exhibited a steady gradual reduction to the lowest titres 
at 96 hpi. Despite this, the titres generated by H120 were lower than M41-CK at all time 
points except 1 h (p<0.0005). Overall, the replication patterns of both H120 and M41-CK 
were different to that of Beau-R which peaked at 24 h and then exhibited a more rapid 
decline. Beau-R infection generated lower PFU/ml than M41-CK at 48, 72 and 96 h (p<0.05), 
and also lower than H120 at 72 and 96 hpi, though only the latter reached statistical 
significance (p<0.05). Despite H120 maintaining a productive infection, the peak titres were 
lower than both Beau-R (p<0.0001) and M41-CK (p<0.0005). This was not the case, 
however, at 41°C in which the titres of M41-CK and H120 were comparable at all time points 
(Figure 5.5C). Additionally, the replication patterns were indistinguishable therefore 
demonstrating that similarly to M41-CK, and unlike Beau-R, H120 could both initiate and 
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sustain productive replication at 41°C. This replication however was sensitive to the higher 
temperatures at later time points during the experiment (Figure 5.6D) with lower titres of 
H120 generated at 41°C in comparison to 37°C at 48, 72 and 96 hpi; a comparable pattern 
to M41-CK (Figure 5.6E). The comparable replication, at 41°C, of H120 and M41-CK 





Figure 5.6: H120 shares the same replication phenotype as M41-CK at 41°C. CK cells 
seeded in six well plates were inoculated with 105 PFU of H120, M41-CK or Beau-R, and 
incubated at either 37°C or 41°C. Supernatant was harvested at 24 h intervals and the 
quantity of infectious progeny determined via titration in triplicate in CK cells. Each point 
represents the mean of three independent experiments with error bars representing SEM. 
Graph (A) represents all data gathered,  (B) the data generated at 37°C, (C) at 41°C, (D) 
from H120 infection and (E) M41-CK. Statistical differences were assessed using a two-way 
ANOVA stating time and temperature as independent factors, followed by a Tukey test for 
multiple comparisons. Statistical differences at each time point are highlighted by * (p<0.05), 
** (p<0.005), *** (p<0.0005) and **** (p<0.0001).  (B) Statistical differences between Beau-R 
and H120 are highlighted by orange *, H120 and M41-CK by purple * and M41-CK and 
Beau-R green *. (C) Statistical differences, which are comparable between Beau-R and 
H120, and M41-CK and H120 are highlighted; there is no difference between M41-CK and 
H120 at any time point. The experimental data was generated by Michael Oade whilst I 
analysed the data.   
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Analysis of the replication patterns of the M41-CK serially egg passaged isolates, M41-SK-
106A, M41-SK-106A1, M41-SK-106C and M41-SK-106D at both 41°C and 37°C were also 
compared (Figure 5.7). Viral titres produced by the attenuated M41-CK serially passaged 
isolates at 1, 72 and 96 h were comparable to each other at 37°C (Figure 5.7B). At 24 h both 
M41-SK-106A and A1 produced higher titres than M41-SK-106C and D (p<0.05). Each of 
the isolates produced lower titres of infectious progeny at all time points in comparison to 
M41-CK with statistical significance reached at 48 to 96 h (p<0.005, Table 5.3). At 41°C viral 
titres were comparable between M41-SK-106A, M41-SK-106A1 and M41-CK (Figure 5.7C). 
M41-SK-106D produced less infectious progeny virus than M41-CK at all time-points 
however this was not significant. There was a small significant difference between titres of 
both M41-SK-106A and M41-SK-106A1 in comparison to M41-SK-106D at 24 h (p<0.05) 
with the latter producing less infectious progeny. Despite some minor differences overall the 
replication kinetics of the serially passaged isolates M41-SK-106A, M41-SK-106A1, M41-SK-
106C and M41-SK-106D are comparable to the parental virus M41-CK at both 37°C and 
41°C.  
 
Further analysis of the data set indicates that similarly to M41-CK, all the serially passaged 
isolates produced lower titres of infectious progeny at 41°C in comparison to 37°C from 48 to 
96 h (p<0.05). Interestingly unlike M41-CK, there is no difference in viral titre between the 
two temperatures at 24 h for M41-SK-106A, A1 and D indicating at this time point viral 
replication in not sensitive to temperature. The isolate M41-SK-106C has a slightly different 
replication pattern with peak titres at 41°C significantly lower than at 37°C (p<0.0005). 
Overall, none of the isolates demonstrated a reduction in viral titres at 41°C as seen by the 
attenuated rIBV Beau-R. For these viruses therefore, similarly to H120, it does not appear 
that temperature sensitivity and the attenuated phenotype observed in vivo (Oade et al., 







Figure 5.7: The replication of attenuated egg passaged isolates, M41-SK-106A, A1, C 
and D is comparable to the parent virus M41-CK at 41°C. CK cells seeded in six well 
plates were inoculated with 105 PFU of M41-CK, M41-SK-106A, M41-SK-106A1, M41-SK-
106C and M41-SK-106D, and incubated at either 37°C or 41°C. Supernatant was harvested 
at 24 h intervals and the quantity of infectious progeny was determined via titration in 
triplicate in CK cells. Each point represents the mean of three independent experiments with 
error bars representing SEM. Graph (A) represents all data gathered, (B) displays only the 
data generated at 37°C, (C) at 41°C, (D) M41-CK, (E) M41-SK-106A, (F) M41-SK-106A1, 
(G) M41-SK-106C and (H) M41-SK-106D. Statistical differences were assessed using a two-
way ANOVA stating time and temperature as independent factors followed by a Tukey test 
for multiple comparisons. Statistical differences at each time point on graph C between M41-
SK-106A1 and M41-SK-106C are highlighted by * (p<0.05) and between M41-SK-106A and 
M41-SK-106C by ** (p<0.005). Statistical differences on graph (D) to (H) at each time point 
highlighted by * (p<0.05), ** (p<0.005), *** (p<0.0005) and **** (p<0.0001). Statistical 




Table 5.3: Statistical differences between viral titres produced from M41-CK and M41-
SK-106A, A1, C and D infection of CK cells at 37°C 
 
 
Notes:  Statistical differences were assessed using a two-way ANOVA stating time and virus 
as independent factors followed by a Tukey test for multiple comparisons. Differences 
between M41-CK and A, A1, C and D are highlighted in pink, purple, blue and green 
respectively. Differences between the attenuated egg passaged isolates are highlighted in 
orange. NS denotes not significant.  
M41-CK  vs. M41-SK-106A ns
M41-CK  vs. M41-SK-106A1 ns
M41-CK  vs. M41-SK-106C ***
M41-CK  vs. M41-SK-106D ***
M41-SK-106A  vs. M41-SK-106A1 ns
M41-SK-106A  vs. M41-SK-106C *
M41-SK-106A  vs. M41-SK-106D *
M41-SK-106A1  vs. M41-SK-106C *
M41-SK-106A1  vs. M41-SK-106D *
M41-SK-106C vs. M41-SK-106D ns
M41-CK  vs. M41-SK-106A **
M41-CK  vs. M41-SK-106A1 *
M41-CK  vs. M41-SK-106C ****
M41-CK  vs. M41-SK-106D ****
M41-SK-106A  vs. M41-SK-106A1 ns
M41-SK-106A  vs. M41-SK-106C ns
M41-SK-106A  vs. M41-SK-106D *
M41-SK-106A1  vs. M41-SK-106C *
M41-SK-106A1  vs. M41-SK-106D **
M41-SK-106C  vs. M41-SK-106D ns
M41-CK  vs. M41-SK-106A **
M41-CK  vs. M41-SK-106A1 **
M41-CK  vs. M41-SK-106C ****
M41-CK  vs. M41-SK-106D ****
M41-SK-106A  vs. M41-SK-106A1 ns
M41-SK-106A  vs. M41-SK-106C ns
M41-SK-106A  vs. M41-SK-106D ns
M41-SK-106A1  vs. M41-SK-106C ns
M41-SK-106A1  vs. M41-SK-106D ns
M41-SK-106C  vs. M41-SK-106D ns
M41-CK  vs. M41-SK-106A **
M41-CK  vs. M41-SK-106A1 ***
M41-CK  vs. M41-SK-106C ****
M41-CK  vs. M41-SK-106D ****
M41-SK-106A  vs. M41-SK-106A1 ns
M41-SK-106A  vs. M41-SK-106C ns
M41-SK-106A  vs. M41-SK-106D ns
M41-SK-106A1  vs. M41-SK-106C ns
M41-SK-106A1  vs. M41-SK-106D ns







5.2.5 The ability to replicate at higher temperatures may be a shared 
characteristic of pathogenic isolates. 
 
Whilst it appeared that temperature sensitivity was not a shared characteristic of 
apathogenic strains, it was possible that the ability to replicate at 41°C was a trait of 
pathogenic strains. It was hypothesised that the ability to replicate at higher temperatures 
aided the virus in initiating and sustaining productive replication in tissues other than the 
respiratory tract. To investigate this, the replication of the nephropathogenic strain D388 was 
assessed at 37°C and 41°C and compared to M41-CK. D388 was chosen as infection in vivo 
results in severe IB, with viral infection identified not only in the respiratory tract but also the 
kidneys and oviducts (de Wit et al., 2014).  
 
CK cells were infected with either M41-CK or D388 and incubated at either 37°C or 41°C 
(Figure 5.8). The supernatant was harvested at 24 h intervals and assessed for infectious 
viral progeny through titration in CK cells. The titres produced by both M41-CK and D388 
were found to be comparable between both temperatures at all time points assessed (Figure 
5.8B and C). Comparison of the titres of infectious progeny produced from D388 infection at 
37°C and 41°C indicates that D388 replication is largely unaffected by temperature (Figure 
5.8D). At both 24 and 48 h titres are comparable, with a small decrease in infectious progeny 
detected at 72 and 96 h with only the latter time point reaching statistical significance 
(p<0.05). M41-CK exhibited larger decreases in titres at 41°C in comparison to 37°C from 48 
to 96 h (Figure 5.8E), however productive replication as seen previously is sustained. The 
ability of D388 to establish and maintain replication at 41°C suggests that whilst attenuation 
and temperature sensitivity may not be intrinsically linked, the ability to replicate at higher 






Figure 5.8: Productive replication of D388 at 41°C is comparable to 37°C. CK cells 
seeded in 12 well plates were inoculated with 1.5 log10 CD50 of M41-CK or D388 and 
incubated at either 37°C or 41°C. Supernatant was harvested at 24 h intervals and the 
quantity of infectious progeny was determined via titration in triplicate in CK cells. Each point 
represents the mean of three independent experiments with error bars representing SEM. 
Graph (A) represents all data gathered, (B) data generation at 37°C, (C) 41°C, (D) from 
D388 infection and (E) from M41-CK infection. Statistical differences were assessed using a 
two-way ANOVA stating time and temperature as independent factors, followed by a Tukey 
test for multiple comparisons. Statistical differences at each time point are highlighted by * 




5.2.6 Entry at permissive temperatures cannot recover replication at non-
permissive temperatures.  
 
To determine whether entry was the prohibitive step to establishing a productive infection of 
Beau-R at 41°C, a temperature swap experiment was carried out (Figure 5.9A). CK cells 
were infected with M41-CK, Beau-R, H120, or D388 and incubated at either 37°C or 41°C for 
1 h allowing for viral attachment and entry. After 1 h the virus was removed and the cells 
were incubated at either the same temperature or were swapped to be incubated at the 
other. The resulting supernatant was assessed for infectious viral progeny in CK cells 
(Figure 5.9B to 5.9E).   
 
The titre in PFU/ml of viable infectious progeny virus produced from CK cells infected with 
D388 and H120 was unaffected by changes in the incubation temperature. This was 
expected as the replication of D388 (Figure 5.8D) and H120 (Figure 5.6D) at 24 hpi, is not 
affected by a change in temperature between 37°C and 41°C. For both Beau-R (Figure 
5.9D) and M41-CK (Figure 5.9E) a swap in incubation temperatures did affect the quantity of 
infectious viral progeny produced. The titres of viral progeny generated from both M41-CK 
and Beau-R infection was similar in those cells incubated at 37°C for binding and entry 
followed by incubation of 37°C for the remainder of the replication cycles (37-37), and those 
incubated at the first temperature of 41°C and then a second incubation temperature of 37°C 
(41-37). Titres were also similar when incubated at a first temperature of 37°C and then a 
second temperature of 41°C (37-41) and those at 41°C and then again at 41°C (41-41). A 
difference in the first incubation temperature therefore had no effect on the quantity of 
infectious viral progeny produced. This indicated that the temperature at which viral 
attachment and entry occurred was not the determining factor in whether a productive 
infection was established.  
 
A significant difference in the titre of viral progeny of Beau-R and M41-CK was however 
identified between groups that had different second incubation temperatures. The titres 
generated when incubating at 41-41 were lower than 41-37 (p<0.0001), and similarly were 
lower when incubating at 37-41 when compared to 37-37 (p<0.0001). This therefore 
demonstrated that the second incubation temperature, in which the virus is undergoing 
active replication, assembly and egress, was the determining factor to whether a productive 





Figure 5.9: Entry does not restrict replication of Beau-R at 41°C. (A) Schematic detailing 
experimental protocol. CK cells seeded in six well plates were inoculated in triplicate with 105 
PFU of either D388, H120, Beau-R or M41-CK. Cells were incubated for 1 h at either 37°C 
(blue) or 41°C (red), after which the viral inoculum was removed and the cells washed to 
remove any unbound virus. Cells were then incubated at either 37°C or 41°C for 23 h. The 
quantity of infectious viral progeny was assessed through titration in triplicate in CK cells.  
Graph (B) represents data generated from D388 infection, (C) H120, (D) Beau-R and (E), 
M41-CK. Each point represents the mean titre of infectious progeny virus generated from 
one independent experimental replicate. Error bars represent the SEM from three 
independent experimental replicates. Statistical differences were assessed using a one-way 
ANOVA with a Tukey test for multiple comparisons. Statistical differences are highlighted by 
** (p<0.005) and **** (p<0.0001).   
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5.2.7 The spike glycoprotein from M41-CK cannot rescue Beau-R replication at 
non-permissive temperatures.  
 
Temperature swap growth kinetic assays (Figure 5.9) suggested that viral entry was not the 
determining factor for replication at non-permissive temperatures. Coronavirus entry is 
mediated by the S glycoprotein (reviewed by Belouzard et al., 2012). To investigate the role 
of the S protein in replication at non-permissive temperatures the rIBV BeauR-M41(S) 
containing the ectodomain of the S protein from M41-CK, in replacement of the Beau-R 
sequence (Casais et al., 2003) was investigated (Figure 5.9). This experiment was 
completed by Phoebe Stevenson-Leggett.  
 
CK cells were infected with either Beau-R or BeauR-M41(S) and incubated at either 37°C or 
41°C (Figure 5.10). Supernatant was harvested every 24 h and the quantity of infectious viral 
progeny was determined by titration in CK cells. At both temperatures and at all time points 
the titres of Beau-R and BeauR-M41(S) were comparable to each other (Figure 5.10). The 
comparable replication of BeauR-M41(S) to Beau-R at 41°C demonstrated that the M41-CK 
derived S gene could not transfer the ability of M41-CK to replicate at 41°C to Beau-R and 
additionally supported the evidence that the S glycoprotein was not the determinant of 




Figure 5.10: The S gene from M41-CK cannot rescue Beau-R infection at 41°C. CK cells 
seeded in six well plates were inoculated with 104 PFU of Beau-R or BeauR-M41(S) and 
incubated at either 37°C or 41°C. Supernatant was harvested at 24 h intervals and the 
quantity of infectious progeny was determined via titration in triplicate in CK cells. Each point 
represents the mean of three independent experiments with error bars representing SEM. 
Statistical differences at each time point were assessed using a two-way ANOVA stating 
virus and temperature as independent factors followed by a Tukey test for multiple 
comparisons. Statistical differences between the quantity of progeny virus produced by 
Beau-R at 37°C and Beau-R at 41°C, as well as BeauR-M41(S) at 37°C and 41°C at each 
time point are highlighted by **** (p<0.0001). There is no statistical difference between 




5.2.8 The replicase gene is a determinant of temperature sensitivity.  
 
The results of the temperature swap assays alongside the inability of BeauR-M41(S) to 
replicate at 41°C suggested that the temperature in which the virus was undergoing active 
replication and not entry, determined whether a productive infection was established. To rule 
out a role for the other structural genes, as well as the accessory proteins, the growth of rIBV 
BeauR-Rep-M41-Struct (Armesto et al., 2009) was assessed at both permissive and non-
permissive temperatures (Figure 5.10). BeauR-Rep-M41-Struct contains Beau-R derived 
sequence encoding the 5′ UTR and replicase gene, whilst the structural and accessory 
genes as well as the 3′ UTR derived from M41-CK sequence.  
 
Similar to the previous assays, CK cells were infected with Beau-R or BeauR-Rep-M41-
Struct, and incubated at either 37°C or 41°C (Figure 5.11). The supernatant was harvested 
at 24 intervals and assessed by plaque assay for infectious viral progeny. At 37°C titres of 
Beau-R and BeauR-Rep-M41-Struct were similar at 1, 48, 72 and 96 hpi with the titre of 
BeauR-Rep-M41-Struct at 24 hpi lower (p<0.05). At 41°C the titres of Beau-R and BeauR-
Rep-M41-Struct were comparable to each other at all time points, demonstrating that 
similarly to Beau-R, BeauR-Rep-M41-Struct was unable to replicate and produce infectious 
progeny virus at 41°C (Figure 5.10). The M41-CK derived structural and accessory genes 
were therefore unable to transfer the ability of M41-CK to replicate at 41°C, suggesting the 





Figure 5.11: The structural and accessory genes from M41-CK cannot recover Beau-R 
replication at 41°C. CK cells seeded in 12 well plates were inoculated with 105 PFU of 
Beau-R or BeauR-Rep-M41-Struct and incubated at either 37°C or 41°C. Supernatant was 
harvested at 24 h intervals and the quantity of infectious progeny was determined via titration 
in triplicate in CK cells. Each point represents the mean of three independent experiments 
with error bars representing SEM. Statistical differences at each time point were assessed 
using a two-way ANOVA stating virus and temperature as independent factors followed by a 
Tukey test for multiple comparisons. Statistical differences between the quantity of progeny 
virus produced by Beau-R at 37°C and Beau-R at 41°C, as well as BeauR-Rep-M41-Struct 
at 37°C and 41°C at each time point are highlighted by **** (p<0.0001). There is no statistical 
difference between Beau-R and BeauR-Rep-M41-Struct at either temperature except for 24 





5.3 Discussion.   
 
The data presented in this chapter identifies that the attenuated rIBV Beau-R has a 
temperature sensitive replication phenotype with little or no infectious progeny virus 
produced during infection at 41°C in both CK and DF1 cells (Figure 5.4 and 5.5). The 
inability of Beau-R to establish a productive infection at 41°C may account for the restricted 
replication observed in vivo, in which viable virus could only be consistently detected in the 
nasal turbinates’ (Table 5.2). In contrast, M41-CK was able to produce infectious progeny 
virus from CK cells incubated at 41°C and viable virus could be isolated from nasal 
turbinates, eyelids and trachea sections harvested from M41-CK infected birds. Additionally 
M41-CK infected birds, unlike Beau-R infected birds displayed clinical symptoms including a 
reduction in ciliary activity, associated with IB (Figures 5.2 and 5.3). These observations 
match previous reports that M41-CK displays a pathogenic phenotype in vivo and Beau-R an 
attenuated phenotype (Hodgson et al., 2004; Armesto et al., 2009; Ellis et al., 2018; Keep et 
al., 2018).  
 
In birds as well as mammals the continuous movement of air through the respiratory tract will 
result in a temperature gradient in which the upper respiratory tract including the nasal 
cavities, mouth and throat is cooler than the trachea and lungs that constitute the lower 
respiratory tract (Alford et al., 1966). For human pathogen research including influenza, 
rhinovirus and RSV, the upper respiratory tract is assumed to be 33-34oC and the lower to 
be 37°C, commonly denoted as permissive and non-permissive temperatures respectively 
(Juhasz et al., 1999; Bradel-Tretheway et al., 2008; Foxman et al., 2015; Nogales et al., 
2016). Unlike humans which have a core body temperature of 37°C, chickens exhibit a core 
temperature of 41°C, which means it is likely the temperature of upper respiratory tract is 37-
38oC, increasing to 41°C in the lower respiratory tract. The effect of this localised 
temperature change on the replication on several respiratory pathogens including influenza, 
rhinovirus and RSV is well documented and has been linked to viral dissemination through 
the host, viral pathogenicity and interspecies transmission (Juhasz et al., 1999; Bradel-
Trethway et al., 2008; Massin et al., 2010; Foxman et al., 2015; Broadbent et al., 2014; 
Nogales et al., 2016; Deng et al., 2019). It must be noted whilst Beau-R has been re-isolated 
from nasal turbinates (Table 5.2) indicating that replication may be temperature restricted in 
vivo, it has not been determined whether the virus is actively replicating in this tissue. The 
only way to establish whether active replication is occurring is to assess sgmRNA synthesis 
either through Northern blotting or via a leader-body junction RT-PCR as described by 
Bentley et al., (2013).  
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Temperature sensitivity is not a novel topic in the field of virology and has been widely 
studied for influenza and RSV since the mid 1900’s (Alford 1966; Maassah, 1967; Maassah 
1968). The analysis of temperature sensitive mutants has been used in the identification of 
genes involved in viral replication and pathogenesis and the generation of vaccine viruses, 
notably against influenza (Hall et al., 1992; Ray et al., 1996; Belshe et al., 1998; reviewed by 
Maassab and Bryant, 1999; Jin et al., 2003; Sawicki et al., 2005; Burke Schinkel et al., 2017, 
Deng et al., 2019). Whilst temperature sensitivity has not been a popular research subject for 
IBV with literature searches only identifying two publications (Yachida et al., 1981; Gelb et 
al., 1991), several temperature sensitive mutants of the betacoronavirus MHV have been 
generated (Sawicki et al., 2005; Mielech et al., 2015; Deng et al., 2019). These mutants that 
all have mutations within the replicase gene, have proved useful tools for elucidating the 
specific role of individual replicase proteins (nsps) as well as protein-protein and protein-
RNA interactions during the coronavirus replication cycle (Sawicki et al., 2005; Clementz et 
al., 2008;  Mielech et al., 20015; Deng et al., 2019). Additionally, temperature sensitive 
mutants have identified pathogenic determinants within the MHV genome and have been 
demonstrated to protect mice against lethal challenge (Mielech et al., 2015; Deng et al., 
2019).  
 
Similarly to MHV, the data presented in this chapter suggests the temperature sensitive 
phenotype exhibited by Beau-R is conferred by the replicase gene. Neither the S gene from 
M41-CK nor the remainder of the structural, accessory genes and 3′ UTR could transfer the 
ability of M41-CK to replicate at 41°C to Beau-R (Figure 5.10 and 5.11). Additionally 
temperature swap experiments (Figure 5.9) also demonstrated that the temperature in which 
binding, attachment and entry occur is not the determinant to whether productive replication 
at 41°C is established.  The data presented in this chapter however does not rule out a 
collaborative role of the 5′ UTR and 3′ UTR which interact during genome and sgmRNA 
synthesis (reviewed by Sola et al., 2011). The rIBV BeauR-rep-M41-Struct contains Beau-R 
derived 5′UTR sequence and M41-CK derived 3′UTR sequence (Armesto et al., 2009). It is 
possible that if the 5′UTR was replaced with M41-CK, that the resulting rIBV may be able to 
replicate at 41°C despite the replicase proteins being Beau-R derived. Swapping the 3′ UTR 
and 5′ UTR regions is a relatively straightforward modification to make using the reverse 
genetic systems described by Britton et al., (2005). The development of a reverse genetics 
systems for the pathogenic lab strain M41-CK which is discussed in Chapter 6 also enables 
the investigation of whether the 5′ UTR and/or 3′ UTR as well as the replicase gene from 





Why the productive replication of Beau-R is highly restricted at 41°C remains an unanswered 
question. There are several possibilities which all require investigation. The most obvious 
hypothesis, given the restriction is likely the result of the replicase gene, is that RNA 
replication and/or sgmRNA transcription is affected by temperature. Defects in RNA 
synthesis and transcription at non-permissive temperatures have been reported for RSV, 
Influenza, Mumps virus, human parainfluenza virus type 3 (HPIV3) and Sendai virus L as 
well as MHV (Ray et al., 1995; Juhasz et al., 1999; Feller et al., 2000; Sawicki et al., 2005; 
Dalton et al., 2006; Bradel-Thretheway et al., 2008; Burke Schinkel et al., 2017). There is a 
well-defined set of five mutations that impart temperature sensitivity on influenza virus; four 
of which are located on the polymerase subunits, PB1 and PB2 (Jin et al., 2003). In addition, 
mutations in the L protein (the polymerase) of RSV and Mumps virus also induce a 
temperature sensitive phenotype (Juhasz et al., 1999; Burke Schinkel et al., 2017). Future 
research should therefore establish whether both Beau-R and M41-CK exhibit defects in viral 
RNA synthesis at non-permissive temperatures. Such experiments could utilise techniques 
such as Northern blotting and qRT-PCR analysis.  
 
 
If defects in viral RNA synthesis are identified at non-permissive temperature, it is not 
necessarily indicative for a determining role of nsp 12, the RNA-dependant RNA polymerase 
(RdRp). As discussed in Chapter 1, the coronavirus replication cycle is complex and involves 
both positive and negative strand RNA synthesis (reviewed by Sola et al., 2011; Fehr and 
Perlman 2015). Additionally, the structural and accessory genes are transcribed through a 
process of discontinuous transcription during negative strand synthesis (Sawicki and 
Sawicki, 1995). Viral RNA synthesis is therefore a complex activity, which requires the 
formation of replication-transcription complexes, which are formed by several nsps including, 
and not exclusively, nsp 10, 12, 13 and 14, as well as possibly a number of yet undefined 
viral proteins and cellular factors (reviewed by Sola et al., 2011; Fehr and Perlman 2015). 
Research into temperature sensitive mutants of MHV have identified a mutation in nsp 10 
(Gln65Glu) that affects negative strand synthesis, nsp 5 (Phe219Leu) that affects the 
conversion of negative strand to positive strand RNA, as well as a mutation in nsp 12 
(His868Arg) that results in a reduction in elongation of both positive and negative strand 
(Swaicki et al., 2005). Furthermore, it is possible that temperature sensitive phenotype 
inducing mutations do not directly affect the enzymatic function of an nsp but rather affects 
protein-protein interactions, which subsequently result in a downstream reduction in viral 
RNA synthesis.    
 
 
An alternative hypothesis is that temperature has no effect on viral RNA synthesis, but rather 
affects proteolytic cleavage of the pp1a and pp1ab polyproteins, protein stability, protein-
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protein interactions or virus-host interactions. Sparks et al., (2008) identified a mutation in 
nsp 5 of MHV that resulted in reduced viral replication in vitro at non-permissive 
temperatures with hypothesis that the mutation had affected proteolytic cleavage. Similary 
Stobart et al., (2012) also identified a mutation in MHV within nsp 5 that effected polyprotein 
processing and consequently viral replication. Research by Deng et al., (2019) demonstrated 
that mutations in the ADRP and PLP2 domains of nsp 3 in MHV affect protein stability 
thereby affecting viral replication at non-permissive temperatures. Additionally, temperature 
sensitivity conferring mutations within the ubiquitin like domain preceding the PLP2 domain 
were found to affect thermal stability of PLP2 and as a consequence protease activity 
(Mielech et al., 2015). It is of course possible that mutations affect the host response with 
both Deng et al., (2019) and Mielech et al., (2015) indicating an elevated innate immune 
response to infection with temperature sensitive mutant virus both in vitro and in vivo.  
Interestingly research utilising mouse adapted rhinovirus also demonstrated an elevated 
antiviral response at non permissive temperatures (Foxman et al., 2015). 
 
 
Despite the unknown mechanism of the temperature sensitive phenotype of Beau-R, the 
identification of the phenotype may have implications for the development of Beau-R as a 
vaccine viral vector. It is well established the Beaudette strain replicates poorly in vivo, with 
Beau-R behaving comparably (Hodgson et al., 2004).  Additionally, vaccination of birds with 
Beau-R cannot induce a protective immune response against an M41-CK challenge 
(Hodgson et al., 2004) nor, as discussed in Chapter 3, can vaccination with Beau-R 
expressing heterologous S genes offer protection that meets the European Pharmacopoeia 
standards against homologous challenge (Hodgson et al., 2004; Armesto et al., 2011; Ellis et 
al., 2018). It cannot be stated that the temperature sensitive replication phenotype of Beau-R 
observed in vitro (Figure 5.3 and 5.4) is the cause of the attenuated phenotype in vivo nor 
the poor replication or the inadequate protection induced by vaccine viruses BeauR-M41(S) 
and BeauR-4/91(S). Whilst it does seem logical that the restricted replication of Beau-R in 
vivo is a consequence of temperature sensitivity there may be several other attenuating 
mutations within the viral genome. As discussed in Chapter 3 and 4 there may be alternative 
reasons for the less than desired protection rate induced by Beau-R based vaccine viruses, 
which are independent of vaccine virus replication in vivo.  In its current state however it 
does appear that the Beau-R backbone is too attenuated for further vaccine development.  
 
 
The temperature sensitive phenotype is often associated with an attenuated in vivo 
phenotype which has led to vaccine development. Dual temperature sensitive and 
attenuated phenotypes have been reported for influenza virus, mumps, HIPV3, RSV and 
MHV (Hall et al., 1992; Ray et al., 1995; Juhasz et al., 1999; Foxman et al., 2014; Burke 
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Schinkel et al., 2017; Mielech et al., 2015; Deng et al., 2019). It is not always clear how 
mutations that induce a temperature sensitive replication phenotype also attribute an 
attenuated phenotype. In some cases the in vivo temperature will simply not allow productive 
viral replication to be initiated or sustained at a level that will induce clinical disease. In other 
cases the non-permissive temperatures investigated in vitro are higher than that seen in 
vivo, leading to a false impression that the temperature sensitive and attenuated phenotypes 
are directly linked. In other cases temperature sensitive and attenuated mutations are simply 
independent of each other.    
 
 
From the data presented in this chapter it remains unclear as to whether attenuation and 
temperature sensitivity for IBV are directly linked. Unlike Beau-R, the attenuated egg 
passaged viruses M41-SK-106A, M41-SK106A1, M41-SK-106C, M41-SK-106D and the 
vaccine virus H120 do not display a temperature sensitive phenotype in CK cells (Figure 5.6 
and 5.7). However, it has not been assessed whether replication in ex vivo tracheal organ 
cultures (TOCs) would produce the same result. There is evidence from research into 
influenza virus that temperature sensitive phenotypes may be dependant of the cell type 
infected (Dalton et al., 2006). It must be noted however that IBV RNA could be detected in 
trachea extracted from birds infected with the egg passaged M41 isolates, M41-SK-106A, 
M41-SK106A1, M41-SK-106C, M41-SK-106D, 4 dpi (Oade et al., 2019) indicating that is it 
likely that a temperature sensitive phenotype would not be observed in ex vivo TOCs. 
Additionally, infectious H120 has been detected in the trachea extracted from infected birds 
3 dpi, alongside a 40% drop in ciliary activity (Hodgson et al., 2004). It seems likely therefore 
similarly to the M41 egg passaged isolates that H120 simply does not have a temperature 
sensitive phenotype and that the attenuated phenotypes observed in vivo are achieved by a 
different molecular mechanism.  
 
Whether the ability to replicate at higher temperatures is a shared characteristic of all 
pathogenic strains is an interesting question. In this chapter both the nephropathogenic 
strain D388 and the pathogenic strain M41-CK were found to be able to establish a 
productive infection at 41°C (Figure 5.8). The titres produced in D388 infected CK cells 
incubated at 37°C and 41°C were comparable, indicating that there were no differences in 
productive replication at the two temperatures.  This is not an unexpected result as it seems 
logical that all nephropathogenic strains would be able to replicate at 41°C as these strains 
infect the kidneys and oviducts, organs that are deep within the body of the bird, and which 
will certainly reside at a much higher temperature than that of the upper respiratory tract. 
However, to say with any conviction whether temperature sensitivity is a defining trait of all 
nephropathogenic strains further research is required to assess other nephropathogenic IBV 
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viruses. Further research could include the well characterised B1648 strain (Meulemans et al 
1987; Lambrechts et al., 1993; Cook et al., 2001) which has been adapted for replication in 
CK cells (Britton, unpublished data).  
 
The classical respiratory strains such as M41-CK may however present a more complex 
story, as unlike D388, M41-CK exhibits a consistent reduction in viral titres produced at 41°C 
in comparison to 37°C (Figure 5.4, 5.6, 5.7 and 5.8). It must be noted that in some assays 
productive replication is not affected by temperature at 24 hpi which could indicate a 
population effect in which some viruses within the population are not temperature sensitive 
and some are. It is not surprising that M41-CK can establish replication at temperatures 
higher than 37°C, since, as previously discussed it is likely that the temperature of the 
respiratory tract is in the region of 37- 41°C, and productive replication of M41-CK in tracheal 
tissue in vivo as demonstrated in this chapter (Table 5.2, Figure 5.3) is well documented 
(Hodgson et al., 2004; Armesto et al., 2011; Keep et al., 2018; Ellis et al., 2018). What is 
interesting is the drop in viral titres produced in cells infected at 41°C in comparison to 37°C 
(Figure 5.4, 5.6, 5.7, 5.8 and 5.9) which raises the question does such a drop in productive 
infection occur in vivo? Is less infectious M41-CK produced from cells located in the lower 
trachea in comparison to upper sections? Is increasing temperature prohibitive to 
dissemination of M41-CK from the primary sites of infection such as the upper trachea, 
eyelid and nasal turbinates to other tissues/organs within the bird? Is it possible that 
temperature may be a factor in why M41-CK has not been detected in kidney or lung tissue 
harvested from infected birds (Stevenson-Leggett, 2018)?  
 
Whilst the M41-CK data presented in this chapter is interesting, one question that arises is 
the M41-CK temperature phenotype representative of all classical respiratory strains of IBV? 
The M41 strain, whilst pathogenic, is like Beaudette a lab adapted IBV. The M41 strain has 
been documented to induce kidney damage in vivo (Jones, 1974), however, M41 and M41-
CK although related, are two distinct viruses with the latter produced through serially 
passage in TOCs and CK cells (Cook et al., 1976; Darbyshire et al., 1979). This passaging 
notably occurred at the lower temperature of 37°C and therefore may have imparted a 
degree of cold adaption onto M41-CK. The vaccine strain H120, although not pathogenic, 
also exhibits the same reduction in viral titre at 41°C in comparison to 37°C (Figure 5.6). This 
virus was also generated through serially passaging an IBV strain, H, first isolated in infected 
birds in The Netherlands in the 1950s (reviewed by Bijlenga et al., 2004). It therefore 
remains to be determined whether non lab adapted classical respiratory strains of IBV do 
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exhibit reduced replication at 41°C or whether the reduction in viral titres observed for M41-
CK is an artefact of its passaging history.  
 
In summary, the data presented in this chapter identifies that the attenuated rIBV Beau-R 
exhibits restricted replication in vivo with infectious virus only consistently isolated from nasal 
turbinates harvested from infected birds. Replication in vitro in both primary CK cells and the 
continuous cell line DF1 was found to be temperature sensitive with productive infection 
highly restricted at 41°C. In contrast it has been identified that the pathogenic IBV M41-CK 
can be re-isolated from the nasal turbinates, eyelids and trachea harvested from infected 
birds and is able to produce infectious progeny virus at 41°C.  Investigation into attenuated 
and pathogenic viruses indicates that whilst attenuation and temperature sensitivity may not 
be intrinsically linked, the ability to replicate at higher temperatures may be a characteristic 
of pathogenic isolates. Finally, the restricted replication of Beau-R is likely to be conferred by 




Chapter 6: Recombinant Infectious Bronchitis Virus, M41-R, as 




The results of the in vivo vaccine-challenge experiments presented in chapter 3 and 4 
indicate that rIBV Beau-R may not be an ideal vaccine vector. The observation in chapter 5 
that the replication of Beau-R is temperature sensitive, and is highly restricted in vivo, further 
supports this.  
 
Since the generation of the Beaudette based (Beau-R) reverse genetic system in the early 
2000s (Casais et al., 2001), a reverse genetics system based on the pathogenic IBV, M41-
CK, has been developed. The M41-CK system was developed from the existing Beaudette-
based system; briefly within the rVV vector, the Beaudette genome was sequentially deleted 
and replaced with the corresponding M41-CK sequence. This led to the generation of a full-
length cDNA copy of the M41-CK genome encoded by an rVV vector, which was then 
“recovered” producing rIBV. The first full length clone of M41-CK, M41-R, was demonstrated 
to be apathogenic in vivo; a finding that was unexpected. The results of this in vivo study are 
presented in this chapter. Deep sequencing of a pathogenic M41-CK virus isolate highlighted 
a number of differences between the M41-R and M41-CK genome, notably four-point 
mutations within nsp 10, 14, 15 and 16. These mutations were repaired in M41-R cDNA 
within the rVV, to make the genome more M41-CK like, which lead to the generation of the 
second infectious clone. The second clone of M41-CK, M41-K, was determined to be 
pathogenic based on clinical signs and ciliary activity observed in vivo (Keep and Bickerton, 
unpublished data) identifying that the repair of the coding mutations in the replicase gene 
enabled the restoration of a pathogenic in vivo phenotype.  The generation of the M41-CK 
reverse genetics system and the assessment of both M41-K and M41-R in vivo was 
research I conducted prior to the start of this PhD project.  
 
In this chapter, the data generated as part of the in vivo pathogenicity experiment examining 
M41-R, that I carried out before the start of this PhD project, has been re-analysed and 
expanded in the context of using M41-R as a vaccine vector. The in vivo dissemination of 
M41-R was compared to both Beau-R and M41-CK. The results of these analyses 
highlighted that M41-R could be a favourable vaccine backbone so further investigations 
were carried out, including the ability of M41-R to replicate in ex vivo TOCs, and in vitro in 
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CK cells at 41°C. Finally this chapter also describes the design of two new rIBVs based on 
M41-R that have potential to act as vaccine viruses; M41R-4/91(S) and M41R-4/91(S1). 
These potential vaccine viruses are similar to the vaccine candidates assessed in chapter 3 
and 4 that used rIBVs, based on the apathogenic Beaudette system, to express a 
heterologous S glycoprotein, or S1 subunit.   
 
6.2 Results.  
 
6.2.1 M41-R infection in vivo does not result in IB related clinical signs.   
 
To establish whether M41-R infection in vivo resulted in IB, a pathogenicity experiment in 
chickens compared M41-R to the pathogenic parent virus M41-CK, and also to the 
apathogenic rIBV Beau-R. During the cloning of M41-CK, two isolates of M41-R were 
generated and independently recovered, M41-R 6 and M41-R 12; both isolates were 
included in the pathogenicity experiment.  
 
In groups of 12, 8 day old SPF RIR chickens were infected with either Beau-R, M41-CK, one 
of two isolates of M41-R, or 1 X BES medium for mock infection (Figure 6.1, Table 6.1). 
Clinical signs including snicking and rales (Figure 6.2) were observed at regular intervals 
from 3 to 7 dpi. The rate of snicking (Figure 6.2A) peaked at 5 dpi with M41-CK infected 
birds exhibiting 1.56 snicks per bird per min. In contrast M41-R birds exhibited a snicking 
rate of 0.31 (M41-R 12) and 0.17 (M41-R 6), while Beau-R infected birds had a rate of 0.02 
snicks per bird per min. No snicking was observed from mock infected birds on 5 dpi. Overall 
throughout the study the rate of snicking observed in the groups infected with both isolates of 
M41-R were lower than M41-CK but higher when compared to both the Beau-R and mock 
infected groups. Although the snicking rate displayed by M41-R infected birds remained 
below 0.5 snicks per bird per min, it could be concluded on the clinical sign of snicking alone 






Figure 6.1: Schematic of experimental protocol: pathogenicity experiment M41-R. 
Groups of eight-day old SPF RIR chickens were inoculated with Beau-R, M41-R 6, M41-R 
12, M41-CK or 1 x BES. The birds were assessed daily for the presence of clinical signs 
from two dpi; birds were 10 days old. On days 4 and 6 dpi randomly chosen birds were 
culled from each group and a variety of tissues harvested. The experiment ended on 7 dpi 
with all remaining birds culled. Tracheal ciliary activity was assessed on 4, 6 and 7 dpi.   
 
Table 6.1: Groups and sampling numbers for M41-R pathogenicity experiment.  
 
As well as snicking, rales was also assessed from 3 to 7 dpi (Figure 6.1B). The percentage 
of birds infected with M41-CK exhibiting rales peaked on day 5 pi at 89%. Rales were not 
observed in those birds infected with Beau-R, M41-R 12 or those birds that were mock 
infected. Birds infected with M41-R 6 exhibited rales on 4 dpi, however at 9 % this was 
greatly reduced in comparison to M41-CK at 58 %.  
 
 
Total no. of 
birds per group
A PBS (mock) 3 3 6 12
B Beau-R 3 3 6 12
C M41-R6 3 3 6 12
D M41-R 12 3 3 6 12
E M41-CK 6 6 6 12
No. of days post infection (dpi) 0 4 6 7




Figure 6.1: M41-R infected birds display rates of snicking and rales comparable to 
mock and Beau-R infected birds. SPF chickens were inoculated at 8 days of age with 105 
PFU of either Beau-R, M41-R 6, M41-R 12, M41-CK or 1 X BES medium for mock infection. 
(A) Snicking was assessed from 3 to 7 dpi, with the number of snicks in a 2 min time period 
counted independently by 2 or 3 persons with the average of these scores presented. (B) 
Chickens were assessed individually for the presence of tracheal rales 3 to 7 dpi. The 
percentage of birds exhibiting rales per group was calculated. 
 
 
In summary, the overall observed data indicated that neither infection with M41-R 6 nor M41-
R 12 resulted in IB related clinical signs when compared to the pathogenic M41-CK control 
virus, and was more comparable to infection with the non-pathogenic rIBV Beau-R. The 
clinical signs data alone therefore suggests that M41-R is attenuated in vivo. 
 
6.2.2: Ciliary activity 4 dpi in M41-R infected birds is comparable to mock 
infected birds. 
 
One of the defining characteristics of an in vivo infection with a pathogenic IBV is ciliostasis 
in the trachea (Cavanagh et al., 1997; Cook et al., 1999). It is considered that a reduction of 
50% (or greater) tracheal ciliary activity is indicative of the presence of a pathogenic isolate 
(Cavanagh et al., 1997; Cook et al., 1999; European Pharmacopoeia, 2010). To assess 
whether M41-R infection affected tracheal ciliary activity, tracheas were removed from three 
randomly selected birds per group on 4, 6 and 7 dpi. The percentage ciliary activities in ten 1 
mm sections from three different regions per extracted trachea were assessed and the mean 
activities calculated (Figure 6.3).  The tracheal ciliary activities observed at 4 dpi in birds 
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infected with M41-R 6 and M41-R 12 were comparable to both Beau-R and mock infected 
birds, with the group means of 84%, 74%, 87% and 92%, respectively. In contrast the ciliary 
activities in tracheas harvested from the M41-CK infected birds were 0% (p<0.0001). 
 
 
Figure 6.2: Tracheal ciliary activity in M41-R infected birds was higher than in M41-CK 
infected birds 4 and 7 dpi. SPF chickens were inoculated at 8 days of age with Beau-R, 
M41-R 6, M41-R 12, M41-CK or 1 X BES medium for mock infection. Tracheas were 
removed from 3 randomly chosen birds per group at 4, 6 and 7 dpi. Each trachea was 
sectioned into 10 x 1mm rings and the ciliary activity of each ring was assessed by light 
microscopy and the percentage activity calculated. Plotted points represent individual 
animals and the mean activity of the 10 rings assessed. Error bars represent SD. Statistical 
differences between groups were evaluated using a One-Way ANOVA followed by Tukey 
test for multiple comparisons, and are represented by * (p<0.05) and ****(p<0.0001). Both 
isolates of M41-R exhibited higher ciliary activity than the M41-CK control group at 4 and 7 
dpi. Higher ciliary activities in the Mock and Beau-R infected group compared to the M41-CK 
infected group were observed 4, 6 and 7 dpi.  
 
 
On day 6 pi ciliary activities were comparable between the mock and the Beau-R infected 
groups at 85% and 89%, respectively. Ciliary activities in birds infected with M41-CK were 
again 0% (p <0.05). However, birds infected with either M41-R isolate displayed variable 
tracheal ciliary activities, ranging from 40% to 88% (M41-R 6) and 0% to 95% (M41-R 12) 
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with overall mean activities still above 50%, at 66% and 63%, respectively. This variability in 
the ciliary activities observed has meant there are no significant differences between the 
mean ciliary activities observed in the M41-R infected groups in comparison to both the M41-
CK infected and mock infected group. There was much more consistency in the ciliary 
activities observed in tracheas harvested from birds at 7 dpi with values ranging from 85% to 
92% for M41-R 6 and 65% to 93 % for M41-R 12. The observed ciliary activities at this time 
point were comparable to both mock infected and Beau-R infected birds, but significantly 
different to those observed in tracheas from M41-CK infected birds (p<0.0001). 
 
In summary, the in vivo observations demonstrated that the two M41-R isolates showed 
significantly reduced pathogenicity when compared to the parental M41-CK virus but 
retained some virulence in terms of snicking when compared to the apathogenic Beau-R. 
The IBV Beaudette strain is not accepted as a potential vaccine candidate due to it lacking 
any retained virulence that may have resulted in its inability to induce a protective immune 
response. It is generally accepted that a vaccine candidate needs to retain some virulence in 
order to stimulate an effective protective immune response but not sufficient to induce 
disease or harmful pathology (reviewed by Bijlenga et al., 2004). The in vivo observations 
therefore indicate that M41-R may have potential as a vaccine candidate.   
 
6.2.3 M41-R derived RNA could not be detected in the trachea 4 dpi but was 
detected in harderian glands. 
 
Trachea and Harderian glands (HG) were removed from randomly selected birds from all 
groups on 4 dpi and assessed by qRT-PCR for the presence of IBV RNA. No IBV RNA was 
detected in the tracheas from Beau-R, M41-R 6 or M41-R 12 infected birds indicating that 
neither virus had established a productive infection, or had been cleared by 4 dpi. All 
sampled birds infected with M41-CK were positive for the presence of IBV RNA (Table 6.2). 
In addition, RNA extracted from the HGs removed from the birds at 4 dpi was also assessed 
for the presence of IBV, as published work using an Arkansas strain of IBV had identified the 
virus in the HG as well as in tears (van Ginkel et al., 2008). No IBV RNA was detected in 
HGs extracted from birds infected with Beau-R or mock infected with PBS (Table 6.2). 
However, the HGs sampled from all birds infected with M41-R 6 were positive for IBV RNA 
and one of the three birds infected with M41-R 12 was also positive for IBV RNA. The HGs 





Table 6.2: The presence of IBV RNA in the trachea and Harderian gland harvested 4 
dpi as assessed by qRT-PCR. 
 
Notes: Total RNA was extracted from 30 µg of tracheal sections and 30 µg of one harderian 
gland harvested per bird at 4 dpi. The presence of IBV derived RNA was assessed using 
qRT-PCR using a PrimerdesignTM genesig® Kit for Avian Infectious Bronchitis Virus, 
Advanced. This work was completed by Dr. Erica Bickerton. 
 
6.2.4 M41-R derived RNA could be detected in the trachea 6 and 7 dpi. 
 
Tracheal sections harvested on 6 and 7 dpi were also assessed by qRT-PCR for the 
presence of IBV derived RNA. IBV RNA was only detected in two of the three birds sampled 
at 6 dpi that had been infected with M41-CK; all other tracheal samples were negative for 
IBV RNA.  Similarly, two of three birds in the M41-CK group samples at 7 dpi were also 
positive for IBV RNA. No IBV derived RNA could be detected in tracheas harvested from 
Beau-R and mock infected birds. Interestingly, tracheal samples at 7 dpi from three birds 
infected with isolates of M41-R, one with M41-R 6 and 2 with M41-R 12, were positive for 















Table 6.3: The presence of IBV RNA in the trachea harvested 6 and 7 dpi as assessed 
by qRT-PCR. 
 
Notes: Total RNA was extracted from 30 µg of tracheal sections harvested per bird at 6 and 
7 dpi. The presence of IBV derived RNA was assessed using qRT-PCR using a 
PrimerdesignTM genesig® Kit for Avian Infectious Bronchitis Virus, Advanced. This work 
was completed by Dr. Erica Bickerton. 
 
6.2.5 Investigation as to whether infectious M41-R could be recovered from 
trachea harvested 4 and 6 dpi. 
 
Supernatants derived from homogenised tracheas harvested 4 and 6 dpi, were used to infect 
ex vivo tracheal organ cultures (TOCs).  The supernatants harvested from the TOCs were 
subsequently assessed for the presence of IBV derived RNA by RT-PCR analysis utilising a 
random primer for the RT step and primers BG56 and 93/100 for the PCR step which are 
specific for the IBV 3′ UTR. Infectious IBV could not be recovered from tracheas harvested 
from either mock, Beau-R or M41-R 6 infected birds on either 4 or 6 dpi (Table 6.4). This 
was expected as trachea sections from these birds were negative for the presence of IBV 
derived RNA when screened by qRT-PCR (Table 6.2 and 6.3). Similarly to M41-R 6 no 
infectious virus was re-isolated from the trachea of the M41-R 12 birds sampled 6 dpi, 
however virus could be re-isolated from one M41-R 12 infected bird on 4 dpi (Table 6.4). 
This was unexpected as all the tracheas extracted from M41-R infected birds had previously 
been screened negative for the presence of IBV derived RNA (Table 6.2). 
 
Infectious virus could be re-isolated from all birds infected with M41-CK on both 4 and 6 dpi 
(Table 6.4). The latter time point is interesting as only two of the three birds were positive for 
6 dpi 7 dpi




M41-R 6 0/3 1/6




IBV RNA in the trachea as examined by qRT-PCR (Table 6.3). Further investigation 
highlighted that the bird in which infectious virus could be re-isolated from trachea that had 
been screened negative for IBV RNA in the trachea was positive for IBV RNA in the HG. 
This therefore raised a question to whether active viral replication in this bird was occurring 
in the HG and infectious particles had been caught in the mucous that lines the trachea, 
which were then subsequently re-isolated. Unlike the M41-CK bird discussed here, the M41-
R bird 4 dpi in which infectious virus was re-isolated was also negative for IBV RNA in the 
HG.  
 
Table 6.4: The presence of infectious IBV in the trachea 4 and 6 dpi. 
 
Notes: Ex vivo TOCs prepared from 19 day old SPF RIR hen’s eggs were inoculated in 
triplicate with tissue derived supernatant prepared from trachea harvested at 4 and 6 dpi. 
Supernatant harvested from the TOCs was screened for the presence of IBV RNA by RT-
PCR utilising a random primer for the RT step and IBV specific primers BG56 and 93/100 for 
the PCR step.  
 
6.2.6 Infectious M41-R could not be re-isolated from Harderian glands harvested 
4 dpi.  
 
The results of the qRT-PCR data suggested that M41-R may be replicating in the HG. To 
investigate whether infectious M41-R, Beau-R and M41-CK could be re-isolated, supernatant 
derived from homogenised HGs harvested 4 dpi was used to inoculate SPF Valo 
embryonated hens’ eggs. Allantoic fluid from each inoculated egg was harvested 24 hpi and 
the RNA extracted. The presence of IBV derived RNA was assessed by RT-PCR analysis 
utilising primers BG56 and 93/100 (Figure 6.4). IBV RNA could be detected in all samples 
4 dpi 6 dpi
Beau-R 0/3 0/3
Group
No. of birds positive for infectious IBV/total no. of birds per group
Mock 0/3 0/3
M41-CK 3/3 3/3
M41-R 6 0/3 0/3
M41-R 12 1/3 0/3
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from the M41-CK group, indicating that HGs from M41-CK infected birds did contain 
infectious IBV. No IBV derived RNA could be detected in eggs inoculated with M41-R 6 or 
M41-R 12 HG derived supernatant. Interestingly Beau-R derived RNA could be detected in 




Figure 6.4: Viral isolation from Harderian glands harvested 4 dpi. SPF embryonated 
hens’ eggs were inoculated with tissue derived supernatant prepared from 1 HG per bird 
harvested 4 dpi; one egg was inoculated with supernatant derived from 1 HG. Allantoic fluid 
was screened for the presence of IBV related RNA by RT-PCR utilising a random primer for 
the RT step and IBV specific primers BG56 and 93/100 for the PCR step. A positive Beau-R 
RNA control as well as a negative no template control was included in the RT-PCR reaction 
and are denoted by + and – respectively. All samples were run on a 0.8 % agarose gel 
alongside a 1 KB+ ladder (Life Technologies). The expected PCR product size for M41-R 
and M41-CK derived RNA is ~450 bp and Beau-R is 650 bp.   
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6.2.7 The attenuated in vivo phenotype of M41-R is the result of 4 point 
mutations with the replicase gene.  
 
The retention of ciliary activity, comparable to the attenuated rIBV Beau-R at both 4 and 7 
dpi demonstrated that both rIBV M41-R 6 and M41-R 12 displayed an attenuated phenotype 
in vivo (Figure 6.3). The lack of clinical signs in M41-R infected birds in comparison to M41-
CK (Figure 6.2), and the lack of M41-R RNA in extracted trachea (Table 6.2 and 6.3) further 
demonstrated that M41-R displayed in vivo characteristics associated with the attenuated 
rIBV Beau-R rather than the pathogenic strain M41-CK. This was unexpected since M41-R is 
the molecular clone of M41-CK. As part of another project, the M41-CK genome was 
investigated by high throughput sequencing; this identified a number of differences between 
the previous M41-CK genome data that had been generated by Sanger consensus 
sequencing. The sequence of M41-R was based on the latter dataset and sequencing of the 
M41-R genome within the vaccinia virus vector confirmed this. Comparison of the M41-R 
genome sequence to the newly generated M41-CK genome sequence identified a number of 
differences which are summarised in Table 6.5. Interestingly, all the sequence differences 
are located in the replicase gene, a previously identified pathogenic determinant (Armesto et 
al., 2009). Most of the sequence changes do not result in amino acid changes however there 
are four coding point mutations located in nsp 10 (C12139T), 14 (G18119C), 15 (T19052A) 
and 16 (G20144A). It was therefore reasonable to hypothesise that the difference in the in 







Table 6.5: Sequence differences between M41-CK and M41-R. 
 
Notes: The nucleotide position corresponding to M41-CK is highlighted in red and M41-R in 
black. The sections in green highlight coding point mutations.  
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Prior to this PhD project I repaired the coding point mutations in M41-R which generated 
rIBV M41-K (Figure 6.4). Analysis of M41-K in vivo demonstrated a pathogenic phenotype 
confirming the role of the point mutations C12139T, G18119C, T19052A and G20144A in 
attenuation. The generation of neither M41-K nor the in vivo data will be discussed further in 
this chapter. M41-K however will be discussed as part of experiments that aimed to 
characterize M41-R in vitro and its potential to act as a vaccine vector. From this point 
onward, including the data presented in Figure 6.5, all experiments were performed during 




Figure 6.5: Flow chart describing the relationship between M41-CK, M41-R and M41-K, 
and the order in which M41-K and M41-R were generated.   
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6.2.8 M41-R is able to replicate in ex vivo tracheal organ cultures.  
 
The attenuated in vivo phenotype of M41-R, together with the retention of some virulence 
characteristics in comparison to Beau-R, highlighted the possibility of utilising M41-R as a 
vaccine virus. To ensure that M41-R was capable of replicating in trachea tissue, and 
therefore had the potential to induce local immune responses, ex vivo TOCs prepared from 
three week old SPF RIR chickens were infected with either M41-R, M41-K or M41-CK. As 
both isolates of M41-R behaved similarly in vivo, one isolate, M41-R 12, was selected for the 
in vitro experiments. Supernatants were harvested at regular intervals over a 96 h time 
period and assessed for virus progeny (Figure 6.6). Titres of both M41-K and M41-R were 
comparable throughout the duration of the experiment. The titres of both M41-R and M41-K 
were lower in comparison to M41-CK throughout the experiment, with statistical significance 
reached at 48 and 72 h (p<0.005 and p<0.05 respectively).  Despite this, the replication 
pattern of both M41-R and M41-K were similar to the parent virus M41-CK, demonstrating 
that M41-R has the ability to replicate in tracheal tissue and therefore is likely to induce local 
immune responses in vivo. The ability of M41-R to replicate in ex vivo TOCs does however 
raise the question regarding why neither isolate of M41-R was consistently detected in 





Figure 6.6: M41-R is able to replicate in ex vivo TOCs.  Ex vivo TOCs were prepared from 
three week old SPF chickens. TOCs were inoculated in triplicate with 104 PFU of M41-K, 
M41-R or M41-CK. Supernatant was harvested at 24 h intervals and the quantity of 
infectious progeny assessed through titration, in triplicate, in CK cells. Each point plotted 
represents the mean of three independent replicates, with error bars representing SEM. 
Statistical differences at each time point were assessed using a One-Way ANOVA with 
Tukey analysis for multiple comparisons. Statistical differences between M41-CK and M41-R 
are highlighted by ** (p<0.005) and M41-CK and M41-K by * (p<0.05). There were no 
statistical differences between M41-K and M41-R at any time point assessed.  
 
6.2.9 M41-R replication is sensitive to temperature in vitro.  
 
As discussed in chapter 5 rIBV Beau-R is able to establish a productive infection in ex vivo 
TOCs but cannot establish a productive infection in tracheal tissue in vivo when delivered by 
the ocular/nasal route. This is possibly the consequence of the replication of Beau-R being 
sensitive to temperature and in particular, highly restricted at 41°C. To investigate whether 
the replication of rIBV M41-R was also temperature sensitive, which would help inform about 
its suitability as a vaccine vector, CK cells were infected with M41-R, M41-K or M41-CK and 
incubated at either 37°C or 41°C. The quantity of the resulting viral progeny harvested over a 
96 h time period was assessed via titration in CK cells (Figure 6.7 and 6.8). The complete 
dataset generated is displayed in Figures 6.7 and 6.8, and split apart for clarity to allow 




The titres of infectious progeny virus generated by M41-CK and M41-R infection at 37°C 
were comparable from 1 to 96 h (Figure 6.7B) indicating at these time points and 
temperature the replication kinetics of the pathogenic M41-CK and the non-pathogenic M41-
R were similar. The titres of M41-K at 24 and 48 h were lower than M41-CK (p<0.05) and 
also lower than M41-R at 24 h (p<0.0001). Despite the slightly lower titres however the 
replication pattern at 37°C of the pathogenic rIBV M41-K was similar to both the non-






Figure 6.7: Assessment of M41-R replication at 37°C and 41°C. CK cells seeded in 6 well 
plates were inoculated with 105 PFU M41-K, M41-CK or M41-R, and incubated at either 
37°C or 41°C. Supernatant was harvested at 24 h intervals and the quantity of infectious 
progeny was determined via titration in triplicate in CK cells. Each point represents the mean 
of three independent experiments with error bars representing SEM. (A) represents all data 
gathered during the experiment, and (B) displays only the data generated through incubation 
at 37°C and (C) at 41°C. Statistical differences were assessed using a Two-way ANOVA 
stating time and virus as independent factors, followed by a Tukey test for multiple 
comparisons. (B) Statistical differences between M41-CK and M41-K are highlighted by **** 
(p<0.0001) and ** (p<0.005). Differences between M41-R and M41-CK are highlight by * 
(p<0.05). (C) Statistical differences between M41-CK and M41-R are highlighted by **** 
(p<0.0001) and differences between M41-K and M41-R are highlighted by **** (p<0.0001) 




At 41°C differences in the replication kinetics were observed between M41-CK, M41-K and 
M41-R. The replication patterns of M41-K and M41-CK were similar with the titres of 
infectious progeny virus comparable at all time points assessed (Figure 6.7C). In contrast the 
titres of M41-R were lower than both M41-K and M41-CK at 48 to 96 h (p<0.005). At 24 h 
M41-R exhibited lower titres than both M41-K and M41-CK however only the latter reached 
statistical significance (p<0.005). The pattern of replication of M41-R was different to both 
M41-K and M41-CK. Similarly to M41-CK, titres of M41-R peaked at 24 h, albeit at a lower 
level whereas titres of M41-K peaked at 48 h. After the peak titre, both M41-K and M41-CK 
displayed a gradual and steady decline in infectious progeny virus from 24 or 48 to 96 h; 
M41-R on the other hand exhibited a sharp decline between 24 – 48 h. This difference in 
replication kinetics could therefore indicate that the point mutations differentiating M41-CK 
and M41-K from M41-R, nsp 10 (C12139T), 14 (G18119C), 15 (T19052A) and 16 
(G20144A), may have a determining role in the restricted in vitro replication phenotype 
observed at 41°C.  
 
Further analysis of the growth curve data highlights that overall replication at 41°C of both 
M41-K and M41-R produces lower titres of infectious progeny virus than replication at 37°C 
(Figure 6.8B and 6.8D). This was comparable to the parent virus, M41-CK, which also 
generally produces lower quantities of infectious progeny at 41°C (Figure 6.8C); an 
observation also noted in Chapter 5. This pattern of lower titres produced at 41°C compared 
to 37°C is largely comparable between M41-K and M41-CK. There is one interesting 
exception; at 24 hpi the titres produced by M41-K infection at 37°C and 41°C are similar, 
indicating that at this time point replication is either not affected by temperature, or not 




Figure 6.8: Replication kinetics of M41-CK, M41-K and M41-R at 37°C and 41°C. CK 
cells seeded in 6 well plates were inoculated with 105 PFU M41-K, M41-CK or M41-R, and 
incubated at either 37°C or 41°C. Supernatant was harvested at 24 h intervals and the 
quantity of infectious progeny was determined via titration in triplicate in CK cells. Each point 
represents the mean of three independent experiments with error bars representing SEM. 
Graph A represents all data gathered during the experiment, and graph B, C and D only 
displays data generated by M41-R, M41-CK and M41-K respectively. Statistical differences 
were assessed using a Two-way ANOVA stating time and temperature as independent 
factors, followed by a Tukey test for multiple comparisons. Statistical differences at each 
time point are highlighted by ** (p<0.005) and **** (p<0.0001).   
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The difference in the replication patterns of M41-R at 37°C and 41°C is not comparable to 
the replication patterns observed for M41-K or M41-CK. The differences in the amounts of 
infectious progeny produced by M41-R at 37°C and 41°C at 24 hpi are much greater than 
those for M41-CK and M41-K, which do not exhibit a difference (Figure 6.8). The titre, 
(PFU/ml), produced by M41-CK infection at 41°C is lower than the titre observed at 37°C by 
approximately a magnitude of 1.5 – 2 log10, whereas the titre of M41-R is reduced by 3.5 – 4 
log10. The differences exhibited between M41-R infection at 37°C and 41°C become more 
prominent as the infection proceeds with no detectable progeny produced at 72 and 96 h.  
This is in contrast to both M41-CK and M41-K which produced a seemingly steady quantity 
of infectious virus at both incubation temperatures at 48 to 96 hpi. At these time points for 
both viruses the difference in PFU/ml between 37°C and 41°C is approximately 1.5 – 2 log10. 
This growth kinetic experiment therefore demonstrates that the replication of M41-R is 
restricted at 41°C identifying that M41-R replication can be classified as temperature 
sensitive.  
 
6.2.10 Entry of M41-R in vitro is not sensitive to temperature.  
 
To determine whether entry was the prohibitive step to establishing a productive infection at 
41°C, a temperature swap experiment was carried out (Figure 6.9A). CK cells were infected 
with M41-K or M41-R and incubated at either 37°C or 41°C for 1 h allowing for viral 
attachment and entry. After 1 h the virus was removed and the cells washed in PBSa to 
remove any residual virus, after which the cells were incubated at either the same 
temperature or were swapped to be incubated at the other. The resulting supernatant was 
assessed for infectious viable progeny virus (Figure 6.9B and 6.9C).   
 
Titres of M41-K in all treatment groups were comparable to each other (Figure 6.9B) 
indicating that productive replication of M41-K is unaffected by the swap in incubation 
temperatures. This was expected as the replication of M41-K, in terms of the generation of 
infectious viable progeny virus, is not sensitive to temperature at 24 h (Figure 6.8D). In 
contrast, the swap in incubation temperatures did have an effect on the replication of M41-R 
(Figure 6.9C). The titres of M41-R were comparable between those groups in which 
inoculated cells were incubated at a first temperature of 37°C for virus entry and then a 
second temperature of 37°C for viral replication (37-37) and for those that were initially 
incubated at a temperature of 41°C and then incubated at a temperature of 37°C (41-37). 
Similarly titres were comparable between groups in which infected cells were initially 
incubated at 37°C and then incubated at 41°C (37-41), and those incubated at 41°C and 
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then continued at 41°C (41-41).  A difference in the first incubation temperature therefore 
had no effect of the quantity of infectious viable progeny virus produced indicating the 




Figure 6.8: Entry does not restrict replication of M41-R at 41°C. (A) Schematic detailing 
experimental protocol. CK cells seeded in 6 well plates were inoculated in triplicate with 105 
PFU of either M41-K or M41-R. Cells were incubated for 1 h at either 37°C (blue) or 41°C 
(red), after which the viral inoculum was removed and the cells washed to remove any 
unbound virus. Cells were then incubated at either 37°C or 41°C for 23 h. The quantity of 
infectious viral progeny was assessed through titration in triplicate in CK cells.  Graph (B) 
represents data generated from M41-K infection and graph (C), M41-R. Each point 
represents the mean titre of infectious progeny virus generated from one independent 
experimental replicate. Error bars represented the SEM from three independent 
experimental replicates. Statistical differences were assessed using a one-way ANOVA with 
a Tukey test for multiple comparisons. Statistical differences are highlighted by **** 
(p<0.0001).   
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Differences in the titres of M41-R were observed in groups that had different secondary 
incubation temperatures. The titres produced from infections incubated at 37-41 were lower 
than those incubated at 37-37 (p<0.0001), similarly infections at 41-41 produced much lower 
titres than those incubated at 41-37 (p<0.0001). It is therefore the second incubation 
temperature in which the virus was expected to undergo active replication, assembly and 
egress that affects the production of viable progeny viruses and is therefore the determining 
factor. Coronavirus entry is mediated by the S glycoprotein and therefore the results of the 
temperature swap experiment, which tend to rule out entry, also rule out a potential 
determinant role for the S glycoprotein. This in turn further indicates the role of the replicase 
located mutations C12139T, G18119C, T19052A and G20144A in the restricted replication 
phenotype of M41-R observed at 41°C. In addition, the results of the temperature swap 
experiments also indicate the potential to generate rIBVs based on the M41-R genome that 
express heterologous S glycoproteins without affecting the temperature sensitive phenotype; 
this would be an important benefit for the development of M41-R as a vaccine vector.   
 
6.2.11 The replication of M41-R is not comparable to Beau-R at 41°C. 
 
The finding that M41-R was temperature sensitive raised some concerns regarding its 
potential role as a vaccine vector. Whilst it appeared that M41-R could establish a limited 
infection at 41°C, in terms of both time and quantity of infectious viral progeny, there was a 
concern that M41-R may not offer much improvement in terms of in vivo replication 
compared to that of Beau-R. A growth kinetic assay was performed to directly compare 
productive viral replication of both Beau-R and M41-R (Figure 6.10). CK cells were 
inoculated with Beau-R or M41-R and incubated at either 37°C or 41°C. The quantity of 
viable infectious virus progeny over a 48 h time period was assessed. The pathogenic clone, 
M41-K, was also included in the experiment as a positive control to confirm that the CK cells 
incubated at 41°C were capable of supporting a productive infection.  
 
The titres of viable infectious progeny virus were comparable between cells incubated at 
37°C infected for both Beau-R and M41-R at all-time points (Figure 6.10). M41-K infected 
cells produced lower titres of progeny virus in comparison to Beau-R at 24 hpi (p<0.005), but 
titres were comparable at both 1 and 48 hpi. However, at 41°C, at 24 and 48 hpi, titres of 
virus produced from both Beau-R and M41-R infected cells were lower than those observed 
for M41-K (p<0.005). Interestingly, at 41°C, the titres of infectious progeny virus were higher 
from cells infected with M41-R at both 24 and 48 hpi when compared to cells infected with 
Beau-R (p<0.05), indicating that M41-R and Beau-R do not share the same replication 
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phenotype at 41°C. The observation that M41-R is able to produce infectious progeny virus 
at 41°C, unlike Beau-R, alongside the identification that M41-R exhibits an attenuated 
phenotype in vivo supports the development of M41-R as a vaccine vector. In addition, the 
growth kinetic assays (Figure 6.7, 6.8 and 6.10) highlight the possibility that M41-R may be 
able to replicate in vivo for a defined period of time, for up to 48 h.  
 
   
Figure 6.10: Productive M41-R replication is higher than Beau-R replication at 41°C. 
CK cells seeded in 12 well plates were inoculated with 104 PFU Beau-R, M41-R or M41-K 
and incubated at either (A) 37°C or (B) 41°C. Supernatant was harvested at 1, 24, and 48 
hpi and the quantity of infectious progeny virus assessed through titration, in triplicate, in CK 
cells. Error bars represent the SEM of three independent experiments.  Statistical differences 
at each time point were assessed using a one way ANOVA with Tukey analysis for multiple 
comparisons and are highlighted by * (p<0.05) and ** (p<0.005).  
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6.2.12 M41-R as a vaccine vector; the generation of rIBV M41R-4/91(S1) and 
M41R-4/91(S). 
 
To investigate whether M41-R would be a suitable vaccine vector, two rIBVs were designed 
based on the M41-R genome with modifications to the S glycoproteins. The UK field isolate 
4/91 was chosen as the “donor S” strain, primarily due to the previous construction of rIBV 
BeauR-4/91(S) which demonstrated that it was possible to construct a rIBV expressing a 
heterologous 4/91 S glycoprotein. In addition, as discussed in chapters 3 and 4, BeauR-
4/91(S) can, under experimental conditions, induce a protective immune response against 
homologous 4/91 challenge in vivo (Armesto et al., 2011). This response is not as robust as 
was expected with a protection level, as defined by ciliary activity, of 65%; comparable to the 
protection induced by BeauR-M41(S) (Hodgson et al., 2004; Ellis et al., 2018). Similar to 
BeauR-M41(S) it is theorised that the protection level would be improved if the 4/91(S) was 
expressed in a less attenuated IBV vector, that is not based on the Beaudette genome.   
 
One of the rIBVs designed as a potential vaccine candidate based on the M41-R genome 
was M41R-4/91(S), containing the ectodomain of the S glycoprotein from the virulent IBV 
field strain 4/91 (UK). Similarly to BeauR-4/91(S) the S glycoprotein signal sequence and 
cytoplasmic tail are derived from the vector backbone sequence, in this case M41-R, with the 
rest of the S glycoprotein from 4/91 (UK). The generation of rIBV M41R-4/91(S) would allow 
a direct comparison to BeauR-4/91(S) in an in vivo homologous vaccine challenge 
experiment thereby answering the question of whether protection levels are improved 
utilising a less attenuated IBV vector for antigen delivery. The second rIBV designed and 
based on the M41-R genome was M41R-4/91(S1); this contains a chimeric S gene with the 
sequence of the S1 subunit derived from the UK field strain 4/91, and the remainder of the S 
gene from M41-R. Whilst results presented in Chapter 3 indicated that a homologous S1 and 
S2 glycoprotein was required for the induction of a robust protective immune response using 
Beau-R as the vector backbone, it was theorised that a heterologous S1 subunit alone could 
be used for protection if delivered by a less attenuated IBV vector backbone. Therefore, rIBV 
M41R-4/91(S1) would be included in the same homologous in vivo vaccine challenge 
experiment as both rIBV M41R-4/91(S) and rIBV BeauR-4/91(S). This would allow the 
investigation to determine whether the S1 subunit is sufficient to induce a protective immune 
response when expressed in a less attenuated IBV vector, or whether a spike glycoprotein 




6.2.12.1 Generation of recombinant vaccinia viruses.  
 
The first stage to making a rIBV is to construct an rVV containing a full-length cDNA copy of 
the IBV genome containing the desired modification (Keep et al., 2015). The process of 
constructing an rVV is described in Chapter 2, and will not be discussed in detail here.  
 
Briefly, to construct a rVV containing the M41R-4/91(S1) genome sequence, the rVV M41-R  
containing the full-length genome sequence of M41-R was used in the reverse genetic 
system alongside plasmid pGPT-M41-4/91(S1) (see appendix for sequence of the insert, 
Figure 8.1). This generated four isolates of rVV M41R-4/91(S1) as well as generating several 
rVVs with varying chimeric 4/91/M41 S1 subunits. The rVVs containing chimeric S1 
sequences were not fully investigated as part of this PhD project. Similarly, four isolates of 
M41R-4/91(S) were generated using the reverse genetic system utilising rVV M41R-del-S, 
which encodes the M41-R genome but with the S gene deleted, alongside the plasmid 
pGPT-M41R-4/91(S) (see appendix for sequence of the insert, Figure 8.2). This was a more 
targeted approach than that used for the construction of M41R-4/91(S1) as chimeric 
sequences were not desired. In all the rVV isolates generated, eight in total, the presence of 
correct S gene sequence in the correct position was confirmed by Sanger sequence 
analysis.  
 
6.2.12.2 The recovery of infectious rIBV 
 
The four isolates of rVV M41R-4/91(S1) and four isolates of rVV M41R-4/91(S) were taken 
forward for the recovery of infectious rIBV in CK cells. The detailed method used for the 
recovery process is described in Chapter 2. Despite several attempts none of the four 
isolates of rVV M41R-4/91(S1) generated infectious rIBV M41R-4/91(S1), which could 
indicate the 4/91 S1 subunit is not compatible with an M41 S2 subunit. Similarly, the four 
isolates of rVV M41R-4/91(S) also failed to generate rIBV, which could indicate an overall 
incompatibility of the 4/91 S glycoprotein with an M41-R vector, although I personally think 






The results of the in vivo vaccine-challenge experiments presented in Chapter 3 and 4 
indicated that rIBV Beau-R may not be an ideal vaccine vector. The identification in Chapter 
5 that the replication of Beau-R is temperature sensitive, and is highly restricted at 41°C, the 
core body temperature of a chicken, further supported the idea that a new vaccine vector 
should be considered. This chapter details results indicating that rIBV M41-R is a possible 
and more suitable alternative to Beau-R as a vaccine vector.   
 
The in vivo pathogenicity experiment confirmed that similar to Beau-R, in vivo infection with 
M41-R does not induce IB related clinical signs (Figure 6.2). Also, similarly to Beau-R, 
infection with M41-R does not reduce tracheal ciliary activity at 4 or 7 dpi (Figure 6.3). This is 
in contrast to the pathogenic IBV M41-CK in which infection did result in IB-related clinical 
signs and a reduction in ciliary activity at 4, 6 and 7 dpi (Figure 6.2 and 6.3). It is unclear at 
this stage whether the reduced ciliary activity observed at 6 dpi in the M41-R infected groups 
is a true representation of an M41-R infection. In the groups infected with M41-R 6 and M41-
R 12, one bird in each group exhibited less than 50% ciliary activity at 6 dpi. Interestingly 
both these birds were negative for IBV RNA in the trachea, and no infectious progeny virus 
could be re-isolated. All birds infected with M41-CK exhibited a 100% reduction in ciliary 
activity on both 4 and 6 dpi, and on 4 dpi were positive for IBV RNA and for presence of 
infectious progeny virus. A larger sample size is required to establish whether it is a pattern 
with M41-R infection that one third of birds will exhibit a reduction in tracheal ciliary activity at 
6 dpi or whether these birds discussed above could be classified as outliers, and another 
factor in these individual birds played a role in the reduced ciliary activity observed. Overall, 
the lack of IB related clinical signs alongside the retention of ciliary activity comparable to 
both mock and Beau-R infected birds at 4 dpi demonstrated that M41-R displays an 
attenuated phenotype in vivo when compared to the parental M41-CK virus.  
 
A comparison of the dataset generated from sequencing the M41-R full genome within the 
vaccinia virus vector with the dataset of the M41-CK genome generated by high throughput 
sequencing methods, identified four coding mutations as well as a number of non-coding 
mutations within the replicase gene (Table 6.5). The coding mutations that differentiate M41-
R from the pathogenic parent M41-CK are C12139T (nsp 10), G18119C (nsp 14), T19052A 
(nsp 15) and G20144A (nsp 16). The replicase gene has previously been reported as a 
pathogenic determinant of IBV (Armesto et al., 2009, Ammayappan et al., 2009, Huo et al., 
2016). In addition, there have been several publications that have linked nsp 10, 14, 15 and 
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16 to pathogenicity in other coronaviruses including SARS-CoV and MHV (Zust et al., 2011; 
Menachery et al., 2014; Deng et al., 2017; Kindler et al., 2017; Graham et al., 2012; Sperry 
et al., 2005). 
 
The point mutations located in nsp 15, T19052A, and 16, G20144A, have resulted in 
conservative amino acid changes within the respective proteins, Leu183Ile and Val209Ile. In 
both cases, a non-polar amino acid has been replaced by another non-polar amino acid 
likely reducing the possibility of the mutations having induced major conformational changes 
to the respective protein structure. In addition, the amino acid changes are also found 
amongst other coronaviruses; amino acid residue 209 in nsp 16 is also an Ile in TCoV, 
SARS-CoV, MHV and HKU1 and amino acid residue 183 in nsp 15 is also an Ile in HKU1 
and MHV (Appendix, Figure 8.8). Furthermore the mutation in nsp 15, Leu183Ile is not within 
the proposed NendU core domain (Deng and Baker, 2018). Similarly, the mutation in nsp 16, 
Val209Ile is not part of the essential KDKE motif required for 2’O-methyltransferase activity, 
and it is not one of the residues reported to be essential for effective interaction with the 
stimulatory co-factor, nsp 10 (Chen et al., 2011, Decroly et al., 2011; Lugari et al., 2010). It 
therefore seems unlikely that the point mutations in nsp 15 and 16 have played a major 
contributory role in the attenuated phenotype observed during M41-R in vivo infection. 
 
Quick inspection suggests the point mutation in nsp 10 (C12139T) has also resulted in 
conservative amino acid change, both non-polar to non-polar. However, in nsp 10 the point 
mutation has resulted in a change at residue 85 from Pro to Leu; the structure of the two 
amino acids is quite different as proline contains a cyclic structure raising the possibility that 
the mutation has resulted in conformational changes. In addition, unlike the nsp 15 and 16 
mutations, the Pro85Leu mutation has occurred at a highly conserved residue (Appendix, 
Figure 8.10). Furthermore nsp 10 consists of two zinc fingers that are co-ordinated by a 
number of Cys and His residues (Joseph et al., 2006), one of which is located at residue 84, 
neighbouring the Pro85Leu mutation. It is also interesting that an Ala substitution at position 
82 in MHV, equivalent to residue 83 in IBV, was lethal in that no viable virus could be 
recovered (Donaldson et al., 2007). Alanine mutagenesis studies utilising SARS-CoV have 
also identified several residues near to the Pro85Leu mutation that have reduced the binding 
of nsp 10 to 14 (Bouvet et al., 2014). Further work is therefore required to establish whether 
this mutation has played a major role the attenuated in vivo phenotype of M41-R, and if so, 




The mutation in nsp 14 is also a conservative change, Val to Leu at residue 393. Similar to 
the nsp 10 mutation, Val393Leu has occurred at a position conserved amongst other 
coronaviruses, and in addition has occurred in a conserved area (Appendix, Figure 8.11). 
Nsp 14 is a bifunctional enzyme with both ExoN activity (Minskaia et al., 2006, Ma et al., 
2015) and N7-MTase activity (Chen et al., 2009; Ma et al., 2015). The mutation Val393Leu 
has occurred within the N7-MTase domain (Appendix, Figure 8.11), however it is not one of 
the critical residues for catalytic activity or for methyl donor substrate binding (Chen et al., 
2013; Jin et al., 2013). It is also not within the nsp 10 binding area which is located in the 
ExoN I domain (Ma et al., 2015). The residue is however located amongst a number of 
residues that have been identified to support the methyl donor substrate binding pocket 
(Chen et al., 2013). In addition, residue Phe401 has been identified as being involved in 
purine binding in SARS-CoV (Ma et al., 2015); the equivalent residue in IBV is Tyr396, 
located only three amino acids from the Val393Leu mutation. It is therefore plausible that the 
Val393Leu mutation has affected N7-MTase capping activity which in turn due to the 
presence of uncapped RNA molecules may affect the ability of the virus to evade host RNA 
sensors in vivo (Zust et al., 2011), and/or have effects on RNA degradation and viral 
translation, both of which could result in lower viral load and consequently less disease 
burden (reviewed by Savajol et al., 2014). 
 
The mutations in both nsp 10 and nsp 14 are of interest, and it is possible an interaction 
between the two also plays a role in the attenuated in vivo phenotype of M41-R. Whilst nsp 
10 has not been demonstrated to be a stimulatory factor to the nsp 14 N7-MTase activities 
(Bouvet et al., 2010), it does bind to the EXoN domain which is theorised to result in a 
stabilisation effect (Ma et al., 2015). The two domains of nsp 14 do not exist independently 
and a number of residues are involved (Ma et al., 2015); it therefore seems reasonable to 
hypothesise that nsp 10 binding stabilises the entire nsp 14 protein structure. Further 
research is required to identify the effect that all the mutations present in M41-R are having, 
including whether nsp 10 can efficiently bind to nsp 14, and also whether the N7-MTase 
activity of nsp 14 has been detrimentally affected. One important point to note is that the 
addition of a cap-1 structure to viral mRNA is a sequential process (Bouvet et al., 2010; Ma 
et al., 2015), with nsp 14 N7-MTase activity preceding nsp 16 2’O-methyltransferase capping 
activity (Chapter 1, Figure 1.6). It therefore remains a possibility that the attenuation of M41-
R is the result of the collaborative effect of mutations in nsp 10, 14 and 16.  
 
Despite the unknown molecular mechanism, the attenuated in vivo phenotype observed 
highlighted that M41-R had the potential to act as a vaccine vector. The in vivo dissemination 
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pattern in trachea and HG harvested from M41-R infected birds was compared to Beau-R 
infected and M41-CK infected birds. Whilst M41-CK could consistently be detected in 
harvested tracheal tissue at all time points assessed, similarly to Beau-R, M41-R could not 
(Table 6.2 and 6.3). Whilst this is a concern for IBV vaccine vectors as they need to induce 
robust local immune responses (reviewed by Bijlenga et al., 2004), it must be noted that it is 
possible M41-R can replicate in the trachea earlier in infection, particularly as growth kinetic 
assays in ex vivo TOCs (Figure 6.6) highlight that M41-R can replicate in tracheal tissue. 
Future studies should assess earlier time points during in vivo infection, including at both 1 
and 2 dpi and should additionally include assessment of nasal turbinates, eyelids and lung 
tissue.  A kinetic study in ex vivo TOCs using a lower PFU should also be carried out as it is 
possible that M41-R may not be able to initiate and sustain a productive infection at lower 
titre than the 104 PFU used to generate the data in Figure 6.6. In the bird, infectious virus will 
be caught in mucous produced in the trachea, making it very unlikely that tracheal tissue is 
infected with large quantities of virus.  
 
In HGs examined at 4 dpi, both M41-R and M41-CK derived RNA could be detected 
whereas Beau-R was not (Table 6.2). Interestingly, also at 4 dpi, infectious Beau-R could be 
re-isolated from the HG of one bird whereas HGs extracted from M41-R infected birds 
yielded no infectious virus (Figure 6.4). All three HGs extracted at 4 dpi from the M41-CK 
infected birds yielded infectious virus, yet only two were positive for IBV derived RNA (Table 
6.2, Figure 6.4). It must be noted that whilst both HGs from each sampled bird were 
harvested, one was taken forward for RNA extraction and subsequent qRT-PCR analysis 
and the other for viral isolation. Discrepancies between the qRT-PCR and the viral isolation 
data may be a reflection of this process as it is possible that the virus replication was 
localised to one HG only. The same phenomenon is seen in trachea harvested from one bird 
infected with M41-R 12 at 4 dpi; no IBV RNA was detected, but infectious virus was 
recovered. This discrepancy may again be the reflection of the process of using one section 
of trachea for RNA extraction and one for virus isolation. It could also however be a reflection 
of the sensitivity of the two techniques. Virus isolation is a very sensitive method, and is 
considered the “gold standard” technique at determining viral presence (reviewed by de Wit 
and Cook 2014) however qRT-PCR is thought to be up to one hundred times more sensitive 
(Jackwood et al., 2012) although can give false negatives if the samples contain substances 
that inhibit the reaction (Jackwood et al., 1997). One final possibility for the discrepancies is 
contamination of samples, however this seem extremely unlikely as all the relevant negative 
controls, as well samples harvested from the mock infected birds, are all identified as 
negative for IBV RNA by qRT-PCR and infectious IBV by virus isolation.  
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IBV specific humoral immune responses have been identified in HGs extracted from 
experimentally infected SPF chickens (van Ginkel et al., 2008). The detection of M41-R 
derived RNA in HGs supports the development of M41-R as a vaccine vector as this finding 
highlights the possibility that this rIBV can induce local responses in immune active tissues. 
It remains to be determined how efficiently M41-R is replicating in the HG, and the dynamics 
of replication from 1 to 7 dpi. This in vivo experiment was completed before the start of this 
PhD project and not with the objective of using M41-R as a vaccine vector; as such the 
optimal time points for antigen delivery were not necessarily included. Further research is 
required to establish the in vivo dissemination pattern of M41-R through early infection to the 
point of viral clearance in the trachea and HG as well as in a variety of tissues not harvested 
during this experiment. It is likely given the results of the Beau-R/M41-CK pathogenicity 
study presented in Chapter 5 in which Beau-R was re-isolated from nasal tissue harvested 1 
and 4 dpi, that M41-R would also be detected in this tissue at these time points. It will also 
be important to identify if M41-R can spread from infected birds to naïve birds thus indicating 
how an M41-R vaccine virus may disseminate through a poultry flock, and if there is a risk of 
recombination with either field or other vaccine isolates.   
 
The data gathered from the in vivo experiment identified that M41-R exhibited an attenuated 
phenotype which subsequently highlighted the potential for M41-R to act as a vaccine vector. 
Further investigation demonstrated that like M41-CK and the pathogenic clone, M41-K, M41-
R has the ability to productively replicate in ex vivo TOCs and therefore in tracheal tissue 
(Figure 6.6). In vitro assays however identified that M41-R replication is temperature 
sensitive and is limited in terms of both time and quantity of infectious viral progeny 
production at 41°C (Figure 6.7 and 6.8). In comparison to both M41-K and M41-CK, peak 
titres of M41-R are reduced and the period of productive replication is much shorter, with no 
M41-R detected at 96 h (4 dpi). It is plausible that this temperature sensitivity accounts for 
the lack of M41-R detected in tracheal tissue harvested during the in vivo experiment. If 
M41-R did establish an infection in the trachea, it is likely that the productive infection had 
run its course before the first time point, at 4 dpi, when trachea was harvested from infected 
birds. Whilst the temperature sensitive phenotype identified in this chapter may initially 
appear to be a disadvantage in terms of using M41-R as a vaccine, it may actually provide 
several benefits which will be discussed later in this section.   
 
The restricted replication of M41-R at 41°C is likely to be the result of one or more or some 
combination of the four coding mutations that differentiate M41-R from M41-CK and M41-K; 
C12139T (nsp 10), G18119C (nsp 14), T19052A (nsp 15) and G20144A (nsp 16). The role 
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of the non-coding mutations at this stage cannot be completely ruled out, as there may be 
potential functions in the maintenance of secondary RNA structure and the regulation of viral 
transcription. As discussed the proteins in which the coding mutations are present, nsp 10, 
14, 15 and 16, have several roles in the virus life cycle including capping of the viral RNA 
and proofreading. It cannot be stated with certainty that the same mechanism by which M41-
R has been attenuated by these point mutations is also the same mechanism which has 
resulted in a temperature sensitive phenotype or vice versa. Temperature sensitivity and the 
replication of IBV as well as other coronaviruses, has been discussed in detail in Chapter 5. 
With regards to M41-R further research is required to assess the function of the relevant 
nsps at both 37°C and 41°C, and also whether interactions between the nsps is affected at 
the different temperatures. It is interesting to note that temperature sensitive MHV mutants 
have been identified with mutations in Gln65Glu in nsp 10, Cys376Tyr and Cys408Arg in nsp 
14 and Pro12Ser and Leu153Pro in nsp 16 (Sawicki et al., 2005). Expression in yeast of 
SARS-CoV derived nsp 14 containing mutations equivalent to the MHV mutations 
Cys376Tyr and Cys408Arg, also led to a temperature sensitive phenotype, with the authors 
indicating that the higher temperatures had destabilised the structure of the N7-MTase 
domain (Chen et al., 2013). There is precedent therefore for nsp 10, 14 and 16 to have a role 
in temperature sensitivity of viral replication. 
 
The identification that M41-R replication was temperature sensitive raised concerns that 
M41-R may not offer much improvement over Beau-R as a vaccine vector. It has been 
theorised that the inability of the Beau-R based vaccine virus, BeauR-M41(S), to induce a 
fully protective immune response against homologous challenge is due to the inability of the 
vaccine virus to establish a sufficiently prolonged infection in vivo, which is the result of 
replication being temperature sensitive and highly restricted at 41°C; this has been 
discussed in more detail in Chapter 5. Growth kinetic assays, however highlighted that 
whereas Beau-R cannot establish a productive infection at 41°C, M41-R can, albeit limited 
(Figure 6.7 and 6.10) therefore suggesting that M41-R will not exhibit that same restrictions 
as Beau-R in delivering antigen in vivo. Recent research has in fact demonstrated that birds 
inoculated with M41-R are protected against homolgous M41-CK challenge to standards set 
the by European Pharmacopoeia (2010; unpublished date), indicating therefore that M41-R 
can deliver sufficient antigen in vivo. Further more, research has demonstrated successful in 
ovo vaccination that also offers homologous protection (unpublished data). The limited 
replication kinetics observed at higher temperatures may actually therefore be advantageous 
for continued vaccine development as it suggests that it may be possible that M41-R based 
vaccines could replicate in vivo for a small period of time, and in a restricted number of 
tissues. The growth curve data presented in this chapter indicate that replication of the M41-
R vaccine viruses would likely diminish over a 72 h period thus limiting spread to naïve birds, 
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limting vaccine re-infection, reducing the window of possibility for recombination with other 
IBV strains, and also reducing opournunities for potential reversion to virulence. In addition, 
temperature swap assays indicated that the restricted in vitro replication phenotype at 41°C 
is not the result of temperature prohibiting viral entry (Figure 6.8). This relates to findings in 
Chapter 5, and advantagously enables the modification of the S glycoprotein without 
impacting replication at 41°C.  
 
To further investigate M41-R as a vaccine vector, two rIBVs were designed; one expressing 
a chimeric 4/91(S1)/M41(S2) glycoprotein and the second expressing the 4/91 S 
ectodomain. Unfortunately, neither rIBV M41R-4/91(S1) nor rIBV M41R-4/91(S) could be 
successfully recovered from the respective rVV vectors in the time frame available during 
this PhD project. The latter was unexpected as rIBV BeauR-4/91(S) has previously been 
successfully rescued (Armesto et al., 2011) and was found to replicate well in ex vivo TOCS. 
It is possible that the M41-R background cannot support expression of heterologous genes, 
however, this seem unlikely considering it has been possible to generate an rIBV M41-R 
expressing a H120(S1)/Beau-R(S2) glycoprotein (Keep, 2013) and a rIBV M41-R expressing 
the Beau-R S glycoprotein (Stevenson-Leggett, unpublished data). It has also been possible 
to generate M41-K expressing the 4/91(S) (Stevenson-Leggett,  2018), however it must be 
noted that this virus was rescued after multiple failed attempts. It seems likely that the failure 
of M41R-4/91(S) to be successfully recovered from the rVV vector is simply the result of the 
low probabilities of rescuing rIBV in CK cells (Chapter 2, Figure 2.10). Despite the many 
successful recoveries of rIBV by our group (Casais  et al., 2001; Casais et al., 2003; Casais 
et al., 2005; Hodgson et al., 2006; Armesto et al., 2009; Armesto et al., 2011; Bentley et al., 
2013; Bentley et al., 2013B; Bickerton et al., 2018; Bickerton et al., 2018B; Keep et al., 
2018), the rescue of rIBV is always considered a low probability event, as the process 
involves infecting primary CK cells, and then transfecting the same cells with both rVV DNA 
and a plasmid expressing the N protein. CK cells are a mixed population and not all the cells 
in the dish will support IBV replication. There will also be many cells in the dish which are 
either transfected or infected, and some neither. In addition CK cells, being a primary cell 
line, are not easily transfected, and in my experience transfection efficiency is generally 
lower in cells previously infected. Typically each rescue involves replicates of ten in an effort 
to increase the probability of a successful rescue. 
 
The probability of successfully recovering rIBV from the respective rVV vector is further 
compounded when the rIBV is not able to be propagated in CK cells. The S glycoprotein is a 
determinant of tropism (Casais et al., 2003), and rIBVs take on the tropism of the donor S 
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strain (Casais et al., 2003; Armesto et al., 2011; Bickerton et al., 2018). The 4/91 strain of 
IBV is unable to be propagated in CK cells, and as such neither is BeauR-4/91(S) or M41K-
4/91(S), and nor will M41R-4/91(S). In the rescue process, S mediated entry is not a 
restriction as the rVV DNA encoding the IBV genome of interest is transfected into the cell. 
Progeny rIBV expressing the 4/91 S glycoprotein however, will not be able to exit the cells so 
infected/transfected cells are lysed through freeze-thaw and titration. This treatment as well 
as lysing the cells can damage the small quantities of rIBV that may be present, thereby 
reducing the overall probability of a successful rescue attempt. Future work will continue to 
attempt to successfully recover M41R-4/91(S) from its rVV vector.  
The failure of M41R-4/91(S1) to be recovered from the corresponding rVV vector may also 
be the result of the issue above, or may be the result of an incompatibility of the 4/91(S1) 
with a M41 S2 subunit. Although rIBVs have been successfully rescued containing chimeric 
S glycoproteins, the S2 subunit has always been derived from Beau-R (Bickerton et al., 
2018; Bickerton et al., 2018b, Keep, 2013). The S2 subunit from Beau-R is unusual as it 
contains a second cleavage site and confers Beaudette’s unique ability to replicate in Vero 
cells (Bickerton et al., 2018) and may also confer the ability to replicate in CK cells (Bickerton 
et al., 2018b). It therefore may be the case that it is not possible to generate chimeric S 
glycoproteins containing the M41 S2 subunit. As discussed in Chapter 3 and Chapter 4 is 
possible there are conformational changes in a chimeric S1/S2 glycoprotein in comparison to 
the WT counterpart. It is subsequently possible that the functions of the M41 S2 subunit may 
be more sensitive to such conformational changes than the Beau-R S2 subunit, thereby 
restricting the ability of any rIBV to productively replicate. However, before any further 
research investigating this possibility is undertaken, further attempts at recovering M41R-
4/91(S1) from its vaccinia vector should be carried out. 
 
Whilst there are several other alternative reverse genetic technologies as discussed in 
Chapter 1, the M41R-491(S) and M41R-4/91(S1) cDNA is already assembled; it is the 
recovery stage that is posing the problem. It is possible during the TDS process even with 
the proofreading capability of the vaccinia virus vector that errors have been introduced into 
the IBV cDNA which are preventing rescue; sequencing the full IBV genome would enable 
any mutations to be identified. One option for the recovery of rIBV that could be investigated 
would be to perform in vitro transcription on the rVV DNA containing M41R-4/91(S) and 
M41R-4/91(S1) which then could then be transfected into CK cells (Thiel et al., 2001). This 
may increase the possibility of a successful rescue as it circumvents the need to successfully 




In summary, despite the inability to rescue rIBV M41-R expressing modified spike 
glycoproteins, the data presented in this chapter supports the continual development of M41-
R as a vaccine vector. Mutations in nsp 10, 14, 15 and 16 have resulted in an attenuated 
phenotype in vivo indicating the role of these nsps as pathogenicity factors. The same 
mutations have also resulted in a restricted replication phenotype at 41°C.  Notably this 
replication phenotype offers improvement when compared to the highly restricted replication 
of Beau-R at 41°C and may in fact offer benefits for vaccine development in terms of limiting 
vaccine dissemination within the bird, as well as from one bird to another. Further research is 
required to investigate the role of each of the mutations and each of the nsps in both 
pathogenicity and temperature sensitivity and to establish whether there is a direct link 




Chapter 7: Final discussion.  
 
The overall aim of this PhD project was to evaluate the protection offered by live attenuated 
vaccine candidates that had been rationally designed and generated through reverse 
genetics. All the vaccine candidates assessed through in vivo vaccine challenge studies 
were based on the attenuated rIBV Beau-R and expressed either a heterologous S 
glycoprotein or a heterologous S1 or S2 subunit, and consequently therefore a chimeric S 
glycoprotein.  Protection was assessed in vivo and was defined by the standards set by the 
European Pharmacopeia (2010). According to these standards none of the vaccine 
candidates offered full protection against a virulent IBV challenge. Partial protection at ~65% 
was however observed with rIBV Beau-R expressing a heterologous S glycoprotein derived 
from the pathogenic M41-CK strain, BeauR-M41(S), against homologous challenge; this 
result has been published by Ellis et al., (2018). The demonstration that the S glycoprotein 
expressed in a rIBV vector can induce a partially protective immune response confirms 
previous findings by Hodgson et al., (2004) and Armesto et al., (2011).   
 
The inability of rIBV expressing heterologous S1 subunits to protect against homolgous 
challenge was an unexpected result as previous literature had indicated that the 
immunodominant S1 subunit alone could induce protective immunity (Song et al., 1998; 
Johnson et al., 2003; Yan et al., 2013; Toro et al., 2014). On closer inspection of this 
literature however it is difficult to compare previous in vivo studies with those detailed in this 
PhD thesis due to technical and methodical differences including age and breed of bird, 
route of vaccination and sampling points post challenge. The inability of the vaccine 
candidates to offer complete protection has raised questions regarding the possible mis-
folding of a chimeric S glycoprotein in comparison to WT and the presence of important 
protective epitopes in S2 subunit. These are questions that are important to answer and are 
questions that have also been raised by Eldemery et al., (2017) and Shirvani et al., (2018). 
Future research should therefore investigate whether neutralising epitopes presented by a 
chimeric S glycoprotein are comparable to WT. Neutralisation assays utilising monoclonal 
antibodies or polyclonal sera against a panel of rIBVs expressing heterologous S1 or S2 
subunits would provide an indication as to whether conformational neutralising epitopes have 
been altered.  
 
The protection induced by rIBVs expressing heterologous S glycoproteins, rIBV BeauR-
M41(S) and BeauR-4/91(S), against a heterologous QX challenge was also assessed. Birds 
received either the same primary and secondary vaccination or a different secondary 
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vaccination to the primary. None of the combinations offered full protection against the QX 
challenge which was unexpected as groups have reported success in using 4/91 and M41 
based vaccines against a QX challenge (Terregino et al., 2008; Awad et al., 2016, de Wit et 
al., (2011). One notable difference is that rIBVs used in this thesis are only expressing the 
4/91 and M41 S glycoproteins and not any of the other structural proteins. The inability of the 
vaccine candidates to offer protection against loss of ciliary activity after a QX challenge as 
well as the incomplete protection against homologous challenge raised a question regarding 
the potential role of the other structural proteins in the induction of a completely protective 
immune response. It will be important to assess in the future if a rIBV expressing both a 
heterologous S and N protein for example gives improved protection in comparison to a rIBV 
expressing a heterologous S glycoprotein alone. An interesting rIBV to assess in a vaccine-
challenge experiment would be BeauR-Rep-M41-Struct generated by Armesto et al., (2009).  
This rIBV contains the replicase gene from Beau-R and the structural and accessory genes 
from M41-CK.  
 
One other question that this thesis has raised is the level of in vivo replication required for a 
live attenuated vaccine candidate to induce a fully protective immune response. Investigation 
of the rIBVs expressing heterologous S glycoproteins and rIBVs expressing chimeric S 
glycoproteins in vitro have indicated that the modifications have not impacted productive viral 
replication, however replication was not detected in vivo in tissues harvested pv. The in vitro 
research was completed in primary CK cells but should be repeated in ex vivo TOCs, a more 
biologically relevant tissue. It is possible that rIBVs expressing chimeric S glycoproteins 
cannot bind to tracheal tissue as effectively as a WT glycoprotein due to possible 
conformational changes.  The research investigating in vitro replication of the vaccine 
candidates in Chapter 3 was completed at 37°C, however it has been demonstrated in 
Chapter 5 that productive replication of the Beau-R backbone is temperature sensitive and is 
highly restricted at 41°C, the core body temperature of a chicken.  Further research identified 
the replicase gene as the likely restricting factor. Whether replication is highly restricted at 
38°C or 39°C, a temperature more relatable to the respiratory tract, remains to be 
determined. It is however likely that temperature sensitivity does play a role in the restricted 
replication of the vaccine candidates in vivo.  
 
Temperature sensitivity has been used in vaccine development for several other viruses 
including influenza (Jin et al., 2003; Juhasz et al., 1999). Whilst this thesis has identified that 
productive replication of Beau-R is temperature sensitive, it has not determined the 
mechanism. There are a number of possibilities including RNA synthesis, protein production, 
viral assembly and cellular responses, all of which will require further investigation.  Western 
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blots and confocal microscopy could be used to assess viral protein production and Northern 
blot to assess sgmRNA synthesis. Reverse genetics could be utilised to look at the role of 
individual nsps or combinations of nsps or the role of the 3’ and 5’ UTR that may have 
resulted in the temperature sensitive replication phenotype of Beau-R.  Although it does 
appear that temperature sensitivity is not a shared characteristic of attenuated strains it is 
important to identify mechanisms of temperature sensitivity as this may be beneficial to the 
design of rationally attenuated rIBVs that could be used as vaccine candidates. Future work 
should also assess whether the ability to replicate at higher temperatures is a shared 
characteristic of pathogenic strains and particularly those that are classified as 
nephropathogenic. It is possible that temperature is a factor that effects viral dissemination 
through the host enabling virulent isolates to sustain replication in secondary sites of 
infection including the lungs, kidneys and oviducts.  
 
Finally the research detailed in this thesis identifies a potential alternative rIBV for the design 
of rationally designed vaccine candidates. This backbone, rIBV M41-R, is a molecular clone 
of the pathogenic lab strain M41-CK that has been attenuated by four point mutations in the 
replicase gene. These point mutations, located in nsp 10, 14, 15 and 16, have also imparted 
a replication temperature sensitive phenotype. Whether temperature sensitivity is a direct 
cause of the attenuated in vivo phenotype is not known, and it is possible the mechanism of 
attenuation and temperature sensitivity are unrelated. Further research should investigate 
the role of nsp 10, 14, 15 and 16 in both attenuation and temperature sensitivity. However, 
regardless of the mechnism, recent research has demonstrated that M41-R can be used as 
an in ovo and in vivo vaccine against homologous challenge with M41-CK (unpublished 
research). This is of significant interest to poultry industries as in ovo vaccination in particular 
offers an effective means of vaccination that is highly controlled with every embroyo 
receiving the correct dose. Not only does this mean that the chicks are protected from the 
point of hatch, it is also advantageous over spray and drinking water administered vaccines 
where it is impossible to know that every chick has received the correct vaccine dosage. 
Additionally, the temperature sensitive replication phenotype of M41-R offers a number of 
possible advantages offer current live attenuated vaccines such as H120, including limited 
replication in vivo, restricted dissemination through the host and limited oppurnunity to 
spread to naiive chicks, and potentially more limited opportunities to revert to a pathogenic 
phenotype. Further research should therefore also continue to assess M41-R as a vaccine 
virus, as well as the ability to modify the M41-R genome, particularly the ability to generate 




In summary this thesis has provided research that will impact the design of the next 
generation of rationally designed rationally attenuated rIBVs be used as live attenuated 
vaccine candidates. This thesis has also raised questions that provide avenues for future 
research in both vaccine development and molecular virology, not only for IBV but also for 














































Figure 8.1: Nucleotide sequence cloned into pGPT-Neb-193 generating pGPT-4/91(S1).  
Sequence encoding Sal I restriction sites are underlined. Red indicates M41-CK derived nsp 





































































Figure 8.2: Nucleotide sequence cloned into pGPT-Neb-193 generating pGPT-4/91(S).  
Sequence encoding Sal I restriction sites are underlined. Red indicates M41-CK derived nsp 




Beau      MLVTPLLLVTLLCALCSAVLYDS-SSYVYYYQSAFRPPSGWHLQGGAYAV 49    
M41       MLVTPLLLVTLLCVLCSAALYDS-SSYVYYYQSAFRPPNGWHLHGGAYAV 49    
4/91(UK)  MLGKPLLLVTLWYALCSALLYDK-NTYVYYYQSAFRPGQGWHLHGGAYAV 49    
QX        MLVKSLFLVTILCALCSANLFDSDNNYVYYYQSAFRPPNGWHLQGGAYAV 50    
 
Beau      VNISSEFNNAGSSSGCTVGIIHGGRVVNASSIAMTAPSSGMAWSSSQFCT 99    
M41       VNISSESNNAGSSPGCIVGTIHGGRVVNASSIAMTAPSSGMAWSSSQFCT 99    
4/91(UK)  DKVFNGTNNAVSVSDCTAGTFYESYNISAASVAMTVPPAGMSWSVSQFCT 99    
QX        VNSTNYTNNAGSAHECTVGVIKDVYNQSVASIAMTAPLQGMAWSKSQFCS 100   
 
Beau      AHCNFSDTTVFVTHCYKHGG--CPLTGMLQQNLIRVSAMKNGQLFYNLTV 147   
M41       AHCNFSDTTVFVTHCYKYDG--CPITGMLQKNFLRVSAMKNGQLFYNLTV 147   
4/91(UK)  AHCNFSDFTVFVTHCFKSQQGSCPLTGMIPQNHIRISAMRSGFLFYNLTV 149   
QX        AHCNFSEITVFVTHCYSSGSGSCPITGMIPRDHIRISAMKNGSLFYNLTV 150   
 
Beau      SVAKYPTFRSFQCVNNLTSVYLNGDLVYTSNETIDVTSAGVYFKAGGPIT 197   
M41       SVAKYPTFKSFQCVNNLTSVYLNGDLVYTSNETTDVTSAGVYFKAGGPIT 197   
4/91(UK)  SVSKYPKFKSLQCVGNSTSVYLNGDLVFTSNETTHVTGAGVYFKSGGPVT 199   
QX        SVSKYPNFKSFQCVNNFTSVYLNGDLVFTSNKTTDVTSAGVYFKAGGPVN 200   
 
Beau      YKVMREVKALAYFVNGTAQDVILCDGSPRGLLACQYNTGNFSDGFYPFTN 247   
M41       YKVMREVKALAYFVNGTAQDVILCDGSPRGLLACQYNTGNFSDGFYPFIN 247   
4/91(UK)  YKVMKEVKALAYFINGTAQEVILCDNSPRGLLACQYNTGNFSDGFYPFTN 249   
QX        YSIMKEFKVLAYFVNGTAQDVVLCDNSPKGLLACQYNTGNFSDGFYPFTN 250   
 
Beau      SSLVKQKFIVYRENSVNTTCTLHNFIFHNETGANPNPSGVQNIQTYQTKT 297   
M41       SSLVKQKFIVYRENSVNTTFTLHNFTFHNETGANPNPSGVQNIQTYQTQT 297   
4/91(UK)  SSLVKDRFIVYRESSTNTTLELTNFTFTNVSNASPNSGGVDTFQLYQTHT 299   
QX        STLVREKFIVYRESSVNTTLALTNFTFTNVSNAQPNSGGVNTFHLYQTQT 300   
 
Beau      AQSGYYNFNFSFLSSFVYKESNFMYGSYHPSCKFRLETINNGLWFNSLSV 347   
M41       AQSGYYNFNFSFLSSFVYKESNFMYGSYHPSCNFRLETINNGLWFNSLSV 347   
4/91(UK)  AQDGYYNFNLSFLSSFVYKPSDFMYGSYHPNCNFRPENINNGLWFNSLSV 349   
QX        AQSGYYNFNLSFLSQFVYKASDFMYGSYHPSCSFRPETINSGLWFNSLSV 350   
 
Beau      SIAYGPLQGGCKQSVFKGRATCCYAYSYGGPSLCKGVYSGELDHNFECGL 397   
M41       SIAYGPLQGGCKQSVFSGRATCCYAYSYGGPSLCKGVYSGELDLNFECGL 397   
4/91(UK)  SLTYGPIQGGCKQSVFSNKATCCYAYSYRGPTRCKGVYRGELTQYFECGL 399   
QX        SLTYGPLQGGCKQSVFSGKATCCYAYSYKGPMACKGVYSGELSTNFECGL 400   
 
Beau      LVYVTKSGGSRIQTATEPPVITQNNYNNITLNTCVDYNIYGRTGQGFITN 447   
M41       LVYVTKSGGSRIQTATEPPVITRHNYNNITLNTCVDYNIYGRTGQGFITN 447   
4/91(UK)  LVYVTKSDGSRIQTRSEPLVLTQYNYNNITLNKCVEYNIYGRVGQGFITN 449   
QX        LVYVTKSDGSRIQTRTEPLVLTQYNYNNITLDKCVAYNIYGRVGQGFITN 450   
 
Beau      VTDSAVSYNYLADAGLAILDTSGSIDIFVVQGEYGLNYYKVNPCEDVNQQ 497   
M41       VTDSAVSYNYLADAGLAILDTSGSIDIFVVQGEYGLTYYKVYPCEDVNQQ 497   
4/91(UK)  VTEATANYSYLADGGLAILDTSGAIDIFVVRGAYGLNYYKVNPCEDVNQQ 499   
QX        VTDSAANFSYLADGGLAILDTSGAIDVFVVQGIYGLNYYKVNPCEDVNQQ 500   
 
Beau      FVVSGGKLVGILTSRNETGSQLLENQFYIKITNGTRRFRRSITENVANCP 547   
M41       FVVSGGKLVGILTSRNETGSQLLENQFYIKITNGTRRFRRSITENVANCP 547   
4/91(UK)  FVVSGGNLVGILTSHNETDSEFIENQFYIKLTNGTRRSRRSVTGNVTNCP 549   
QX        FVVSGGNIVGILTSRNETGSEQVENQFYVKLTNSSHRRRRSIGQNVTSCP 550   
 
Beau      YVSYGKFCIKPDGSIATIVPKQLEQFVAPLFNVTENVLIPNSFNLTVTDE 597   
M41       YVSYGKFCIKPDGSIATIVPKQLEQFVAPLLNVTENVLIPNSFNLTVTDE 597   
4/91(UK)  YVSYGKFCIKPDGSLFIIVPQELEQFVAPLLNVTEHVLIPDSFNLTVTDE 599   




Beau      YIQTRMDKVQINCLQYVCGSSLDCRKLFQQYGPVCDNILSVVNSVGQKED 647   
M41       YIQTRMDKVQINCLQYVCGKSLDCRDLFQQYGPVCDNILSVVNSIGQKED 647   
4/91(UK)  YIQTRMDKVQINCLQYVCGNSIECRKLFQQYGPVCDNILSVVNGVGQRED 649   
QX        YIQTRMDKVQINCLQYVCGNSLECRKLFQQYGPVCDNILSVVNSVSQKED 650   
 
Beau      MELLNFYSSTKPAGFNTPVLSNVSTGEFNISLLLTNPSSRRKRSLIEDLL 697   
M41       MELLNFYSSTKPAGFNTPFLSNVSTGEFNISLLLTTPSSPRRRSFIEDLL 697   
4/91(UK)  MELLSFYSSTKPSGYNTPIFNNVSTGDFNISLLLTPPNSPTGRSFIEDLL 699   
QX        MELLSFYSSTKPKGYDTPVLSNVSTGEFNISLLLKPPSSPSGRSFIEDLL 700   
 
Beau      FTSVESVGLPTNDAYKNCTAGPLGFFKDLACAREYNGLLVLPPIITAEMQ 747   
M41       FTSVESVGLPTDDAYKNCTAGPLGFLKDLACAREYNGLLVLPPIITAEMQ 747   
4/91(UK)  FTSVESVGLPTDEEYKKCTAGPLGFVKDLVCAREYNGLLVLPPIITADMQ 749   
QX        FTSVETVGLPTDAEYKKCTAGPLGTLKDLICAREYNGLLVLPPIITADMQ 750   
 
Beau      ALYTSSLVASMAFGGITAAGAIPFATQLQARINHLGITQSLLLKNQEKIA 797   
M41       ILYTSSLVASMAFGGITAAGAIPFATQLQARINHLGITQSLLLKNQEKIA 797   
4/91(UK)  TMYTSSLVASMALGGITAAGAIPFATQLQARINHLGITNSLLLKNQEKIA 799   
QX        TMYTASLVGAMAFGGITSAAAIPFATQIQARINHLGITQSLLMKNQEKIA 800   
 
Beau      ASFNKAIGHMQEGFRSTSLALQQIQDVVSKQSAILTETMASLNKNFGAIS 847   
M41       ASFNKAIGRMQEGFRSTSLALQQIQDVVNKQSAILTETMASLNKNFGAIS 847   
4/91(UK)  ASFNKAIGHMQGGFKSTSLALQQIQDVVNKQSSILTETMQSLNKNFGAIS 849   
QX        ASFNKAIGHMQEGFRSTSLALQQIQDVVNKQSAILTETMNSLNKNFGAIT 850   
 
Beau      SVIQEIYQQFDAIQANAQVDRLITGRLSSLSVLASAKQAEYIRVSQQREL 897   
M41       SMIQEIYQQLDAIQANAQVDRLITGRLSSLSVLASAKQAEHIRVSQQREL 897   
4/91(UK)  SVLQDIYQQLDAIQADAQVDRLITGRLSSLSVLASAKQAEYHRVSQQREL 899   
QX        SVIQDIYAQLDAIQADAQVDRLITGRLSSLSVLASAKQSEYIRVSQQREL 900   
 
Beau      ATQKINECVKSQSIRYSFCGNGRHVLTIPQNAPNGIVFIHFSYTPDSFVN 947   
M41       ATQKINECVKSQSIRYSFCGNGRHVLTIPQNAPNGIVFIHFSYTPDSFVN 947   
4/91(UK)  ATQKINECVKSQSNRYSFCGNGRHVLTIPQNAPNGIVFIHFTYTPESFVN 949   
QX        ATQKINECVKSQSNRYGFCGSGRHVLSIPQNAPNGIVFIHFTYTPESFVN 950   
 
Beau      VTAIVGFCVKPANASQYAIVPANGRGIFIQVNGSYYITARDMYMPRAITA 997   
M41       VTAIVGFCVKPANASQYAIVPANGRGIFIQVNGSYYITARDMYMPRAITA 997   
4/91(UK)  VTAIVGFCVNPANASQYAIVPVNNRGIFIQVNGSYYITARDMYMPRDITA 999   
QX        VTAIVGFCVNPANASQYAIVPANGRGIFIQVNGTYYITARDMYMPRDITA 1000  
 
Beau      GDVVTLTSCQANYVSVNKTVITTFVDNDDFDFNDELSKWWNDTKHELPDF 1047  
M41       GDIVTLTSCQANYVSVNKTVITTFVDNDDFDFNDELSKWWNDTKHELPDF 1047  
4/91(UK)  GDIVTLTSCQANYVSVNKTVITTFVDNDDFDFDDELSKWWNDTKHELPDF 1049  
QX        GDIVTLTSCQANYVNVNKTVITTFVEDDDFDFDDELSKWWNDTKHQLPDF 1050  
 
Beau      DKFNYTVPILDIDSEIDRIQGVIQGLNDSLIDLEKLSILKTYIKWPWYVW 1097  
M41       DKFNYTVPILDIDSEIDRIQGVIQGLNDSLIDLEKLSILKTYIKWPWYVW 1097  
4/91(UK)  DEFNYTVPVLNISNEIDRIQEVIQGLNDSLIDLETLSILKTYIKWPWYVW 1099  
QX        DDFNYTVPILNISGEIDYIQGVIQGLNDSLINLEELSIIKTYIKWPWYVW 1100  
 
Beau      LAIAFATIIFILILGWVFFMTGCCGCCCGCFGIMPLMSKCGKKSSYYTTF 1147  
M41       LAIAFATIIFILILGWVFFMTGCCGCCCGCFGIMPLMSKCGKKSSYYTTF 1147  
4/91(UK)  LAIAFAIIIFILILGWVFFMTGCCGCCCGCFGIMPLMSKCGKKSSYYTTF 1149  
QX        LAIGFAIIIFILILGWVFFMTGCCGCCCGCFGIIPLMSKCGKKSSYYTTF 1150  
 
Beau      DNDVVTEQYRPKKSV 1162  
M41       DNDVVT--------- 1153  
4/91(UK)  DNDVVTEQYRPKKSV 1164  
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QX        DNDVVTEQYRPKKSV 1165  
 
 
Figure 8.3: Amino acid alignment of the Spike (S) glycoprotein from a variety of 
strains. Sequences were aligned using BioEdit, version 7.2.5. Sequences were downloaded 
from GenBank, accession numbers KY933089.1 (QX), MK728875.1 (M41), AJ311317.1 




Figure 8.4. Amino acid identidy between the Membrane (M) proteins of different IBV 
strains. 
Amino acid sequences were aligned using mafft (version 7.31; Katoh and Standley, 2013) 
using default parameters. Pairwise sequence identity and similar were calculated using SIAS 
– sequence identity and similarity tool (http://imed.med.ucm.es/Tools/sias.html), setting 
sequence length as the length of the multiple sequence alignment (MSA) and selecting 
BLOSUM62 similarity matrix. All other parameters were set to default. This work was 
completed by Michael Oade using in house sequences for Beau-CK, CR88, H120, M41-CK, 










Figure 8.5: Amino acid identity between the Envelope (E) proteins of different IBV 
strains. Amino acid sequences were aligned using mafft (version 7.31; Katoh and Standley, 
2013) using default parameters. Pairwise sequence identity and similar were calculated 
using SIAS – sequence identity and similarity tool (http://imed.med.ucm.es/Tools/sias.html), 
setting sequence length as the length of the multiple sequence alignment (MSA) and 
selecting BLOSUM62 similarity matrix. All other parameters were set to default. This work 
was completed by Michael Oade using in house sequences for Beau-CK, CR88, H120, M41-










Figure 8.6: Amino acid identity between the Nucleocapsid (N) proteins of different IBV 
strains.  Amino acid sequences were aligned using mafft (version 7.31; Katoh and Standley, 
2013) using default parameters. Pairwise sequence identity and similar were calculated 
using SIAS – sequence identity and similarity tool (http://imed.med.ucm.es/Tools/sias.html), 
setting sequence length as the length of the multiple sequence alignment (MSA) and 
selecting BLOSUM62 similarity matrix. All other parameters were set to default. This work 
was completed by Michael Oade using in house sequences for Beau-CK, CR88, H120, M41-














Figure 8.7: Amino acid identity between the Spike (S) proteins of different IBV strains. 
Amino acid sequences were aligned using mafft (version 7.31; Katoh and Standley, 2013) 
using default parameters. Pairwise sequence identity and similar were calculated using SIAS 
– sequence identity and similarity tool (http://imed.med.ucm.es/Tools/sias.html), setting 
sequence length as the length of the multiple sequence alignment (MSA) and selecting 
BLOSUM62 similarity matrix. All other parameters were set to default. This work was 
completed by Michael Oade using in house sequences for Beau-CK, CR88, H120, M41-CK, 








Figure 8.8: Nsp 15 amino acid sequence alignment.  * Denotes location of the coding 
mutation, leucine to isoleucine, within the M41-R genome sequence. # indicates silent 
marker mutation.  The accession numbers of the strains compared are as follows: HCoV-
229E, KF514433.1; HCoV-HKU1, NC_006577.2; MHV, KF268339.1; SARS-CoV, KF514395; 
TCoV: NC_010800.1. The IBV sequence used was M41 sequence generated “in house.” 






Figure 8.9: Nsp 16 amino acid sequence alignment. * Denotes location of the coding 
mutation, valine to isoleucine , within the M41-R genome sequence. # indicates silent marker 
mutation.  Arrows indicate the catalytic KDKE motif. The accession numbers of the strains 
compared are as follows: HCoV-229E, KF514433.1; HCoV-HKU1, NC_006577.2; MHV, 
KF268339.1; SARS-CoV, KF514395; TCoV: NC_010800.1. The IBV sequence used was 
M41 sequence generated “in house.” Sequences were aligned by Dr. Erica Bickerton using 








Figure 8.10: Nsp 10 amino acid sequence alignment. * Denotes location of the coding 
mutation, proline to leucine , within the M41-R genome sequence. The accession numbers of 
the strains compared are as follows: HCoV-229E, KF514433.1; HCoV-HKU1, NC_006577.2; 
MHV, KF268339.1; SARS-CoV, KF514395; TCoV: NC_010800.1. The IBV sequence used 
was M41 sequence generated “in house.” Sequences were aligned by  Dr. Erica Bickerton 







Figure 8.11: Nsp 14 amino acid sequence alignment. * Denotes location of the coding 
mutation, valine to leucine , within the M41-R genome sequence. # indicates silent marker 
mutation.  The accession numbers of the strains compared are as follows: HCoV-229E, 
KF514433.1; HCoV-HKU1, NC_006577.2; MHV, KF268339.1; SARS-CoV, KF514395; 
TCoV: NC_010800.1. The IBV sequence used was M41 sequence generated “in house.” 
Sequences were aligned using by Dr. Erica Bickerton BioEdit, version 7.2.5.  
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Figure 8.13 Copyright perimission to use a figure published by Ma et al., (2015).  Taken 
from https://www.pnas.org/page/about/rights-permissions , accessed 19th June 2019.  
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